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Abstract 
 
Metformin has been one of the most widely prescribed oral medications for type II 
diabetes for over six decades.  It has recently received considerable attention 
because there is now evidence to show that metformin has a potential role in 
reducing the risk of cancer development and progression. However, the mechanisms 
behind the growth-inhibitory effect of metformin on breast cancer cells are not fully 
understood with little consensus on which tumour subtypes and/or patient 
populations will benefit from metformin treatment. Furthermore, it should be noted 
that much of the in vitro work published to date has used drug concentrations 
greatly exceeding the recommended clinical dose and most preclinical studies have 
given little attention to the cellular pharmacology of metformin uptake including the 
expression of metformin transporter molecules and intratumoral accumulation. As a 
result these studies may not translate directly into clinical practice. This project 
therefore tests the hypothesis that the anti-tumour effect of clinically relevant doses 
(0.03-0.3 mM) of metformin depends on breast cancer subtype and the presence of 
metformin transporters on breast cancer cells. Using immunohistochemistry on 
patient-derived tissues and various in vitro cell-based assays in a panel of 
increasingly transformed breast cell lines representing an in vitro model of breast 
disease progression, the expression of metformin transporters and the potential anti-
proliferative effects of the clinical (0.03-0.3 mM) and potential tissue accumulation 
(1-5 mM) doses of metformin were evaluated. In parallel, global proteomic 
profiling was performed on three metastatic breast cancer cell lines to identify new 
potential molecular targets for metformin treatment. The data in this thesis show 
that metformin transporters are present on breast epithelial cells, pre-neoplastic, pre-
invasive, invasive and metastatic breast cancer cells and that metformin has a 
cytostatic effect on the proliferation of these cells, causing cell cycle arrest, but not 
apoptosis at clinically relevant doses.  The proteomic data suggest that metformin 
inhibits the expression of proteins within key cellular pathways in both triple 
negative breast cancer and the bone and lung-homed variants, with the lung-homed 
cells showing a greater response to metformin treatment.  Taken together these data 
provide important novel insight into the useful role of metformin in breast cancer 
treatment, but further research is certainly required to identify biomarkers of 
response and mechanisms of action in breast cancer before metformin can be 
recommended in clinical practice.  
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1. Chapter 1: Introduction 
1.1 The Breast     
1.1.1 Breast anatomy and development 
Adolescent female breast development commences at puberty in response to 
cyclical oestrogen and progesterone secretion. The main function of the breast is milk 
production. The acinus or terminal ductal-lobular unit (TDLU) represents the 
fundamental functional glandular unit of the breast and the biological most actively 
proliferating part and hence the more susceptible to mutative changes. The TDLU 
comprises the lobules and its paired terminal ducts, which are lined by columnar 
epithelium, supported by myoepithelial cells, a basement membrane and embedded in 
specialized hormonally responsive fibro-fatty stroma. The acini are interconnected by 
a series of branches of ducts, which increase in calibre until they terminate and exit 
the breast at the nipple via several major lactiferous ducts (Figure 1.1). 
Throughout the lifetime, there are three main periods that constitute the breast 
life cycle; these are the early reproductive life (lobular development), mature 
reproductive life (cyclical hormonal modifications) and involution. These changes 
occur in response to the alteration in hormonal levels of oestrogen and progesterone. 
The aberration of normal development and involution of the breast (ANDI) includes a 
variety of benign breast lesions such as fibroadenoma, cystic diseases and sclerosis1.  
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Figure 1.1: Schematic representation of the basic anatomical structure of the 
breast.   
The normal female breast contains tens of thousands of lobules; each of these lobules 
composed of small grape-like clusters of glandular tissues that lined by the functional 
epithelial cells, which specialized to produce milk. The lobules are interconnected by 
milk ducts, which join to form larger ducts that eventually open into the nipple. ETD: 
Extralobular terminal duct (This figure was produced using Servier Medical Art: 
http://www.servier.com/Powerpoint‐image‐bank). 
 
1.1.2 Benign breast disease and subsequent risk of breast cancer  
Based on the degree of proliferation and atypia, benign lesions of the breast 
are histologically classified into three categories: non-proliferative, proliferative 
without atypia and atypical hyperplasia2 (Table 1.1).  It is noteworthy that the 
fibrocystic changes (FCCs) constitute the most common benign diseases of the breast, 
which comprises both cystic and solid lesions. However, it is currently evaluated 
under the three category classification system depending on the presence or absence 
of cellular atypia2, 3.  
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Table 1.1: Classification of benign breast diseases and relative risk of invasive 
breast cancer 
Class Types Relative risk for 
invasive breast cancer 
Non- proliferative 
breast lesions 
Breast cysts 
Papillary apocrine change 
Mild hyperplasia of usual type 
(UTH)  
Apocrine metaplasia  
Non-sclerosing adenosis  
Mammary duct ectasia  
No increased risk4 
Proliferative 
breast lesions 
without atypia  
Moderate or florid UTH 
Sclerosing adenosis 
Radial scar 
Intra-ductal papilloma 
Slightly increased risk 
(1.5-2 times)4 compared 
with women who have 
not had a breast biopsy 
Proliferative 
breast lesions 
with atypia  
Atypical ductal hyperplasia (ADH) 
Atypical lobular hyperplasia (ALH) 
Moderately increased 
risk (4-5 times, in 10 
years)5, if associated with 
family history of breast 
cancer, the absolute risk 
rises to 20-25%  
 
1.1.3 Pre-malignant breast diseases 
1.1.3.1 Atypical hyperplasia (Ductal and lobular) 
For several decades atypical hyperplasia was known to be one of the few 
benign conditions that has a significant increased risk for developing breast cancer6-9. 
Epithelial hyperplasia is an increase in the number of cells lining the TDLU that can 
be histologically graded into mild, moderate and severe. Atypical hyperplasia (AH) is 
diagnosed if the hyperplastic cells show evidence of cellular atypia. Atypical 
hyperplasia can consist of cells with lobular or ductal morphology. Lesions exhibiting 
an intra-ductal monomorphic cellular proliferation that display all histological 
characteristics of ductal carcinoma in situ but measure less than 2mm are diagnosed 
as atypical ductal hyperplasia (ADH).  However, atypical lobular hyperplasia (ALH) 
is now classified with lobular carcinoma in situ as a well-established histopathological 
entity called lobular intraepithelial neoplasia (IEN)10.  
ADH is recognised as a mid-point in the histological spectrum of invasive 
breast cancer (IBC) evolution. Until recently, it was accepted that usual type 
hyperplasia (UTH) constitutes a non-obligate precursor of ADH and ductal carcinoma 
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in situ (DCIS)6. Perhaps the most persuasive histological evidence to suggest that 
UTH and ADH are progressive stages of an evolutionary continuum is based on the 
association between UTH lesions that showed relative over-expression of oestrogen 
receptors by the their heterogeneous hyperplastic cell population and the pivotal role 
of oestrogen in promoting the growth and proliferation of cancer cells8. However, in 
the majority of UTH lesions no evidence of neoplasia is observed with only rare if 
any random chromosomal changes.  
Recently, columnar cell lesions (CCLs) have been identified as the more likely 
precursor to ADH and DCIS (well-differentiated type) and these represent the link 
between normal breast and ADH10. CCL is characterized by the presence of columnar 
epithelial cells, which are tightly packed. Other features include ovoid nuclei, 
intraluminal secretions and prominent apical cytoplasmic snouts10.   
Despite the plethora of available information, it remains a central issue to 
determine whether to consider the atypical hyperplastic lesions as precursor lesions or 
risk markers for IBC, particularly as IBCs do not necessarily develop in the same 
anatomical area of atypia but might subsequently occur in the contralateral breast.  
Nonetheless, it is well accepted that ADH is the non-obligate precursor of the well-
differentiated DCIS. Moreover, the differentiation between ADH and DCIS is in fact 
arbitrary and subjective, as the similarities between them are not restricted to the 
morphological features only, but also their genetic and immunohistochemical 
features; which for example includes loss of heterozygosity at loci of 16q and 17p 
chromosomes11-14.  
1.1.3.2 In situ carcinomas (Ductal and Lobular) 
In the UK, due to its increasing incidence, in situ breast carcinoma has become 
a formidable clinical challenge. Since the early 1990s, the incidence rates of in situ 
breast cancers increased by more than 172% with the peak incidence rates being in 
females in their 50-60s15. In situ carcinomas refer to the epithelial cells that still reside 
in their normal place within the breast ducts but have become cancerous. The 
malignant cells can accumulate within the ducts and lobules causing them to be 
greatly expanded, but do not break through the basement membrane. It can be further 
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subdivided into ductal carcinoma in situ (DCIS) and lobular carcinoma in situ 
(LCIS)16.   
Ductal carcinoma in situ (DCIS) is the earliest stage of breast cancer (stage 0) 
and the most common type of in situ breast carcinoma, representing 80-90%. The 
widespread introduction of mammographic screening has dramatically increased the 
frequency of DCIS detection, where the majority of lesions are detected as 
mammographic micro-calcifications and confirmed by biopsy17. Around 4,800 cases 
of DCIS are diagnosed each year in the UK accounting for 25-30% of all newly 
diagnosed breast cancer (BC) cases (approximately 1 in 4 BC cases)18.  
Although DCIS is a non-invasive malignancy, if left untreated, up to 30-50% 
of the cases could progress to invasive BC, particularly the high grade DCIS which 
tend to progress more rapidly than the low and moderate grade lesions19. For this 
reason, currently, all DCIS cases are treated as potentially invasive as neither the 
significant drivers of the invasive transition nor a robust marker to identify cases that 
have the potential to progress to IBC from those that are unlikely to, have been 
identified.  
ADH is thought to be a precursor lesion of low-grade ductal carcinoma in situ 
whereas the high-grade ductal carcinoma in situ has no obvious precursor lesion and 
tends to develop into high-grade invasive disease16, 20. Generally, DCIS lesions have a 
relative risk of 8 to 11-fold for the development of subsequent IBC20, 21.  
It is commonly accepted that DCIS is the immediate non-obligate precursor of 
the majority of IBCs cases, due to the fact that there is an evolutionary continuum 
between them where they affect the same anatomical site. This occurs as follows. In 
DCIS, the lumen of the ductal tree becomes filled with proliferating pre-cancerous 
and cancerous cells but is separated from the surrounding stromal compartments by 
the intact myoepithelial–basement membrane interface17. At some point during 
progression, cancer cells breach the myoepithelial cell layer to the interstitial matrix 
and become an established IBC with metastatic potential. Recent work by Allen and 
colleagues discovered changes occur in the myoepithelial cells that switch their 
behaviour from being tumour-suppressor to cancer promoting and that up-regulation 
of the ανβ6 on the myoepithelial cells might be used as a potential tumour marker to 
predict disease progression and recurrence22.  
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Based on the expression patterns of oestrogen, progesterone and human 
epidermal growth factor 2 receptors, DCIS can be classified into similar molecular 
subtypes as IBC17, 23-25. This is because, histologically, the only major difference 
between DCIS and IBC is often that IBC does not retain an intact basement 
membrane. 
Historically, the classification of DCIS was based on the most predominant 
microscopic growth pattern where it was broadly classified into five recognised 
subtypes which include comedo (a central area of necrosis surrounded by a layer of 
malignant cells), cribriform (glandular lumina formed by radially oriented malignant 
cells), solid (ducts are filled with malignant cells), micropapillary (finger-like 
papillary projections extende into the ductal spaces) and papillary (large papillae with 
fibrovascular stalks)26. However, some overlap in the architectural features usually 
exist. Other prognostic features such as the presence or absence of necrosis, 
polarization (architectural differentiation) and nuclear grade (low, intermediate or 
high) were not traditionally taken into account. A relatively recent method of 
classification is based on the degree of differentiation of the tumour cells (the degree 
of tumour cell resemblance to normal cells) as well as the rate of cell proliferation. 
There are also several histological grading systems that assign scores based on certain 
cellular features such as size and shape of the nucleus, mitotic figures, amount of 
necrosis and the degree of gland or papillae formation. The most commonly 
recognized grades are well, moderately, and poorly differentiated DCIS 
corresponding to grade 1, 2 and 3 respectively16.  
If detected, current management strategies for DCIS is actually quite effective, 
namely, breast-conserving surgery followed by radiotherapy and/or selective 
oestrogen modulator (e.g., Tamoxifen), is the treatment option in the vast majority of 
the patients. However, there is growing concern that the majority may never develop 
aggressive IBC and therefore these patients are unnecessarily over-treated.  
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1.1.4 Invasive breast carcinomas  
 
Invasive breast cancer (IBC) emerges through a multistep process or a non-
obligatory series of increasingly abnormal stages that can be broadly attributed to the 
transformation of normal epithelial cells. The multistep model of breast 
carcinogenesis suggested the existence of a continuum in the transition from normal 
to IBC via atypical hyperplasia and in situ carcinoma, over long periods of time, 
plausibly few decades in most cases27. However, this process is non-obligatory in 
nature and only a small proportion of atypical ductal carcinoma lesions progress to 
invasive carcinomas.  
Although the morphological classification of pre-invasive breast lesions 
remains controversial, there is a consensus that the risk of IBC development correlates 
with the degree of cellular proliferation and atypia. Initiation, invasion and metastasis 
of BC are highly complex series of events, involving the interaction between multiple 
cell types and the microenvironment27. Figure 1.2 shows the current consensus of the 
evolution of invasive breast cancer based on the modified Wellings Jensen model of 
breast cancer evolution and some of the factors that influence this multigenic, multi-
step process. This model of breast cancer evolution based almost entirely on the 
evidence of histologic continuity between the hyperplastic breast epithelial cells; 
which gradually enlarge to form hyperplastic epithelial lobular units (HELUs), which 
may progress to more complex lesions including ADH and DCIS.  As the cells 
continue to proliferate and distend the acini the DCIS may eventually progress to 
invasive breast cancer6, 28.  In the context of this multistep cascade, it is crucial to 
distinguish between tumour formation, tumour progression and metastasis. 
Tumorigenesis refers to the ability of a cell to proliferate constantly in the absence of 
stimulation by the initiating carcinogenic agents, while tumour progression refers to 
the evolution of the already transformed tumorigenic populations towards increasing 
malignancy. Also the terms migration and invasion are not equivalent to metastasis; 
both of them are necessary, but insufficient to develop metastasis29.  
1.1.4.1 Epidemiology of invasive breast cancer 
According to the Cancer Registration Statistics, England 2015 (published in 
May-2017), Breast cancer (BC) was the most common cancer diagnosed in 2015, 
affecting 46,083 individuals, accounting for 31.2% or 1 in 3 of female cancer 
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registrations in the UK30. The age-standardised incidence rate of BC has dramatically 
increased from 163.6 to 170.2 cases per 100,000 females between 2005 and 2015 
respectively. 
Worldwide, breast cancer (BC) is the most commonly diagnosed cancer in 
women.  According to GLOBOCAN 201231, it represents 11.9% of all cancers.  Since 
2008, both the incidence and mortality rates of BC have sharply risen by more than 
20% and 14% respectively31, 32.  In 2012, it accounted for 1.67 million of all newly 
diagnosed cancers and 552,000 deaths worldwide, corresponding to 25% of all cancer 
deaths32.  Indeed, it is the most frequently diagnosed and the leading cause of death 
among women globally.  This is because it is the foremost cause of cancer mortality 
in developing countries, whereas in developed countries, it is the second biggest 
contributor to cancer mortality33 despite its higher incidence rates34.  The death 
figures are comparatively high in less developed countries because of the less 
developed facilities for early detection, a lack of education and less advanced 
management plans33. It should be pointed out that although breast cancer is 100 times 
more common in females than males, it also accounts for 2360 newly diagnosed 
cancers and 430 deaths among men each year in the USA alone35.   
 
1.1.4.2 Aetiology of invasive breast cancer 
Some BCs are attributed to the inheritance of a mutation in BRCA1 and 
BRCA2 genes36, accounting for half of those BC patients with strong family history.  
However, the majority of BCs are sporadic and multifactorial.  The two major risk 
factor categories in this sporadic group are (1) reproductive factors, such as early 
menarche, late menopause, low parity, hormonal replacement therapies, late first full-
term pregnancy and shorter duration of breastfeeding37, most of which are related to 
prolonged exposure of breast tissues to the growth-promoting effects of oestrogen and 
the genotoxicity of estradiol metabolites which increase the risk of DNA mutations38; 
and (2) environmental and lifestyle factors, such as obesity, diet rich in unsaturated 
fatty acids, physical inactivity, alcohol ingestion, smoking, vitamin D deficiency and 
environmental contaminants e.g. radiation exposure39, 40, all of which increase the risk 
of DNA mutations and have been extensively reviewed elsewhere.41 
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Figure 1.2: Schematic drawing of the model of multi-step breast cancer evolution and some of the factors involved in each 
step.  
The model shows enlargement of TDLU to hyperplastic epithelial lobular units (HELU). The HELU differentiate to more complex 
lesions such as ADH. ADH may then progress to DCIS and onward to IBC and finally metastasize to distant organs such as bone 
and lungs. Some factors involved in each step are summarised in the boxes, however, the transformation from ADH to DCIS 
requires all the factors mentioned in boxes 1 and 2 (adopted from references27, 42, this model was originally proposed by Wellings 
Jensen28) (Some elements of  this figure were produced using Servier Medical Art: http://www.servier.com/Powerpoint‐image‐bank). 
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1.1.4.3 Classification of invasive breast cancer 
Clinically, morphologically and genomically, IBC is a complex and 
heterogeneous disease.  The growth and survival of BC cells is tightly regulated and 
driven by diverse molecular alterations, which might explain the differences in their 
therapeutic response and prognosis43. Since its discovery, pathologists have 
endeavoured to identify a standard morphological classification of BC.  It was 
difficult to adopt the concept that the differences in biological behaviour among 
different histological subtypes were the only reason behind this heterogeneity44.  This 
remained the case until recently when advances in gene expression profiling 
techniques enabled Perou and colleagues to reveal that the natural biological diversity 
of different types of BC was due to the diversity of genetic expression of specific 
genes45.  This has undeniably changed the biological understanding of the similarity 
and differences in growth rate, cellular composition, and signalling pathways, not 
only within, but also among different breast tumours, and as a result has enabled 
greater tailoring of treatment to the specific type of BC.  
Morphologically, the majority of breast carcinomas are invasive ductal 
carcinomas46.  However, at the molecular level, recent advances in molecular 
profiling have demonstrated that there are several distinct molecular subtypes of BC6, 
24, 47-49.  The main subtype classification is based on their expression of oestrogen, 
progesterone and human epidermal growth factor-2 receptors (HER-2)50.   
These subtypes are: luminal A, luminal B, HER2-positive, basal-like, claudin-
low and normal breast51 (Table 1.2). Although triple-negative (TN) and basal-like is 
an interchangeably used term in clinical practice, 30% discordance has been described 
between the two groups, and therefore they are non-identical52. Both basal-like and 
claudin-low can be considered as subtypes of TN breast cancer46. Moreover, Luminal 
A and B subtypes can be differentiated further by their expression of Ki67-antigen; 
low in luminal A / high in luminal B53, 54. High expression of Ki67 has been reported 
to be associated with increased risk of BC recurrence and mortality55 (Reviewed by 
Eroles et al., 201250). This molecular classification and heterogeneity is extremely 
important not only for further understanding of pathogenesis and speculating the 
drivers of BC development, but also for (1) choosing the most appropriate treatment 
strategies; (2) providing promising targets for most of the currently licensed drugs and 
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the development of novel agents; (3) enhancing patient response to adjuvant therapy56, 
57;  (4) explaining the development of drug resistance; (5) use as biomarkers in 
predicting the disease outcomes and correlating with clinical prognosis; and (6) 
opening the horizon for personalized medicine in the near future46.   
Table 1.2: Intrinsic subtypes of breast cancer  
Receptor type Receptor status Prevalence 
ER PR HER-2 
Luminal A ER+ and PR+/- Negative 50-60%, 
Commonest 
Low histological grade, low proliferative index, 
Ki67 low, endocrine and chemotherapy 
responsive with good prognosis58 
 
Luminal B ER+ and PR+/- Positive 10-20% 
High histological grade, High proliferative 
index, Ki67 high, usually endocrine responsive, 
variable response to chemotherapy with poor 
prognosis59 
 
HER-2 positive Negative Negative Positive 15-20% 
Ki67 high, trastusumab responsive, 
chemotherapy responsive60 
Basal-like or 
Triple negative 
Negative Negative Negative 8-37% 
 Positive for EGFR and/or cytokeratins (5/6), 
Ki67 high, chemotherapy responsive and 
endocrine nonresponsive58 
Normal breast Negative Negative Negative 5-10% 
Express gene characteristics of adipose tissue, 
do not respond to neoadjuvant chemotherapy58 
Claudin-low   Negative Negative Negative 7-14% 
Claudin (3,4,7) and E-cadherin low 
(Intercellular adhesion molecules), enriched in 
epithelial-to-mesenchymal transition (EMT) 
features, intermediate response to 
chemotherapy61, 62 
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1.1.4.4 Current treatment strategies of invasive breast cancer 
Despite this relatively new knowledge about the molecular subtypes of BC, 
complete surgical excision of the primary tumour along with selective axillary surgery 
remains the main stay of treatment. Loco-regional radiotherapy and systemic 
treatment, including chemotherapy, hormone-therapy and treatment with biological 
inhibitors targeting the main receptors, such as Trastuzumab targeting HER2, are used 
mainly as adjuvant therapies63.  The ultimate goal of treatment is to reduce the risk of 
recurrence and improve disease-related morbidity and mortality64-66.  There is no 
doubt that the current management strategies have been greatly influenced by the 
rapid advances in the field of molecular biology and the ability to identify new 
molecules to be targeted by novel drugs.   
The majority of breast cancer cells express oestrogen receptor (~ 75%), 
especially in postmenopausal women67.  The crucial role of oestrogen, the main 
female sex hormone, in BC growth and development has received considerable 
attention.  It was more than a century ago when Beatson reported a regression of the 
tumour size and cellular proliferation of advanced inoperable BC after 
oophorectomy68.  In light of this finding, it has been postulated that growth of BC can 
be either regressed or prevented by the use of oestrogen-depriving agents.  This 
concept has rationalized the use of hormonal therapy as an adjunct to surgery and 
radiotherapy in BC treatment over the past 20 years69. 
It is noteworthy that oestrogen-depriving agents can reversibly inhibit 
oestrogen production or block its action with fewer side effects when compared with 
the cytotoxic effect of chemotherapeutic drugs.  However, treatment using anti-
hormonal therapy needs to take into consideration that the site of oestrogen 
biosynthesis varies according to the menopausal status.  Oestrogen is produced 
exclusively by ovaries in premenopausal and synthesised extra-gonadally by fatty, 
muscular and breast tumour tissues in postmenopausal women70, 71, and therefore the 
treatment may vary depending on the patient’s menopausal status. 
For nearly 3 decades, Tamoxifen - a selective oestrogen receptor modulator, 
has both selective agonistic and antagonistic actions, the former action directed 
against the deleterious effect of oestrogen on breast and endometrium while the latter 
potentiates oestrogen-beneficial activity on bone and brain tissues. It had been the 
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cornerstone of endocrine therapy for patients with ER-positive BC, irrespective of 
menopausal status.  Tamoxifen was approved by US food and drug administration for 
a full range of breast diseases ranging from chemoprevention to advanced metastatic 
disease72.  
However, in postmenopausal women the production of oestrogen relies 
completely on the peripheral conversion of androgen into estradiol E1 and estron E2 
by the aromatase enzyme. Aromatase; a cytochrome P-450 enzyme complex; is a key 
player that control local biosynthesis of oestrogen within the mammary glands38.  
Suppression of aromatase activity has been a subject of intensive research since 
1970s, when the first aromatase inhibitor; aminoglutethimide, was accidentally 
discovered during a preliminary trial testing its efficacy as an anticonvulsant drug and 
reported an inhibition of adrenal glands androgen synthesis as a major side effect73.  
This resulted in the development of aromatase inhibitors as an alternative effective 
hormonal strategy to antagonise/block the growth-promoting effects of oestrogen in 
postmenopausal hormone-sensitive breast cancer by lowering circulating-oestrogen73-
75.  However, it is important to note that AIs have no benefits in premenopausal 
women with functioning ovaries and in postmenopausal with ER-/PR- or HER2+ve 
subtypes of BC.  Generally, the positivity of HER2; he major driver of human BC 
cells proliferation, is considered as a marker of resistance to anti-oestrogen therapy76.   
 AIs have been developed over the past 40 years to increase their potency and 
specificity with three different generations of inhibitors recognised.  Aromatase 
inhibitors are classified into three different generations with the 3rd generation being 
the most potent and specific inhibitors.  Furthermore, they are subdivided according 
to the reversibility of their inhibitory action into: steroidal and non-steroidal 
molecules. Steroidal aromatase inhibitors attached irreversibly to the substrate-
binding site of the aromatase enzyme.  In contrast, non-steroidal inhibitors interact 
reversibly with the heme group of the cytochrome P450 component of the enzyme77. 
Although both steroidal and non-steroidal aromatase inhibitors are believed to 
be equally effective, the 3rd generation aromatase inhibitors are specifically highly 
recommended as a first line endocrine therapy66.  Currently, three of the third 
generation aromatase inhibitors, letrozole, anastrozole and exemestane are licenced 
for postmenopausal ER+ve early BC as primary and extended adjuvant, primary 
adjuvant, and unplanned switching therapies, respectively78.  Results from several 
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randomized clinical studies comparing the efficacy and disease free survival outcome 
between tamoxifen and AIs have proven the superiority of these agents in terms of 
lowering the recurrence rate, improving the disease free survival, increasing 
tolerability, reducing serious side effects such as thromboembolic events and 
endometrial cancer when compared to tamoxifen65, 79.  However, the risk of arthralgia, 
bone loss and fractures increases dramatically among users of AIs80 and needs to be 
carefully monitored.  
1.1.5 Metastatic breast cancer 
Tumour metastasis is a term that comprises specific molecular and biological 
characteristics that together enable the spread of aggressive malignant cells from the 
primary site to the surrounding tissues and distant organs. It is suggested that the 
acquisition of metastatic capacity occurs as a late event in tumour progression. Most 
patients with breast cancer die not because of the primary breast tumour, but rather 
because of its spread to other distant sites. Metastasis can be viewed as an 
evolutionary process and is defined as the progressive growth of cancer cells at a site 
that is distant and discrete from the primary lesion. Tumour cells can disperse into 
blood vessels, lymphatic vessels, or within body cavities (Figure 1.3).  
Currently, it is not possible to precisely predict the risk of breast cancer 
metastasis development or to determine which organ system will be invaded, 
although approximately 40% of the patients may suffer relapse and 90% of these 
patients die of metastatic spread of breast cancer. In an attempt to prevent this 
almost 80% of patients receive adjuvant cytotoxic chemotherapy, some of them 
unnecessarily and therefore needlessly suffer the acute and long-term toxic side 
effects of the chemotherapy81, 82. Despite this, there are some well-established 
clinical features of the primary breast tumour that are indicative of the risk of 
metastatic recurrence which include tumour size, histological grade, axillary lymph 
node status, angioinvasion in patients with negative lymph nodes (the presence of 
tumour emboli in >3 blood vessels), HER2 gene amplification and steroid receptor 
expression; the last two in particular, are also used for adjuvant therapy decision83-87.  
Nonetheless, based on the recent advances of genome-wide technologies, 
primary breast tumours can further be classified into those that have a poor-
prognosis signature or a good-prognosis signature, which means they are more 
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likely or less likely to metastasize, respectively. These signatures can more 
accurately predict patients who are destined to relapse and should therefore receive 
adjuvant therapy. This classification is based on the presence/up-regulation or 
absence/down-regulation of specific genes; for example, the poor-prognosis 
signature included the up-regulation of genes involved in signal transduction, cell 
cycle, angiogenesis, invasion and metastasis. Interestingly, up-regulation of genes 
that are exclusively highly expressed by the tumour stromal cells is also involved in 
the poor-prognosis signature for breast cancer metastasis; an example is the matrix 
metalloproteinases genes (MMP1 and MMP9) which are essential for the 
degradation of extracellular matrix (ECM) and tumour invasion88.  
Under the influence of several factors, different primary tumours metastasize 
to distinct secondary organs. These factors include, the origin of cancer cells, the 
aggressiveness of the primary tumour type, the direction of circulation, and the ability 
of cells to homogenize with the supporting components of the new microenvironment. 
The genetic determinants underlying each of these factors are largely distinct from 
those that mediate the malignant transformation of breast cells. One of the most 
interesting biological aspects of metastasis is the remarkably variable pattern of organ 
dissemination. The dissemination of cancer cells frequently involves invasion through 
the lymphatic system to local lymph nodes, however, some aggressive cells typically 
invade the bloodstream and reach distant tissues89.  
Breast cancer primarily metastasizes to bone and lung and less frequently to 
liver and brain90. While oestrogen receptor positive tumours preferentially spread to 
bone91; oestrogen receptor negative tumours have a predilection for metastasis to 
visceral organs whereas invasive lobular carcinomas (ILC) relapse more frequently 
in the gastrointestinal tract and ovaries92, 93. This can be attributed to the cell of 
origin:  hormone receptor positive tumours emerge from the luminal progenitor cells, 
whereas hormone receptor negative tumours originate from the basal cell layer. The 
striking preference of various breast cancer cells to metastasize to these organs 
forms the basic concept of the “seed and soil” hypothesis by Paget in 1889, in 
which he proposed that the malignant cells (seeds) arrest, survive and proliferate 
only in those tissues that provide a hospitable environment or a congenial ground 
for their growth (soil)94.  Therefore, failure of cells to metastasize can be due to either 
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genetic deficiencies within the malignant cells or impaired responses to the new host 
environment (epigenetics).  
In order to metastasize, cancer cells must fulfil some prerequisites and gain 
certain tumorigenic functions in order to complete the multistep metastatic cascade. 
These include an indefinite proliferative capacity, capacity to evade both cellular and 
environmental constraints, ability to attract a blood supply, and to eventually detach 
from their primary site. If a cell fails any of the many steps in the metastatic cascade, 
then it will not metastasize. The “metastatic cascade” can be divided into six distinct 
steps each of which represents a potential target for development of novel therapeutics 
to reverse or prevent metastatic breast disease (and have been extensively reviewed in 
references 29, 95 ). 
Step 1: Local invasion and intravasation. Tumour dissemination starts when 
the aggressive malignant cells begin to invade the bloodstream through the new 
vasculature they have previously formed through angiogenesis. Tumour cells utilize a 
variety of extracellular proteases to break down extracellular matrix (ECM) and 
invade from primary tumour to the adjacent parenchyma such as urokinease type 
plasminogen activator (uPA) and matrix metalloproteases (MMPs); a family of at 
least 20 zinc-dependant endopeptidases capable of degrading most known 
extracellular matrix components96, of which MMP1 and MMP9 were found to be up-
regulated in breast cancer97. Entry of malignant cells into the circulation is 
facilitated by the pathologically leaky vasculature formed by tumour angiogenesis. 
Departure from the primary site and intravasation can be also enhanced by the 
embryonic plasticity and added motility endowed by the development of epithelial-
to-mesenchymal transition phenotype98,99. Furthermore, the invasion of cancer cells 
can be promoted by the presence of tumour-associated macrophages and 
fibroblasts; both are required for the production of pro-migratory factors and 
deposition of collagen, respectively100-103. 
Step 2: Dissemination in the circulation.  To enhance their survival during 
dissemination, malignant cells may circulate as solitary cells or associate with non-
neoplastic cells and/or platelets to form multi-cellular clusters to protect them from 
immune cell detection and shear stress destruction until they arrest in the narrow 
capillary beds of a discontinuous organ and extravasate83.  
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Step 3 and 4:  Arrest at the distant site and extravasation. Once within the 
parenchyma of the target organ, metastatic cells can breach the microvasculature in 
which they are lodged either by disruption of their walls by the expanding tumour 
emboli or, more frequently, by penetration of the fenestrated capillary walls and 
extravasation into the parenchyma. Following extravasation, the efficient metastatic 
seeding, survival and subsequent tumour growth is directly enhanced by the 
recruitment of the metastasis-associated macrophages; a distinct population of an in 
situ differentiated monocyte104. It is of note that metastasis from breast cancers tend to 
tend to migrate to lung, liver and bone marrow and the homing/establishment of 
metastasis of breast cancer cells to these sites would appear to be mediated by 
interactions of certain receptors on cancer cells and the expression of the appropriate 
ligand in the “preferred” tissue such as CXCR4 and  CXCR8 expression on breast 
cancer cells and the paracrine secretion of CXCL12 in the target organs96. CXCR4 
and CXCR8 are members of the chemokine receptor family while CXCL12 is a 
stromal-cell derived factor (SDF1). The chemokines are by far the most studied 
tumour-derived chemo-attractants. 
Step 5 and 6:  Survival as micrometastasis and colonization of target 
organs.  Once they abandon their original host organ, the tumour cells will encounter 
different stresses caused by the loss of their supportive original microenvironment as 
well as the unfavourable surroundings at the distant sites which do not support the 
growth of individual cells which wander in from elsewhere, and subsequently, most 
cells will die. However, because of their inherent genetic instability, breast cancers 
have a limited chance of generating cells which are able to overcome stringent 
biological barriers, survive the stresses of bloodstream and withstand otherwise 
incompatible microenvironments with their phenotypic attributes. Once extravasated, 
active colonization of secondary organs can be promoted by certain co-opted organ-
specific cells present in the new microenvironment, such as the bone-resorbing 
osteoclasts in the bone microenvironment. From these disseminated tumour cell 
populations only a few cancer cells may establish full colonization where they are 
triggered to proliferate and form metastatic colonies immediately upon their 
extravasation, others may enter a prolonged period of micrometastatic dormancy. The 
survival of dormant lesions, and their prospected activation requires additional factors, 
which might be tumour-intrinsic or tumour-extrinsic. Distinct sets of functions are 
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thought to be required for the cells to preferentially colonize different organs as each 
tissue presents a highly specialized microenvironment89. 
Colonization of distant organs represents the most dangerous aspect of cancer. 
Cancers that remain confined to the breast is associated with excellent cure rates, 
exceeding 90%. As the cells spread, the long-term survival decreases depending on the 
site as well as the extent of colonization. Brian and visceral organs metastasis are the 
most life threatening, with less than 20% of patients surviving for 5-years105.  
 
	
 
Figure 1.3: The steps involved in breast cancer-cell metastasis from a primary 
site to distant organs.  
The proclivity of cells to disseminate can be acquired when the primary malignant 
neoplasm becomes locally aggressive and promotes new blood-vessel formation. The 
cells invade these new blood vessels, and the vasculature carries the cancer cells to 
capillary beds in distant organs as aggregates with other blood cells, which eventually 
form embolisms that arrest in distant capillaries. These cancer cells can then adhere to 
the endothelial cells and escape into the surrounding parenchyma where they become 
exposed to the microenvironment that can support the growth of metastases (This 
figure was produced using Servier Medical Art:  
http://www.servier.com/Powerpoint‐image‐bank). 
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1.2 The emerging hallmark of cancer: deregulating cellular energetics 
The hallmarks of cancer were initially characterized as six biologically 
distinctive capabilities attained during the multistep development of human cancers 
and directly contribute to tumour complexity, tumour growth and metastatic 
dissemination (reviewed in detail in reference106). These hallmarks include sustained 
proliferative signalling, evading growth suppressors, mechanisms to resist cell death, 
replicative immortality, induction of angiogenesis, and activation of invasion and 
metastasis107. Recently, two more characteristics have been added to this list including 
reprogramming of energy metabolism and evasion of immune destruction106.  
Owing to its key role in human malignancies, cancer cell metabolism is now 
the focus of intense research. This concept was identified by Warburg108 in the 1920s 
and is termed the “Warburg effect”109, 110 and in recent years has received a great deal 
of interest and traction. Based on the evident relationship between metabolic 
dysregulation and cancer, attention has focused on the possibility of tackling the 
metabolic alterations as a potential for treating cancer patients, following the recent 
development in methods to study its regulation. 
An example of this concept is the many lines of evidence that suggest a 
connection between the metabolic syndrome, obesity-related insulin resistance and/or 
diabetes mellitus with increased risk of diverse cancer types. Over the past few years, 
multiple meta-analyses and large cohort studies have examined this association and 
strengthened the proposed synergistic relationship between type 2 diabetes mellitus 
and an increased risk and incidence of several site-specific malignancies111, 112 
including breast113, 114, liver115, pancreas116, kidney117, colon118 and endometrial/ 
ovarian119 cancers. It is now becoming clear that sustained hyperglycaemia and 
hyperinsulinemia are critical regulators of not only the development of malignancy 
but also of treatment outcome120. 
This growing awareness has resulted in a desire to extensively investigate the 
potential of anti-diabetic therapy for cancer prevention and treatment. Over the past 
decade research has emphasized an emerging role of metformin in reducing both 
cancer incidence and cancer-related mortality in diabetics. Therefore, metformin 
might have a profound impact on public health worldwide and it is now becoming an 
attractive subject of intense basic and clinical research on both chemoprevention and 
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chemotherapy. This strongly suggests a critical role for metabolic alteration as an 
early change in cancer development and highlights the importance of metabolic 
reprogramming as a potential prevention strategy. However, the potential anti-cancer 
properties of metformin need to be thoroughly investigated to explain how it affects 
cancer cell metabolism and deregulates cellular energetics, and whether it can have 
the same effect in non-diabetic patients.   
1.3 Metformin as a potential chemopreventive and chemotherapeutic agent in 
breast cancer 
Most malignant cells rely primarily on non-efficient, non-oxidative breakdown 
of glucose in the cytosol by a process called “aerobic glycolysis” to generate the 
required energy for their survival, independently of the mitochondrial oxidative 
phosphorylation, a common efficient mechanism of ATP generation by proliferating 
normal cells in presence of oxygen; the “Warburg effect”. Metformin has been 
reported to concomitantly reduce the anti-senescence effects of the ATP-generating 
glycolytic metabolic type thereby down-regulating the self-renewal and proliferation 
of breast cancer stem cells121.  
1.3.1 Metformin’s botanical background 
Metformin (N',N'-dimethylbiguanide hydrochloride) is a safe, non-toxic, low 
cost and widely  prescribed biguanide-derivative for the treatment of high blood 
glucose associated  with type 2 diabetes mellitus (T2DM) worldwide122.  Its use can 
be backdated to ancient Egypt and medieval Europe where it was derived from the 
Galega Officinallis herb (i.e. French Lilac or Goat’s Rue) and it was used to relieve 
polyuria and sweet odour breath, both of which are common symptoms of 
hyperglycemia123.  The isoamylene guanidine was identified as the active ingredient, 
however, when purified, guanidines were discovered to be fairly toxic. Chemists 
made the compounds more tolerable by bonding two guanidines together forming a 
biguanide and agents such as phenformin, buformin and metformin were developed 
for therapeutic uses (Figure 1.4). Phenformin was the first to be commercialized, but 
was withdrawn rapidly and replaced with metformin due to the high incidence of 
lactic acidosis among diabetics using phenformin123.  In 1958, metformin was 
licensed for use in Britain for the prevention and treatment of hyperglycaemia 
associated with T2DM, along with dietary restriction and physical activity124, 125. In 
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addition to its anti-hyperglycaemic effect, metformin has both plasma-lipid and 
weight lowering effects; a mimicry effect of calorie-restriction126.  
	
Figure 1.4: Metformin structure and synthesis.  
Metformin (3) is synthesized by equimolar fusion of hydrochloride dimethylamine (1) 
and dicyandiamide (2) at 130-1500 C for 0.5-2 hours127 (Figure created by 
ChemDraw Prime 16.0). 
 
1.3.2 Clinical pharmacokinetics of metformin 
Chemically, metformin is a small hydrophilic base (molecular weight: 129 
g/mol), which exists as an organic cation at physiological pH. Following oral 
consumption, it is absorbed predominantly from the upper small intestine and has a 
relatively low bioavailability of about 50-60%. The peak plasma concentration of 
metformin is reached within 3 hours while its average elimination half-life in plasma 
is about 6.2 hours128-129. Therefore, effective treatment with metformin can be 
achieved by repeated administration of high doses (e.g. 850 mg twice a day or 500 mg 
three times a day, orally). Metformin tends to accumulate in the kidneys, salivary 
glands and the small intestine. Interestingly, metformin is also distributed to red blood 
cells, and accumulates in these with a much longer elimination half-life of about 17.6 
hours. It is not metabolized in cells and 80 % of it is renally eliminated and excreted 
unchanged in urine124.  
Metformin binding to plasma proteins is negligible and its cellular uptake via 
passive diffusion across cell membranes is very limited129.  Therefore, metformin 
requires a set of influx and efflux transporters to facilitate its transport into and out of 
the cell and mediate its oral absorption, hepatic uptake and renal excretion 
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(Summarized in table 1.3). Several transporters have been identified as putative 
determinants of metformin’s pharmacokinetics in the main organs such as liver, 
kidney and small intestine (Figure 1.5).  
 
 
Figure 1.5: Putative determinants of metformin’s kinetics in main organs.  
After oral administration, metformin is widely distributed into the body tissues 
including the small intestine, liver and kidneys. The absorbed dose is mostly excreted 
unchanged in urine. In the liver and kidneys, organic-cation transporters (OCTs) are 
localized on basolateral membranes, whereas multidrug and toxin extrusion (MATEs) 
proteins are localized on apical membranes. Although metformin is not an exclusive 
substrate of these transporters, the mechanisms underlying its transport kinetics in the 
clearance organs has been quite well investigated. It is noteworthy that OCT1 can act 
as an importer as well as an exporter in the enterocyte (This figure was produced 
using Servier Medical Art: http://www.servier.com/Powerpoint‐image‐bank). 
 
Influx transporters such as organic cation transporters OCT1, OCT2 and 
OCT3, which are members of the solute carrier family 22 encoded SLC22A1, 
SLC22A2 and SLC22A3 genes respectively, are involved in metformin translocation 
into cells130. Recently, metformin has been shown to be a substrate for a novel proton-
activated organic cation transporter known as PMAT (plasma membrane monoamine 
transporter), a member of solute carrier family 29 encoded by SLC29A4 gene, which 
has been shown to be important for intestinal uptake of metformin131.  
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Efflux transporters such as MATE1 and MATE2; the multidrug and toxin 
extrusion family, which are members of solute carrier family 47 encoded by 
SLC47A1, SLC47A2 genes, facilitate the H+ coupled export of metformin from the 
intracellular to the extracellular space (H+/organic cation antiporters; drive the 
secretion of metformin from low to high pH gradient through H+ or proton activated 
pump)132. In terms of transport capacity and substrate affinity, metformin is known to 
be a superior substrate for renal OCT2 more than the hepatic OCT1133, but not for 
OCT3134.  Recently, OCT4 (SLC22A4), also known as carnitine/organic cation 
transporter OCTN1, has also been identified to be involved in metformin absorption 
in the small intestine135. The complex interplay between the influx and efflux 
transporters governs metformin disposition, efficacy and cellular response. Therefore, 
elucidating the difference in transporters expression is central to determine the 
intracellular concentration, and optimum dosing, as well as the most relevant in vitro 
cell model for exploring the anticancer efficacy of metformin.  
Furthermore, the potential importance of glucose transporter-1 expression 
(GLUT1) has been recently demonstrated as a biomarker for response to metformin; 
where AMPK activation has been shown to up-regulate glucose transporter 
expression, in addition to the importance of glucose concentrations in determining the 
sensitivity to biguanides drugs in general136. Additionally, mitochondrial DNA 
mutations in particular in complex I genes (i.e ubiquinone oxidoreductase) may also 
be considered as a key marker of resistance to metformin136.  
Another interesting marker is the glutamine reductive carboxylation pathway 
which allows cancer cells treated with metformin to utilize glutamine as a carbon 
source at a time of mitochondrial toxicity and changes in expression of its regulators 
such as isocitrate dehydrogenase is also of interest137. 
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Table 1.3: Metformin-transporter proteins; their localization, site of expression 
and potential functions 
                 
 
 
 
Transporter Membrane localization and 
tissue distribution 
Functions and relevant studies 
OCT1 
(SLC22A1) 
The main transporter across cell 
membrane which mediates 
hepatic and intestinal uptake of 
metformin128 
 
Mainly on the basolateral 
membrane of hepatocytes and 
enterocytes 
 
Predominantly expressed in liver 
followed by small intestine 
   
OCT1 gene deletion in mice 
reduces hepatocytes metformin 
uptake dramatically138 
 
Human individuals carrying 
SLC22A1 polymorphisms suffer an 
impaired response to metformin in 
reducing blood glucose levels138 
OCT2 
(SLC22A2) 
Mainly on the basolateral 
membrane of renal tubular cells 
 
Expressed in kidney, testis and 
prostate 
 
Responsible for 80% of total 
metformin clearance, it mediates 
the entry of metformin into tubular 
cells and together with MATE1-2 
mediates its secretion into urine132 
OCT3 
(SLC22A3) 
Apical membrane of human 
enterocytes 
 
Expressed by multiple tissues 
and their corresponding tumours 
        
The contribution of OCT3 to 
metformin absorption is still 
unknown130 
PMAT 
(SLC29A4) 
Apical membrane of epithelial 
cells 
 
Expressed by intestinal tract, 
skeletal muscle, liver, kidney 
and brain 
     
May play a role in intestinal 
absorption of metformin131 
MATE1 
(SLC47A1) 
Bile canaliculi of the liver and 
brush border membrane of the 
renal tubular cells 
 
Primarily expressed by Kidneys, 
adrenal glands, testis, liver and 
skeletal muscles 
   
Responsible for renal clearance of 
metformin with OCT2132 
MATE2 
(SLC47A2) 
Widely expressed in humans  
 
Predominantly expressed by 
kidneys 
Renal clearance of metformin132 
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1.3.3 Pharmacodynamics of metformin and insulin-mediated action  
Generally, the biguanides act by reducing hyperglycaemia without leading to 
coincidental hypoglycaemia. Hence, the term “anti-glycaemic” drug was coined for 
metformin. As an anti-hyperglycaemic agent, metformin exerts its effect by reducing 
hepatic gluconeogenesis, the process by which glucose is generated from non-
carbohydrate substrates, and increasing glucose uptake by muscles139, 140. These 
effects are mediated by adenosine monophosphate-activated protein kinase (AMPK) 
transcriptional regulation of genes that encode glucose transporters in liver and 
muscles.  Reduction in blood glucose level will subsequently lead to reduction in 
circulatory insulin, and possible improvement in tissue sensitivity to circulating 
insulin. For this reason, metformin has been classified as an “insulin sensitizer”141, 142.  
Most of the adverse effects of metformin are mild, temporary, reversible and mainly 
gastrointestinal in origin.  These include nausea, gastric upsets and diarrhoea.  This 
may occur in up to 30% of cases and can be overcome by introducing the drug slowly 
and gradually increasing the dose143.  Lactic acidosis, a rare complication, affects 3 in 
10000 of diabetics on metformin, most commonly in elderly patients with impaired 
cardiac, hepatic and renal functions144. When used as a monotherapy, the anti-
hyperglycaemic action of metformin doesn’t affect the pancreatic insulin secretion 
nor cause overt clinical hypoglycaemia in both normal and diabetic subjects143. 
Additionally, at the cellular level, metformin is believed to have pleiotropic effects 
which include disruption of mitochondrial function by partially inhibiting NADH 
dehydrogenase145 or by inhibiting glycerol phosphate dehydrogenase in liver cells 
which results in alterations to the electron transport chain (ETC). Moreover, 
metformin has been documented to affect several processes that are central to 
numerous aspects of cell physiology such as AMPK signalling, protein kinase A 
signalling, folate and anabolic metabolism136, 137, 145. Most of these mechanisms point 
toward the mitochondrial biology as a main mechanistic target for metformin146. 
1.3.4 Metformin and breast cancer; early clues 
In addition to the potent anti-diabetic properties of metformin, it has recently 
received considerable attention because of its potential anti-neoplastic and chemo-
preventive activities.  The term chemoprevention means either stabilization, arrest or 
reversal of the malignant growth during its pre-neoplastic phase, either 
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physiologically or pharmacologically147.  The potential use of metformin in cancer 
was first identified by numerous retrospective observational studies evaluating the 
potential diabetes-cancer association.  Epidemiologic observations reported lower 
incidence and reduced cancer-related mortality among metformin-treated diabetics 
(receiving adult therapeutic dose: 1.5-2.5 gm/day), compared to those on other 
hypoglycaemic agents120, 148-155. This led to speculations about the integral and 
potential role of metformin in reducing the risk of cancer development, progression, 
and metastasis, and improving the overall survival outcomes. Following on from the 
epidemiologic studies, a significant number of preclinical studies have also suggested 
a possible anti-cancer effect of metformin, and attempted to identify the potential 
mechanisms of action, as detailed in section 1.3.5.1.  Indeed, as a result of these pre-
clinical observations more than 100 clinical trials at different phases are currently 
underway to explore the impact of metformin treatment on: prevention, treatment and 
survival outcomes of cancer patients, including prostate, lung, thyroid, ovarian, 
endometrial cancers, with 36 of them evaluating breast cancers (can be viewed at 
www.Clinicaltrials.gov  - last accessed 30th-December-2017). 
1.3.4.1 Breast cancer chemoprevention: clinical aspects and population benefits 
A landmark epidemiologic study in the field of oncology by Evans et al. in 
2005148, reported a reduced overall cancer incidence in diabetics receiving metformin 
in comparison to those on other oral hypoglycaemic agents and this protective effect 
was closely linked to the duration of metformin exposure.  Shortly thereafter, the 
research field expanded rapidly with about 17 more epidemiological studies 
evaluating the potential link between metformin administration and reduced cancer 
burden (reviewed by Dowling et al.156).  
Various epidemiologic and population-based studies have demonstrated an 
association between T2DM and a higher risk of cancer development, morbidity and 
mortality114, 157, 158.  The presence of insulin receptors and insulin-related growth 
factor-1 (IGF-1) on many cancer cells provides a biological rationale for a potential 
role of insulin on breast cancer growth, progression and poor survival outcomes112. 
Since insulin and its related growth factors are widely believed to be mitogenic, 
metformin has been proposed as an anticancer agent based on its ability to 
systemically reduce serum insulin levels.  Initially this was thought to be the main 
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mechanism of action of metformin against cancer, at least in diabetics. Further 
research has suggested a number of additional underlying potential mechanisms of 
action as summarised in Table 1.5. 
In contrast to the large reduction in the risk of liver159 and pancreatic160 
cancers development (60%–80%) reported by several meta-analyses, findings 
regarding breast cancer risk have been mixed.  Of interest, metformin-treated diabetic 
patients have been shown to have a lower risk of breast cancer153, 161 compared to 
their counterparts with diabetes who are non-metformin users, as well as better 
clinical outcomes than the diabetic breast cancer patients treated with other anti-
diabetic drugs161. On the other hand, some observational studies reported a non-
significant reduction in the risk of breast cancer in type 2 diabetic patients162, 163 
(Table 1.4). However, the observational nature and different comparison groups limit 
the interpretation of these studies164.  
The results of numerous epidemiological studies, although inconclusive, 
suggest that metformin use is associated a reduction in most cancer incidents in both 
pre-diabetics and diabetics and better outcomes in cancer patients. However, the 
variations in the response to metformin among breast cancer patients can possibly be 
attributed to the duration of treatment and the cumulative dose.  As the definite data 
on the efficacy of metformin in different subpopulations of breast cancer patients is 
currently largely lacking, it seems important to determine target populations. These 
observations also justify the need for clinical trials to evaluate the potential role of 
metformin in the prevention and treatment of breast cancer. 
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Table 1.4: Observational studies of metformin in breast cancer.  
Author/ 
Reference 
Sample size Study design 
(Endpoint) 
Relative risk 
(95%CI) 
Treatment 
comparison 
Currie et al. 165 n=373  
at risk=7897  
Retrospective 
cohort 
(Incidence) 
1.02 (0.71–
1.45); 
 
Metformin vs. 
sulfonylureas  
Libby et al. 150  n=771  
at risk=8170  
Retrospective 
cohort 
(Incidence and 
mortality) 
0.60 (0.32–
1.10); 
 
Metformin users 
vs. nonusers 
Bodmer et al. 153 n=17  
control= 120  
Retrospective 
nested case-
control 
(Incidence) 
0.44 (0.24–
0.82) 
Metformin users 
of more than 40 
prescriptions for 
> 5 years) vs. 
nonusers 
Bosco et al. 166  n=393  
control=3930 
Retrospective 
nested case-
control 
(Incidence) 
0.81 (0.63–
0.96) 
Metformin for at 
least 1 year vs. 
control 
Ferrara et al.167 n=9082  
at risk 
=252467  
Prospective 
cohort 
(Incidence) 
0.90 (0.80–
1.00); 
 
Ever use of 
metformin and 
pioglitazone vs. 
never use of 
metformin 
Morden et al.168 n=5466  
at risk 
=81681  
Retrospective 
cohort 
(Incidence) 
1.28 (1.05–
1.57); 
 
Metformin vs. not 
in insulin treated 
patients 
Chlebowski et al. 
80, 169  
n=233  
at risk 
=68019  
Prospective 
Cohort  
(Incidence) 
0.65 (0.46–
0.91) 
Metformin vs. 
other anti-diabetic 
drugs 
Ruiter et al. 170  n=3552  
at risk 
=85289  
Prospective 
cohort 
(Incidence) 
0.95 (0.91–
0.98); 
 
Metformin vs. 
sulphonylurea  
Van Staa et al.171   n=109708 
  
 
Retrospective 
cohort 
(Incidence) 
0.96 (0.83, 
1.12) 
 
Metformin vs. 
sulfonylureas, 
thiazolidinediones
, and insulin 
 
1.3.5. Pre-clinical studies with metformin in breast cancer 
A plethora of in vitro and in vivo studies evaluating the role and the 
mechanisms of metformin action in several cancers has emerged and several 
mechanisms have been proposed to explain its anti-neoplastic activity, although the 
exact mechanism remains to be elucidated (Summarized in table 1.5).  Metformin 
activity in vitro has been shown to involve most of the molecular subtypes of BC 
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regardless of their hormone-receptor or p53 statuses172, although not all BC cell lines 
respond, and the reasons why still need to be elucidated173 . 
In ER-expressing BC cell lines (around 75% of cases), metformin has been 
shown to inhibit cellular proliferation and suppress the expression of the aromatase 
gene in vitro, when it is present174. Metformin is also efficacious in reducing the 
proliferation of ER-positive BC cells when combined with tamoxifen175, which may 
be of specific benefit to premenopausal women. The mechanisms involved in the 
suppression of ER-expressing cell lines in vitro, are thought to be activation of the 
AMPK-pathway176, inhibition of the mTOR-pathway177, down-regulation of D1-
cyclin172, 173, caspase and polymerase-dependent cell death178, arrest of cell cycle at 
G1 phase179, induction of apoptosis and necrosis via oxidative stress and activation of 
FOXO3a, a conserved subfamily of proteins involved in tumour suppression via cell 
cycle arrest180. 
In HER-2 expressing BCs (15-20% of patients), both cell lines and mice 
models were sensitive to the growth repressive activity of metformin181, 182. An in vivo 
study has suggested a link between long term treatment of transgenic HER-2/neu 
mice with metformin and a significant reduction in the initiation and progression of 
mammary tumours as well as a reduction in the size of those that do form181. These 
data suggest that metformin could potentially be used as an adjuvant to the standard 
HER-2 targeting therapy such as Herceptin. Furthermore, this may provide one 
possible explanation for the differential response and resistance of different breast 
tumour sub-populations to metformin treatment, i.e. that metformin response is based 
on their HER-2 receptor status, a hypothesis that requires further investigation.  
In triple-negative BCs, which accounts for 30% of all BCs and represent a 
major challenge due to their lack of response to most current therapeutic agents, 
metformin has been shown to induce a response both in vitro and in vivo via AMPK-
dependent suppression of EGF-receptors, MAP-kinase signalling proteins, Cyclin 
D1152 and the metastasis-inducing CD24-protein183 or by dose-dependent activation of 
MAPK-p38 pathway, a significant regulator of the proliferation and invasiveness of 
BC cells in normoglycaemic but not in hyperglycaemic media 184.  
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Findings arising from mechanistic preclinical settings are mostly in favour of a 
potent broad-spectrum effect of metformin in most breast cancer subtypes and this 
effect is to a greater or lesser extent dependent upon the dose and the cell lines used.  
However, these studies are not without limitations and these limitations are discussed 
in section 1.3.7. 
The anticancer action of metformin is exerted through both direct (insulin-
independent) and indirect (insulin-dependent) actions of the drug (Figure 1.6). The 
insulin dependent (indirect) effect of metformin is reviewed in table 1.5.  
1.3.5.1 Direct anti-neoplastic effects of metformin  
The mechanisms involved in the direct anti-neoplastic effects of metformin 
are most likely very diverse. Data from preclinical studies with BC cell lines have 
established that anti-proliferative activity of metformin is mediated by up-regulation 
of AMP-activated protein kinase (AMPK) activity and downstream suppression of 
signaling through the mammalian target of rapamycin (mTOR)182, 185-190. Other 
proposed mechanisms include influences on cancer cell metabolism, cell cycle, 
apoptosis, estrogen biosynthesis and estrogenic signal transduction, all of which are 
reviewed in detail in table 1.5.  
AMPK is an important energy sensor which is triggered by intracellular 
metabolic stresses such as cellular hypoxia191, ischaemia192, glucose deprivation193 
and skeletal muscle contraction194, 195.  Metformin enters the cell via a cellular 
transporter and interrupts complex-I of the mitochondrial respiratory chain (the main 
target of metformin treatment), reducing ATP synthesis leading to increased cellular 
AMP:ATP ratio, thereby activating the AMPK pathway145. Consequently, AMPK 
down-regulates energy-consuming processes, such as protein synthesis and cell cycle 
progression196. Importantly, in cancer settings, metformin-induced AMPK-dependent 
suppression of breast152, pancreatic197 and colon cancer growth198 was demonstrated 
by recent in vivo studies. 
Upon activation of AMPK, the tuberous sclerosis complex 2 (TSC2), which is 
a protein located upstream of mTOR, is phosphorylated and stabilized thus inhibiting 
the tumorigenic effect of mTOR, a pathway thought to increase the risk of metastasis, 
poor outcomes and resistance to targeted therapies187, 189 (Figure 1.6).  Recent 
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evidence from in vitro BC studies suggest that the inhibition of mTOR signalling 
pathway is AMPK-dependent177, 199, however, metformin may also work directly on 
malignant cells by suppressing the mammalian target of rapamycin (mTOR) pathway 
independently of AMPK activation187, 189.    
Metformin can also activate the AMPK-pathway via a set of alternative 
upstream kinases including Liver kinase-B1 (LKB1)200 and Calcium/Calmodulin-
dependent kinase201.  The activation of AMPK seems to be mostly dependent on the 
major upstream LKB1; also known as serine-threonine kinase (STK11), which was 
previously identified as a tumour suppressor gene202.  The activation of LKB1-AMPK 
pathway results in inhibition and down-regulation of all the cellular energy 
consuming processes, which are vital for the growth and survival of all cells, such as 
protein synthesis, lipogenesis and hepatic gluconeogenesis. Therefore, the LKB1-
AMPK pathway activation is responsible for inhibition of anabolism and activation of 
catabolism195, 203 as well as changing gene and protein expression204, 205.  
Indeed, as already stated, in the liver, metformin has been shown to reduce 
hepatic gluconeogenesis, improve insulin sensitivity and decrease insulin level via the 
phosphorylation of AMPK and downstream inactivation of the mTOR transcription 
factor in an LKB1-dependent manner 206, whereas in cancer cells the activation of 
LKB1-AMPK causes cell cycle arrest207. As a tumour suppressor gene, absent or 
mutated LKB1 leads to the development of Peutz-Jeghers syndrome which 
predisposes to the development of several malignancies including breast and colon 
cancers202.  The reduced or absent expression of LKB1 was also associated with 
advanced histological grade and poor survival of BC patients208. A pioneer study by 
Zakikhani and colleagues reported a metformin-induced inhibitory effect on a panel 
of malignant epithelial cells including ovarian, cervical, breast and prostate but not 
the LKB1-deficient cervical cancer cells and this inhibition was linked to the 
phosphorylation of mTOR in an AMPK dependent manner 176. These data therefore 
suggest that metformin may work in an LKB1-dependent manner because it was 
ineffective against the LKB1- deficient cells.   
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Figure 1.6: The proposed direct (non-insulin mediated) and indirect (insulin 
mediated) effects of metformin in oncology.  
 Systemically/Indirectly, metformin reduces hepatic gluconeogenesis, increases 
glucose uptake by muscles, sensitizes tissues to insulin, and indirectly diminishes 
receptor tyrosine kinase activation and PI3K signalling. Within cancer cells/directly, 
metformin (1) Interrupts complex-I of the mitochondrial respiratory chain, leading to 
$ ATP synthesis, # cellular AMP:ATP ratio and stimulates LKB1/AMPK pathway. 
(2) Directly activates AMPK leading to stabilization of TSC2 and inhibition of mTOR 
signalling and protein synthesis.  (3) Activated AMPK also inhibits p53 and down-
regulates cyclin D1, thus arrests cell cycle progression. (4) Activated AMPK 
phosphorylates and inhibits acetyl-CoA carboxylase (ACC), thus decreases fatty acid 
synthesis and intracellular lipid contents. (5) Targets mTOR independently of AMPK. 
Solid Lines represent the activation reactions and dashed lines represent inhibitory 
reactions. ACC, Acetyl-CoA carboxylase; AMP, Adenosine monophosphate; AMPK, 
AMP-activated protein kinase; ATP, Adenosine triphosphate; EGF, Epidermal growth 
factor; IGF1, Insulin-like growth factor-1; LKB1, Liver kinase B1; mTOR, 
Mammalian target of rapamycin; PI3K, Phosphatidylinositol-3-kinase; TSC2, 
Tuberous sclerosis complex 2.  
 
 
 33 
Metformin was also reported as being able to suppress prostate cancer cell 
growth via suspending the progression of cell cycle at the resting phase and down-
regulating Cyclin D1 protein independently of AMPK-activation209.  Similar results 
have been reported on other cancer cell lines including glioma210, melanoma211, 
endeometrial212 and ovarian carcinoma213.  Conversely, cell cycle arrest in BC was 
reported to be AMPK-dependent173.  These data suggest that depending upon the 
cancer type and its molecular pathology, metformin can inhibit the growth of cancer 
cells both dependent on AMPK activation and independently of AMPK activation. 
Moreover, the genetic constitution and particularly the metabolic characteristic of the 
different cancers should be considered to be important variables that might also 
contribute to the mechanism of metformin action, and to the treatment efficacy.  
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Table 1.5: Proposed mechanisms of anti-neoplastic effect of metformin (direct and indirect) 
Proposed mechanism of 
metformin action 
Studies/references  
1. Metformin alters 
circulatory insulin 
levels 
 
(Indirect or insulin- 
mediated action) 
Metformin is known to inhibit hepatic gluconeogenesis, thereby improving tissue sensitivity to insulin, thus reducing the level of 
circulating insulin and overcoming insulin resistance214.  It is possible that this mechanism of action may also be indirectly anti-
tumorigenic as a growing body of evidence has demonstrated a link between increased expression of insulin/insulin-like growth factors 
receptors by most cancer cells and the accelerated proliferation of these transformed cells in response to the stimulatory effect of 
insulin157, 215.  Thus, reducing circulatory insulin is expected to suppress the insulin-mediated mitogenesis and inhibit the proliferation of 
cancer cells. Hyperinsulinemia can also reduce the hepatic production of the circulating sex hormone-binding globulins and increased 
androgen synthesis by ovaries and adrenal glands216. Therefore, increased circulating insulin can indirectly increase the bioavailability of 
oestrogen, which in turn, participates in the development of hormone-dependent malignancies such as breast and endometrial cancers110. 
Thus the reduction in insulin levels caused by metformin may specifically be important in preventing the development of these cancer 
types. 
2. Metformin affects 
cancer cell metabolism 
 
Although data are sparse, at least one epidemiological study has reported hyperglycaemia as a risk factor for cancer 
development111, and although the link is not clear, it could be due to allowing the rapidly dividing cancer cells to consume glucose 
at an accelerated rate.  Therefore, the anti-hyperglycaemic effect of metformin cannot be excluded as a possible anti-neoplastic 
mechanism. In addition to the anti-glycaemic effect, emerging data from recent studies suggest a role of metformin as a negative 
modulator of lipid metabolism within the cancer cells in an AMPK-independent manner217, 218.  This effect might be considered as 
a new prospective strategy in preventing cancer development and progression110. 
3. Metformin effect on 
cancer stem cells 
 
 
 
 
 
 
 
 
Interestingly, in addition to its effects on the general cancer cell population, some data has suggested that metformin has a specific effect 
on cancer stem cells (CSCs).  Cancer stem cells are a genetically distinct subpopulation of cancer cells responsible for treatment 
resistance and recurrence after definitive therapy, thus inhibiting them is a distinct therapeutic advantage219, 220.  The treatment of a BC 
xenograft mouse model with metformin specifically eliminated the CD44+/CD24-/low CSCs and sensitized the tumour cells to 
doxorubicin, resulting in reduced tumour burden and delayed tumour recurrence221. In the same context, metformin has been shown to 
work effectively with other chemotherapeutics such as paclitaxel and carboplatin to reduce tumour growth and prevent recurrence and to 
lower the required dose of the standard chemotherapeutics and improve their efficacy222. Moreover, in HER2-overexpressing tumours, 
metformin was able to target the Herceptin-resistant CSCs223. A possible proposed mechanism of metformin mediated inhibition of 
tumour-initiating stem cells is the reduction of transcriptional factors such as TGF-β cytokines as these factors are the key drivers of 
epithelial to mesenchymal transition (EMT)224.  
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Table 1.5: Continued (Legend on previous page) 
4. Metformin effects on 
cell cycle and apoptosis 
The downstream result of activating the AMPK pathway may lead to cytotoxic, apoptotic or cytostatic effects dependent upon the dose 
of metformin and the cancer cell type.  One recent in vitro study173 suggested that metformin may have alternate effects on different BC 
cells, and reported that some BC cell lines underwent apoptosis in response to metformin treatment (T47D and MCF7) while others 
remain viable and resistant to metformin for up to 14 days of treatment (MDA-MB-453, BT474 and MDA-MB-231).  In metformin-
responsive cells, treatment causes significant, concentration-dependant suppression of cell proliferation with G1 cell cycle arrest, and 
this has been seen in both ER-positive and ER-negative cell lines, although the authors didn’t establish why some cells responded and 
others didn’t179. An in vivo study225 then went on to combine metformin with a chemotherapeutic drug, Paclitaxel, demonstrating that 
when they are in combination, they synergistically inhibit the cell cycle at the DNA-damage checkpoint (G2-M), induce apoptosis and 
reduce tumour burden in severe combined immunodeficient (SCID) mice inoculated with either human MCF-7 BC cells or A549 lung 
cancer cells. In both studies these effects were mediated by the activation of AMPK and inhibition of mTOR signalling pathway.  
5. Metformin effect on 
p53 gene      
 
Several studies suggested that p53 status might be important to metformin activity. p53, is a tumour suppressor gene which tends to be 
mutated or absent in many cancers which is an extremely important determinant of cellular fates, as it is involved in regulation of cell 
cycle and DNA-repair226. Up on activation, p53 pathway can induce AMPK-mediated reversible cell cycle arrest at the glucose-
dependent checkpoint of the cell cycle, which can be reversed upon restoration of normal metabolic conditions, unless AMPK-
stimulation persists in which case it leads to apoptotic cell death226, 227. However, data from mechanistic studies of metformin and p53 
are contradictory.  Although both breast and prostate cancer cells (MCF7 and LNCaP) with functional-p53 were sensitive to the anti -
proliferative effect of metformin in vitro173, 176, 209; the p53-functional cells were as sensitive as the p53-null cells in the same studies. 
Conversely, metformin treatment resulted in selective toxicity and apoptosis-induced activity in colorectal p53-defiecient cells; both in 
vitro and in vivo198.  
6. Metformin effect on 
sex hormones and 
aromatase  
 
Metformin has been shown to reduce the bioavailability of circulating oestrogen and androgens in BC patients.  This action was 
achieved by counteracting the inhibitory effect of insulin on the hepatic synthesis of sex-hormones binding globulins and reducing 
insulin-mediated activation of cytochrome P450 enzyme; responsible for androgen synthesis228.  In addition, two studies have reported 
an AMPK-dependent inhibition of aromatase gene in the adipose stromal cells of the human breast in response to metformin174, 229.  This 
inhibition was influenced by metformin and occurs selectively in breast adipose tissue without suppressing the adrenal glucocorticoids 
synthesis.  
7. Metformin alters 
intracellular pathway 
regulators 
Metformin impairs signalling molecules for cancer survival such as the AMPK which signals to numerous proteins involved in cell 
survival and cell death (Reviewed in section 1.3.5.1) 
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1.3.6 Clinical trials with metformin in breast cancer 
It is not really surprising that enthusiasm for repurposing metformin for use in 
breast cancer clinical trials is continuously growing, based on the evidence presented from 
epidemiological and preclinical studies, the safety, tolerability, favourable toxicity profile, 
and manageable side effects in addition to its current worldwide use by huge number of 
diabetic patients (120 million worldwide)124.  The most recent data suggest metformin has a 
wide spectrum of clinical usefulness for breast cancer ranging from disease prevention, 
neoadjuvant, adjuvant and extended adjuvant (beyond 5 years), as well as use in advanced 
disease settings230.  Moreover, advanced breast cancer clinical trials combining metformin 
with established anticancer agents are under way or proposed.  
In neoadjuvant chemotherapy settings, a remarkable complete pathologic response 
effect among diabetic metformin users has been reported231.  Data from prospective trials 
using the standard diabetic dose of metformin in non-diabetic cancer patients have also 
emerged and are promising. For example, a novel pre-operative trial randomized the 
participants for 2 weeks of metformin treatment pre-operatively in primary operable non-
diabetic BC patients. It was the first study to evaluate both in vivo and systematic effect of 
metformin in BC cases, and reported a significant reduction in Ki-67, a marker of tumour 
proliferation232, suggesting longer treatment may result in tumour shrinkage, alongside 
reduced serum insulin levels233.  Similarly, other neoadjuvant monotherapy trials have 
reported proliferation-inhibitory and apoptosis-stimulatory effects in non-diabetic patients 
newly diagnosed with early BC234.  These studies relieved part of the major concerns that 
the protective and therapeutic effects of metformin might be seen only in presence of 
metabolic derangement.  
Unsurprisingly, as metformin is known to affect insulin, fasting insulin level has 
also reported to be reduced by 22.4% (P=0.024) when metformin is administrated to non-
diabetic patients with non-metastatic disease, an effect which is believed to improve the 
outcome and lower the risk of disease recurrence by modifying the growth-stimulatory 
effect of insulin on tumour cells142.  
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Similarly, in non-diabetic patients with BC, metformin was able to reduce the 
circulating levels of oestrogen, androstenedion and testosterone, hormone parameters 
known to be associated with recurrence of BC228, 235. Table 1.6 summarizes metformin 
trials in non-diabetic BC patients published to date.  Overall, these pre-operative window 
studies in breast cancer demonstrate that metformin is safe for women with primary BC 
and confirm the attraction of metformin as a therapeutic agent. 
However, all of the clinical trials to date have assessed the serum metabolic markers 
as well as markers of intratumoral proliferation (Ki67) and/or apoptosis (TUNEL), using 
immunohistochemistry. Of note, there is now only one ongoing study that uses functional 
imaging to assess the intratumoral pre- and post metformin pharmacodynamics in addition 
to evaluating the metabolic serum markers236. The preliminary results of this study 
suggesting that metformin can directly target cancer cells metabolism by inhibiting fatty 
acids oxidation and altering mitochondrial gene expression, therefore, providing an 
important novel insight to the direct effect that metformin might have on breast cancer cells 
in clinical settings237.  
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Table 1.6: Metformin trials in non-diabetic breast cancer patients  
Author/Reference  Enrolment and study 
population 
Setting Metformin 
dosing 
Effects of metformin on metabolic and 
immunohistochemical markers 
Goodwin et al. 142, 238  (1) 22 early BC patients: 
insulin>45mmol/L 
 
(2)  3649 treated early BC 
patients 
Adjuvant 500 mg three times for 
6 months 
850 twice for 5 years 
(results recorded after 
6 months) 
Metformin treatment significantly reduced the weight 
and blood variables including, insulin, glucose, leptin, 
and CRP at six months. Effects did not vary by baseline 
BMI or fasting insulin. 
Hadad et al. 233, 239  (1)  8 operable IBC 
(2)  47 operable IBC 
Neoadjuvant 
window 
500 mg once a day for 
a week, then 1000 mg 
twice for another 
week  
No significant change in serum insulin.  5.1% reduction 
in the proliferation marker Ki67, decrease in 
phosphorylated Akt and increase in phosphorylated 
AMPK. 
Bonanni et al.240 
Cazzaniga et al.241  
200 operable BC 
 
Neoadjuvant 
window 
850 twice for 4 weeks Metformin treatment significantly reduced glucose, 
total cholesterol and CRP with trend toward decreased 
insulin if BMI>27. 10.5% reduction in the proliferation 
marker Ki67, reduced IGFBP-3. No effect on TUNEL. 
Kalinsky et al.242 35 obese/overweight 
invasive BC or DCIS 
versus matched untreated 
control 
Neoadjuvant 
window 
500 mg am 
1000 mg pm for 2-4 
weeks 
Metformin treatment significantly reduced the weight 
and blood variables including, total cholesterol, leptin, 
and trend toward decrease insulin and adiponectin with 
no significant change in glucose or IGFBP-3. 
Niraula et al.234 
Dowling et al.156 
39 operable BC 
 
Neoadjuvant 
window 
500 mg three times a 
day for 13-40 days  
Metformin treatment significantly reduced the weight 
and blood glucose level. No significant change in 
insulin, leptin and CRP. 3% reduction in the 
proliferation marker Ki67 and 0.5% increase in TUNEL. 
Reduction of phosphorylated Akt, AMPK and ACC. 
ACC, Acetyl-CoA reductase,; AMPK, AMP-activated protein kinase; IBC, Invasive breast cancer; BMI, Body mass index; CRP, C-reactive protein, 
DCIS, Ductal carcinoma in situ; IGFBP-3, Insulin –like growth factor-binding protein 3, TUNEL, Terminal deoxynucleotidyl transferase dUTP nick 
end labelling. 
 39 
1.3.7 Limitations of preclinical models, and translational challenges 
As previously mentioned, not all BC cell lines responded to metformin 
treatment either in vitro or in vivo studies, and as yet it is not clear why some respond 
while others don’t.  Despite that concern, it is clear that metformin does have a great 
impact on BC growth both directly and indirectly. However, much of the in vitro 
work published to date suffers a number of methodological limitations as follows.  
1.3.7.1 Therapeutic concentrations and clinically relevant doses of metformin 
It is of crucial importance when seeking to characterize the pre-clinical effects 
of metformin to distinguish between its therapeutic and supra-therapeutic 
concentrations. Although metformin has now been available for over 50 years, there 
is still no clear definition of its “therapeutic concentrations”; which has resulted in 
huge variation between the concentrations used in different studies. This is due to lack 
of studies that would measure and relate dose efficacy to corresponding plasma 
metformin concentrations in long-term treated patients. The dose efficacy here is 
considered to be in terms of blood glucose control. 
A recent systematic analysis of therapeutic metformin doses used in pre-
clinical studies identified 120 publications that cited 65 different concentrations and 
ranges of therapeutic plasma level of metformin.  Surprisingly, the vast majority of 
these studies (116 publications) have not directly established the therapeutic 
concentrations of the drug and therefore cited previous publications that have not 
cited a supporting reference when referring to the therapeutic concentrations they 
used243. It is noteworthy that except four studies, none of the 116 studies performed so 
far were designed to identify the therapeutic concentration for metformin.  
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Pharmacokinetic parameters are the most reliable criteria to define the 
therapeutic concentrations of metformin i.e. the plasma steady state level achieved by 
the prescribed long-term multiple-dosage regimen. Therefore, the use of a parameter 
such as the maximum plasma concentration (Cmax), which is the peak value obtained 
after administration of a single metformin dose, is conceptually flawed and non-
reliable243.  
Given the aforementioned pitfalls, questions have been raised about the safety 
and relevance of metformin concentrations utilised in the pre-clinical studies and 
whether they are of use in clinical practice. A recent review has already drawn attention 
to the fact that much of the in vitro and in vivo preclinical work published to date 
involved the use of a wide range of extremely high, supra-pharmacological and non-
physiological concentrations of metformin (5-50 mM) which are greatly exceeding the 
feasible recommended clinical dose (2.5 g/day) and far in excess of those doses featured 
in the epidemiological studies and therefore may not translate directly into clinical 
practice156 (Figure 1.7). 
 
 
Figure 1.7: Doses of metformin used in preclinical and clinical studies.  
Most of the population-based studies and clinical trials have featured standard 
pharmacological doses of metformin (up to 2.5 g/day). The vast majority of the 
preclinical studies have utilised extremely high concentrations exceeding 45-1000 fold 
(in vivo and in vitro, respectively) of the recommended therapeutic levels in humans.  
 
 
Clinical 
studies 
Pre-clinical 
studies 
In vivo studies (750mg/kg/day) 
=(2-45-fold)  
In vitro studies (2-50mM) 
=(25-1000-fold)  
Clinical trials and epidemiological 
studies  
Up to 2.5g/day 
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To date, only four original research studies have assayed the plasma 
concentrations of metformin in diabetic subjects and determined a therapeutic 
concentration in long term well-tolerated metformin treatment244, 245 as well as in 
patients with chronic kidney disease246 and in steady state without lactic acidosis129. 
Despite the fact that metformin concentration within tumour tissues has never been 
determined, the clinically relevant doses of metformin were calculated based on a 
consensus in the normal therapeutic and toxic plasma concentrations reported in 
diabetic subjects by these 4 different references 244, 247-249. These concentrations were in 
the range of 4 mg/L up to 40 mg/L respectively. By dividing these concentrations by 
the molecular weight of metformin (129.2 g/mol), a range of 0.03-0.3 mM was obtained 
(normal-to- associated with serious toxicity) that can be considered as 
pharmacologically relevant doses.  However, it has been reported that metformin tissue 
concentrations are 10-20 folds higher than plasma concentrations due to its tendency to 
accumulate in peripheral tissue such as salivary gland, small intestine, stomach, colon, 
liver and kidney and liver; in an in vivo study using diabetic mouse250. Therefore, some 
in vitro studies have gone further and considered 2-8 mM as relevant human therapeutic 
concentrations173, 251, 252. In this thesis, the range of 1-5 mM was considered as potential 
tissue accumulated dose of metformin. 
 
1.3.7.2 Metformin uptake, accumulation and export by cancer cell  
Another important factor for a proper understanding of the cellular uptake, 
intracellular accumulation, excretion and the optimum dosing required to achieve a 
strong inhibitory effect on BC cells, is to explore metformin transport into different 
subtypes of BC cells. This can be achieved by investigating the expression of different 
candidate transporters by BC cell lines (OCT1-3, PMAT and MATE1-2). The potential 
presence and role of these carrier proteins in BC settings should be explored further, as 
this may also provide a further insight into the differential responses of BC cell lines to 
metformin treatment and help to identify a useful in vitro model to assess the anticancer 
effect of metformin in breast cancer (Figure 1.8).  
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Figure 1.8: Requirements of the direct effect of metformin on tumour cells, 
compared to the indirect effect.  
This is a schematic representation of the suggested hypothesis of metformin uptake and 
excretion by cancer cells. It also highlights the importance of using an adequate drug 
concentration that can accumulate in the tumour cell and achieve the anti-cancer effect.  
 
1.3.7.3 Outstanding questions in preclinical and clinical settings  
Despite extensive work on the preclinical effects of metformin on breast cancer 
cell lines, certain questions still remain which include:  
§ How does metformin enter and leave breast cancer cells? 
§ Is there an altered expression of metformin transporters during the progression from 
normal breast tissue into various disease states? 
§ Will the suggested clinically relevant doses of metformin inhibit breast cancer 
proliferation and/or cause cell cycle arrest? 
§ Are there any specific subtypes of breast cancer that respond more than others? 
§ Can metformin help prevent or treat metastatic dissemination of breast cancer, for 
example, to the bone and lung?  
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Clinical trials with metformin as a treatment for BC are still in early phases, and 
a number of unanswered questions still persist. For example, which cancer subtype is 
the most promising target, which population should be targeted, and what should 
metformin be combined with? Equally it is important to look for possible synergy with 
other clinically useful chemotherapeutics to evaluate whether metformin can work as a 
radio- or chemo-sensitizer.   
In the preventative BC clinical trial settings, it is still not clear which tumour 
subtype is likely to benefit more from metformin prevention strategy, which population 
subsets should be targeted in the chemoprevention strategy (diabetics, non-diabetics, 
pre- or postmenopausal women), what is the best time to start the chemoprevention 
strategy, what is the best dose and for how long should the treatment last.  
With regard to the mechanisms of metformin’s action, some unanswered 
questions are:  (A) Is the anticancer effect attributed to its indirect (anti-diabetic), direct 
or both effects; (B) Are hyperinsulinemia and metabolic disturbances required for the 
effectiveness of metformin; (C) Which of the direct effects reported in vitro with the 
supra-pharmacological concentrations is most relevant clinically; (D) Is AMPK 
activation required in both tumour and hepatic tissues to elicit the anti-proliferative 
effect of metformin; and (E) What pharmacokinetics and pharmacodynamics factors 
might contribute to the tissue distribution and the anticancer activity of metformin. 
Despite these continuing questions, there is no doubt that metformin has some 
advantages over the current chemotherapeutic regimes as it is non-toxic and has 
extensive anti-proliferative activity against most of the molecular subtypes of BC. 
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1.4 Project’s hypothesis and aims 
Based on the emerging reports on the potent antitumor activity of metformin in 
various experimental models of hormone-sensitive breast cancers, this PhD project aims 
to test the hypothesis that:   
“The anti-tumour effect of clinically relevant doses of metformin (0.03-0.3mM) 
depends on breast cancer subtype and the presence of metformin transporters on 
breast cancer cells” 
  
To date, data on the effect of the pharmacologically relevant doses of metformin 
on breast cancer is extremely limited and therefore our aims are: 
 
▪ Firstly: To explore the expression of several metformin transporters in a panel 
of increasingly transformed breast cell lines and diverse molecular subtypes including, 
non-transformed, hyperplastic ductal epithelial, in situ ductal carcinoma, luminal A 
(ER+, HER-2-), triple-negative (ER-, PR-, HER-2-) and metastatic bone-seeking cell 
lines.  
   
▪ Secondly: To assess the direct anticancer effect of metformin at clinically 
relevant concentrations against our 2D in vitro model of breast cancer progression 
represented by the panel of increasingly transformed breast cell lines and relate this to 
the expression of metformin transporters.  
 
▪ Thirdly:  To investigate the potential anti-metastasis effect of metformin in 
breast cancer by identifying protein changes in response to metformin using global 
proteomic analysis, and determining whether these changes differ between the wild-type 
triple negative, bone- and lung-homed breast cancer cells. 
 
By combining proteomic and molecular biology approaches, this project will 
provide an exciting opportunity to advance our knowledge and understanding by 
offering an important translational insight to the potency and effectiveness of clinically 
relevant doses of metformin, the key players of its transport in breast cancer as well as 
effects of metformin on specific phenotypic changes in breast cancer metastasis.
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2. Chapter 2: Materials and methods 
2.1 Materials    
All reagents and equipment are listed in alphabetical order 
Table 2.1: General materials listed with suppliers  
Material Supplier 
Ammonium Per Sulphate (APS) Bio-Rad Laboratories Ltd., UK 
Ammonium Bicarbonate Sigma-Aldrich, Poole, Dorset, UK 
Antigen Retrieval Solution (citrate buffer) Dako, Barcelona, Spain 
Bovine Insulin  Sigma-Aldrich, Poole, Dorset, UK 
Cholera Toxin Sigma-Aldrich, Poole, Dorset, UK 
Deionised Water Millipore-QTM Water Purification system 
Developing Solution AGFA, Mortsel, Belgium 
Dimethyl Sulphoxide (DMSO)  Sigma-Aldrich, Poole, Dorset, UK 
1,4-Dithiothreitol (DTT) Sigma-Aldrich, Poole, Dorset, UK 
Dulbecco’s Modified Eagle’s Medium 
(DMEM) 
Lonza, Slough, UK 
Dulbecco's Modified Eagle Medium; 
Nutrient Mixture F-12 (DMEM/F12) 
Lonza, Slough, UK 
Epidermal Growth Factor (EGF) PeproTech EC Ltd., London, UK 
Ethanol Fisher Scientific, Loughborough, UK 
Ethidium Bromide  Sigma-Aldrich, Poole, Dorset, UK 
Fetal Bovin Serum (FBS) Biosera, Ringmer, UK 
Films Amersham HyperfilmTM  ECL, UK 
Filter Paper, Gel Blot Paper GE Healthcare, UK 
Fixing Solution AGFA, Mortsel, Belgium  
Formic Acid Sigma-Aldrich, Poole, Dorset, UK 
Haematoxylin Fisher Scientific, Loughborough, UK 
Horse Serum  Sigma-Aldrich, Poole, Dorset, UK 
Hydrocortisone  Sigma-Aldrich, Poole, Dorset, UK 
Industrial Methylated Spirit (IMS) Fisher Scientific, Loughborough, UK 
Iodoactamide (IAA) Sigma-Aldrich, Poole, Dorset, UK 
L-glutamine  Sigma-Aldrich, Poole, Dorset, UK 
Laemmli Sample Buffer  Sigma-Aldrich, Poole, Dorset, UK 
MEGMTM Mammary Epithelial Cell 
Growth Medium  
Lonza, Slough, UK 
MEGMTM Cell Growth Medium 
Supplement Mix 
Lonza, Slough, UK 
Methanol Fisher Scientific, Loughborough, UK 
Methylene Blue  Sigma-Aldrich, Poole, Dorset, UK 
Nuclease-Free Water  Qiagen, Hilden, Germany 
Penicillin/Streptomycin Invitrogen, Paisley, UK 
Phosphate Buffer Saline (PBS) Lonza, Slough, UK 
Precision Plus ProteinTM Standard Bio-Rad Laboratories Ltd., UK 
Propidium Iodide staining solution (PI) Sigma-Aldrich, Poole, Dorset, UK 
Protease Phosphatase Inhibitor Cocktail  Sigma-Aldrich, Poole, Dorset, UK 
46 
 
Pure Water Sigma-Aldrich, Poole, Dorset, UK 
Ribonuclease A From Bovine Pancreas  Sigma-Aldrich, Poole, Dorset, UK 
RIPA Buffer, Cell Lysis Buffer Fisher Scientific, Loughborough, UK 
Roswell Park Memorial Institute 1640             
(RPMI 1640) Medium 
Lonza, Slough, UK 
Sequencing Grade Modified Trypsin Promega, Southhampton, UK 
SDS-PAGE Running Buffer Sigma-Aldrich, Poole, Dorset, UK 
Stripping Buffer Sigma-Aldrich, Poole, Dorset, UK 
Trypan Blue  Life Technologies, Paisley, UK 
Trypsin (0.05%)/EDTA (0.02%) Sigma-Aldrich, Poole, Dorset, UK 
TBS-Tween 20x Fisher Scientific, Loughborough, UK 
2.1.1 Commercial kits 
Table 2.2: Commercial kits and suppliers 
Commercial Kits Supplier 
Brdu Cell Proliferation ELISA Kit  Abcam, Cambridge, UK 
3,3-Diaminobenzidine (DAB) Substrate  Vector Labs, Peterborough, UK 
Ez-PCR Mycoplasma Test Kit Geneflow Ltd, Litchfield, UK 
High Capacity RNA-To-cDNA Kit Applied Biosystems, Life Technologies, 
Paisly, UK 
MEMGtm Bulletkit Lonza, Slough, UK 
Pierce™ BCA Protein Assay Kit Fisher Scientific, Loughborough, UK 
Rnase-Free Dnase Set  Qiagen, Hilden, Germany 
Rneasy Mini Kit Qiagen, Hilden, Germany 
Vectorstain Elite ABC Kit Vector Labs, Peterborough, UK 
 
2.1.2 Equipment  
Table 2.3: Items listed with suppliers  
Equipment Supplier 
0.2µm Sterile Filters Merck Millipore, Nottingham, UK 
1.8ml Cryo.Stm Cryogenic Tubes Greiner Bio-One Ltd., Stonehouse, UK 
20µl Microloader Tips Eppendorf UK Limited, Stevenage, UK 
15 And 50ml Universal Tubes Sarstedt, Leicester, UK 
6, 12 and 24 Well Tissue Culture Plates Nunc Ltd., London, UK 
25, 75 And 175 Cm2 Tissue Culture 
Flasks 
Greiner Bio-One Ltd., Stonehouse, UK 
96 Well Plate Cole-Parmer, Hanwell, UK 
348 PCR Plate Sigma-Aldrich, Poole, Dorset, UK 
ABI Prism 7900HT Sequence Detection 
System 
Applied Biosystems, Life Technologies, 
Paisley, UK 
Antigen Retriever (Pressure Cooker) Aptum, Southampton, UK 
Biopettetm Variable Volume Pipettes Gilson Inc., Middleton, USA 
Cellquestprotm Software Becton Dickinson, San Jose, USA 
Centifuges Sanyo and Harrier 18/80 
Concentrator Plus Eppendorf UK Limited, Stevenage, UK 
DNA Engine DYADTM Thermal Cycler Bio-Rad Laboratories Ltd., UK 
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Electrophoresis System Bio-Rad Laboratories Ltd., UK 
Flustar Galaxy Microplate Reader BMG LABTECH, London, UK 
Freezer  -20 from REV`ECO, -80 from SANYO 
Grant JB Series Water Bath Wolflabs, UK 
Heat Block Hybride Thermal Reactor, UK 
Ice Machine  Ziegra Eis machine, Stockport, UK 
Immedgetm Hydrophobic Barrier Pen  Vector Labs, Peterborough, UK 
Microamp Optical Adhesive Film Life Technologies, Paisley, UK 
LSRII Cell Sorting Instrument BD Bioscience, London, UK 
Laminar Flow Hood (Class II) Walker Safety Cabinet Ltd., UK 
Minifuge And Microfuge Tubes  Sarstedt, Leicester, UK 
‘Mr.Frosty’ Freezing Container  Nalgene, New York, USA 
Nanodrop© Lite Spetrophotometer Nanodrop Technologies, Wilmington, 
USA  
Nikon Eclipse TS 100 Inverted 
Microscope 
Nikon Uk Ltd., Surrey, UK 
Pierce C-18 Spin Columns Sigma-Aldrich, Poole, Dorset, UK 
Pipettes Tips (P2-P1000) Sarstedt, Leicester, UK 
Powerpactm HC Power Supply  Bio-Rad Laboratories Ltd., UK 
Q Exactive™ HF hybrid quadrupole-
Orbitrap mass spectrometer 
Thermo Scientific, Bremen, Germany 
Shaker Stuart, Staffordshire, UK 
Stirrer Stuart, Staffordshire, UK 
Vortex VWR , Lutterworth, UK 
 
2.1.3 Cell culture media 
The components of all media used for cell culture are summarised in the 
following tables. Once prepared, all media were stored at 40C.  
Table 2.4: MCF10A, MCF10AT and DCIS.com cells growth medium  
Component  Growth Medium Resuspension 
medium 
Dulbecco's Modified Eagle 
Medium/Nutrient Mixture F-12  
(DMEM/F12) (1x) 
469 ml (93.8%) 400 ml 
Horse Serum 25 ml (5% final) 100 ml (20% 
final) 
Epidermal Growth Factor (EGF)  
(100 µg/ml stock) 
100 µl (20 ng/ml final) -- 
Hydrocortisone (1 mg/ml stock) 250 µl (0.5 µg/ml final) -- 
Cholera Toxin (1 mg/ml stock) 50 µl (100 ng/ml final) -- 
Insulin (10 mg/ml stock) 500 µl (10 µg/ml final) -- 
Penicillin/Streptomycin (100x 
solution) 
5 ml (100 IU/ml penicillin 
and 100 µg/ml streptomycin) 
5 ml 
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Notes:  
1. All additives were re-suspended in sterile dH2O; aliquoted and stored at -200C, 
except the hydrocortisone, which was re-suspended in absolute ethanol. 
2. All the appropriate additives were premixed and sterile filtered through a 0.2 µm 
filter before adding to the DMEM/F12 medium.  
3. This medium contains 17.4 mmol/l of glucose, 2 mM L-glutamine and 0.049 uM L-
asparagine monohydrate. 
4. In order to reduce the variability within the experiments, the Mammary Epithelial 
Cell Growth Medium (MEGM)TM Bulletkit containing necessary supplements (Table 
2.5) was used as the assay medium for MCF10A, MCF10AT and DCIS.com cells. 
Table 2.5: MCF10A, MCF10AT and DCIS.com cells assay medium  
Component  Growth Medium Resuspension 
Medium 
Mammary Epithelial Basal Medium 
(MEBM) 
500 ml 400 ml 
Bovine pituitary extract (BPE) 2 ml (5% final) 100 ml (20% final) 
Human Epidermal Growth Factor 
(hEGF) 
500 µl (20 ng/ml final) -- 
Hydrocortisone 500 µl (0.5 mg/ml final) -- 
Human Insulin 500 µl (10 µg/ml final) -- 
Gentamicin sulphate (30 mg/ml) 
Amphotericin-B (15 mg/ml) 
5 ml 5 ml 
50 µl of 100 ng/ml Cholera toxin was added separately to the medium; not provided by 
the kit.  
 
Note: This is the “Mammary Epithelial Cell Growth Medium (MEGM)TM Bulletkit”, 
which contains 15.49 mmol/l of glucose, 2 mM L-glutamine and 0.049 mM L-
asparagine monohydrate. 
 
 
Table 2.6: MCF7, T47D, MDA-MB-231, MDA-MB-231(BM) and HepG2 cell 
culture and assay medium 
Component  Growth Medium 
Roswell Park Memorial Institute 1640 (RPMI 1640) 
medium without L-Glutamine (1x)* 
440 ml (88% final) 
Foetal Bovine Serum 50 ml (10% final) 
L- Glutamine (200 mM) 5 ml (2 mM final) 
Penicillin/Streptomycin 
 (100x solution) 
5 ml (100 IU/ml penicillin and 
100 µg/ml streptomycin) 
*RPMI1640 without L-glutamin formulation contains 15.49 mmol/l of glucose.  
Note: For the MTS assay, RPMI-1640 medium without phenol red was used which 
contains 15.49 mmol/l of glucose and 0.37 mM L-asparagine monohydrate. 
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Table 2.7: MDA-MB-231(LM) cell culture and assay medium 
Component  Growth Medium 
Dulbecco's Modified Eagle Medium (DMEM) 
with L-Glutamine (1x)* 
445 ml (89% final) 
Foetal Bovine Serum 50 ml (10% final) 
Penicillin/Streptomycin 
 (100x solution) 
5 ml (100 IU/ml penicillin and 100 
µg/ml streptomycin) 
*DMEM formulation contains 15.49 mmol/l of D-glucose, 2 mM of L-glutamine and no 
L-asparagine monohydrate.  
2.1.4 Quantitative polymerase chain reaction (qPCR) primers 
Table 2.8: Metformin-transporters validated All-in-One™ qPCR Primers ID and 
sequences (GeneCopoeia) 
Gene Name Primer ID Primers Sequence  
SLC22A1 NM_003057.2 
Catalog number: 
HQP017490 
Forward: TCCCTGTGTGACATAGGTGGG 
Reverse: CAACACCGCAAACAAAATGAGG 
SLC22A2    NM_003058.2 
Catalog number: 
HQP017493 
 
Forward: GACATTGGTGGCATCATCAC 
Reverse: CTCGATGGTCTCAGGCAAAG 
SLC22A3 NM_021977.2 
Catalog number: 
HQP017492 
Forward: AACCATGGCCTTTGAAATTG 
Reverse: GCCGAAAGAGCAGAAATGG 
SLC29A4 NM_001300847.1 
Catalog number: 
HQP071320 
 
Forward: CCATCGCCGTGACCTACTTC 
Reverse: GGATCTTGCCCACGAAGTCT 
SLC47A1  
 
NM_018242.2 
Catalog number: 
HQP014217 
Forward: TAAACAACGTGCCTCGGAGT 
Reverse: GGCAAAGGTTCTTCTTGGCG 
SLC47A2  NM_001099646.1 
Catalog number: 
HQP058785 
Forward: TGAGATCGGGAGCTTCCTCA 
Reverse: GAGCCCCAAGGGAATCATGT 
*GAPDH  
 
NM_002046.3 
Catalog number: 
HQP006940 
Forward: GTGGACCTGACCTGCCGTCT 
Reverse: GGAGGAGTGGGTGTCGCTGT 
*GAPDH was used as an endogenous control 
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2.1.5 Commercial human tissue slides 
Table 2.9: Tissue microarray slides used in this project 
Slide used Details Supplier 
Beast cancer tissue 
array with 
progressive changes 
A breast disease tissue array containing 48 
cases from normal, premalignant and cancer 
tissues with progressive grades and stages. 
Abcam 
(ab178111) 
Breast common 
disease array of 102 
cases 
A breast disease tissue array containing 102 
cases of normal breast, fibrocystic changes, 
proliferative breast diseases (atypical) and 
various types and stages of breast cancers. 
Abcam 
(ab178113) 
Kidney (human) 
normal tissue slides 
Normal human kidney tissue sections used as a 
positive control for some transporters. 
Abcam 
(ab4347) 
 
2.1.6 Antibodies   
Table 2.10: Primary antibodies  
Antibody   Details Dilutions used Product code and 
Supplier 
Anti-SLC22A1 
(OCT1) 
Polyclonal raised in 
rabbit 
Western 
Blot:1:1000 
IHC: 1:200 
Sigma-Aldrich 
(AV41516)  
Anti-SLC22A2 
(OCT2) 
Polyclonal raised in 
rabbit 
Western Blot: 
1:500 
IHC: 1:200 
Abcam 
(Ab198800) 
 
Anti-SLC22A3 
(OCT3) 
Polyclonal raised in 
rabbit 
Western Blot: 1:50 
IHC: 1:100 
Abcam 
(Ab183071) 
Anti-SLC29A4 
(PMAT) 
Polyclonal raised in 
mouse  
Western Blot: 
1:200 
IHC: 1:100 
Abcam (Ab56554)  
Anti-SLC47A1 
(MATE1) 
Polyclonal raised in 
rabbit 
Western Blot: 
1:200 
IHC: 1:100 
Abcam 
(Ab104016) 
Anti-SLC47A2 
(MATE2) 
Polyclonal raised in 
rabbit 
Western Blot: 1:50 
IHC: 1:100 
Abcam (ab106117) 
Anti-STAT3   Rabbit monoclonal Western Blot:  
1:250 
Abcam (ab68153) 
(EPR787Y) 
Anti-PBR 
 
Rabbit monoclonal Western Blot: 
1:10,000 
Abcam (ab109497) 
(EPR5384) 
Anti-TNFAIP8 Rabbit monoclonal Western Blot:  
1:1000 
Abcam (ab195810) 
(EPR10058(3)) 
Anti-GRB2 Rabbit monoclonal Western Blot:  
1:5000 
Abcam (ab32037) 
(Y237) 
Anti-Calmodulin Rabbit monoclonal Western Blot:  
1:250 
Abcam (ab45689) 
(EP799Y) 
Anti Beta-actin Mouse monoclonal  Western Blot: 
1:10000 
Sigma-Aldrich 
(A2228) (AC-74) 
IHC: immunohistochemistry 
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Table 2.11: Secondary antibodies 
Antibody  Details  Supplier Dilutions used  
Anti-mouse IgG-
horseradish 
Peroxidase (HRP)  
Polyclonal raised 
in goat 
Vector Labs,  
PI-2000 
Western Blot: 
1:1000 
Anti-mouse 
biotinylated IgM 
Polyclonal raised 
in goat 
GE healthcare, 
NA931V 
IHC: 1:200 
Anti-rabbit IgG-
horseradish 
Peroxidase (HRP)  
Polyclonal raised 
in goat 
Dako, P0448 Western Blot: 
1:2000-1-20000 
 
Anti-rabbit 
biotinylated IgM 
Polyclonal raised 
in goat 
Vector Labs, BA-
1000 
IHC: 1:200 
IHC: immunohistochemistry 
2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Cell lines     
MCF-10A cell line; is most commonly used in vitro model for studying normal 
breast cell function and transformation. These cells are non-tumorigenic, do not express 
oestrogen receptor, derived from benign proliferative breast tissue (from a patient with 
fibrocystic disease) and spontaneously immortalized after extended cultivation in low 
calcium concentrations253. Purchased from the American Type Culture Collection 
(ATCC® CRL-10317™).  
MCF-10AT cell line; is a model for the evolution of cancer from proliferative 
breast disease, obtained from Dan Arbour institute, USA. Implantation of MCF10AT 
cells in mice gives rise to lesions resembling usual ductal hyperplasia (UH) and atypical 
ductal hyperplasia (ADH) over 12-16 week periods. Therefore, the MCF-10AT cell line 
is considered to represent the pre-malignant stage of breast cancer254.  
DCIS.com cell line; a model of malignant precursor cells; is a clonal breast 
cancer cell line originating from premalignant MCF10AT cells that were injected into 
severe immune deficient mice leading to lesions predominantly resembling ductal 
carcinoma in situ, with further progression to invasive carcinoma (IC) after 9 weeks255. 
DCIS.com cells were obtained from Karmanos institute, USA. 
Three breast cancer cell lines were chosen to represent different breast cancer 
subtypes and aggressiveness, namely MCF7 (ATCC® HTB-22™), T47D (ATCC® 
HTB-133™) and MDA-MB-231 (ATCC® HTB-26™) cell lines, which were purchased 
from the ATCC. Both MCF7 and T47D are classified as luminal A, while MDA-MB-
52 
 
231 is classified as triple negative, highly metastatic cells (Table 2.12).  
The MDA-MB-231(BM) and MDA-MB-231(LM) cells are the metastatic 
variants of the human breast cancer cell line MDA-MB-231 which either home to the 
bone (BM) or lungs (LM) when administered intravenously to nude mice, whereas the 
‘parental’ MDA-MB-231 cells do not. They were generated by injecting the MDA-MB-
231 cells into the tail vein of nude mice then collecting either the bone or lung 
metastatic cells which were then expanded in culture and re-injected into the tail vein, 
and the process repeated.  Once the cells have been passaged through the mice 7 times, 
the cells are fully bone and lung seeking and will establish bone and lung metastases, 
respectively, when injected into the tail vein256, 257. These cells were a kind gift from 
Professor Janet Brown.  
Table 2.12: Classification and characteristics of the invasive breast cancer cell lines 
used 
Cell line Immuno-
profile 
p53-
status 
Classification Tumour type and origin 
MCF7 ER+, PR+, 
HER2– 
Wild 
type 
Luminal A Well differentiated, invasive 
ductal carcinoma, derived 
from pleural effusion from 
patient with adenocarcinoma  
T47D ER+, PR-, 
HER2-   
 
Mutant  Luminal A Differentiated, infiltrating       
ductal carcinoma, derived 
from pleural effusion from 
patient with ductal carcinoma 
MDA-
MB-231 
ER-, PR-, 
HER2- 
Mutant Claudin-low, 
Triple 
negative 
Least differentiated, 
adenocarcinoma, derived from 
pleural effusions from patient 
with adenocarcinoma 
 
HepG2; human-derived hepatocellular carcinoma cell line was used as a 
positive control for OCTs and MATEs receptors expression in the qRT-PCR and 
Western blot experiments. These cells were a kind gift from Dr Karen Sisley.  
MCF-10A, MCF-10AT and MCF10DCIS.com cell lines were cultured in 
advanced DMEM/F12 medium with additional supplements as stated in (Table 2.4). 
MCF7, T47D, MDA-MB-231 and MDA-MB-231(BM) cell lines were cultured in 
supplemented RPMI-1640. MDA-MB-231(LM) cell line was cultured in supplemented 
DMEM medium. The morphology of the premalignant, pre-invasive, invasive and 
metastatic cells is shown in figure 2.1. 
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2.2.1.2 Mycoplasma testing of cell lines       
Routine mycoplasma testing of the cell lines was carried out shortly after their arrival into 
the laboratory and at six-month intervals thereafter. It is noteworthy that no short tandem 
repeat (STR) analysis was performed in this study as most of the human breast cell lines 
used were purchased from ATCC (MCF10A, MCF7, T47D and MDA-MB-231). 
 
Figure 2.1: Microscopic appearance of the cell lines utilized. 
All are 60-70% confluent, at 10x magnification. Scale bar represents 100 μm. 
 
2.2.1.3 Routine cell culture 
All the equipment and solutions were sterile and all the cell culture work was performed in 
a class II laminar flow hood using aseptic techniques. The cabinets were switched on and 
off at least 15 minutes before and after the completion of any work, to allow the air to 
circulate. The cabinets were also cleaned thoroughly with industrial methylated spirit (IMS) 
prior to and following each usage. All cell lines were grown as a monolayer in T75 cm2 
flasks and incubated in a humidified atmosphere at 37oC and 
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5% CO2 in a LEEC incubator. The cultures were monitored on a day-to-day basis to 
make sure that the cells kept growing and were free of contamination. The cells were 
fed with the appropriate full growth media every 48 hours. Upon achievement of 70-
80% confluence, cells were sub-cultured as described below.  
2.2.1.4 Cell subculture 
The cells were routinely passaged upon reaching 70-80% confluence.  The spent 
media in the flasks was discarded and the cell monolayers were washed twice with 10 
ml of phosphate buffered saline (PBS) without calcium and magnesium, to remove any 
residual serum that would block the trypsin action. The PBS was aspirated and 
discarded and then 1-3 ml of pre-warmed 0.05% trypsin in 0.02% EDTA solution was 
added followed by 2-5 minutes incubation at 370C and 5% CO2 to detach the cells from 
the surface of the culture flask. A longer period of incubation of up to 20 minutes was 
necessary to detach the extremely adherent MCF-10A, MCF-10AT and DCIS.com cells 
from the surface of the flask.  To ensure that all cells had detached, the flasks were 
observed under a light microscope and if not, the side of the flask was tapped sharply to 
disrupt the large clumps and release the cells. Once detached, 5-7 ml of fresh media was 
added to neutralize the trypsin activity with extensive pipetting up and down to 
disaggregate all cell clumps in the flask. The mixture was then pelleted by 
centrifugation at 150 x g for 5 minutes. The supernatant was discarded and the cell 
pellet re- suspended in 5 ml of complete media. 0.5-1 ml of the cell suspension was 
added to 10ml of fresh media in T75 flask to generate a split ratio of 1:5-1:10 depending 
on the growth rate of the different cell lines, and maintained as previously described. 
When it was important to generate cells at 70% confluent by a particular date, cell 
counting was performed as described in section 2.2.1.7 and cells seeded at a specific 
number per flask instead of simply using a split ratio. 
2.2.1.5 Cryopreservation of cell culture stocks  
Frozen stocks were prepared using cells at less than 80% confluence, in the Log 
phase of the growth curve. Cells were washed twice with PBS and trypsin added. The 
recovered cells were pelleted in 10ml of relevant media by centrifugation at 800 x g for 
5 minutes. The cell pellet was re-suspended at a concentration of 5x105 cell/ml in a 
solution of the relevant media and dimethyl sulphoxide (DMSO). A mixture of 
DMEM/F12 with 20% FBS and 10% DMSO was used for the normal, pre-malignant 
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and pre-invasive cells. For the invasive and metastatic cells, a solution of 20% DMSO 
in FBS was utilised. 1ml aliquots of cell suspension were added to the cryovials and 
placed in a styrofoam rack (Mr. Frosty) at -800C for 24 hours before being transferred 
for long-term storage in liquid nitrogen.    
2.2.1.6 Retrieval of stored cells    
The previously stored cryovials were thawed rapidly from liquid nitrogen in a 
370C water bath. Cells were spun down at 5000 x g for 5 minutes to remove DMSO 
from the media and then gently re-suspended in 5 ml pre-warmed appropriate full 
growth media and transferred into T25 flasks and kept at 370C. The medium was 
changed to fresh medium the following day. When 70-80% confluent, cells were 
transferred to a T75 flask and cultured by passage as normal.   
2.2.1.7 Cell counting 
Following trypsinization and centrifugation at 1000 x g for 5 minutes (as 
described in section 2.2.1.3), cells were re-suspended in 0.5-5 ml of media. 10 µl was 
taken from each suspension tube and thoroughly mixed with 10 µl of 0.4% trypan blue 
solution (1:1). 10 µl of this mixture was pipetted into one side of the dual-chamber 
counting slide of the TC20™ Automated Cell Counter. Dead cells take up trypan blue; 
therefore this machine detects the % viability, total number of cells and the number of 
viable cells. TC20™ Automated Cell Counter automates the widely used trypan blue 
cell exclusion assay and has replaced the historical cell viability determinations that 
were manually performed using a light microscope and haemocytometer. This 
technique enables accurate, reliable and rapid cell counting.  
2.2.2 Preparation of metformin 
A stock solution of 1 molar of metformin (MW: 165.6) was freshly prepared and 
diluted in purified water prior to each experiment following this formula: 
Mass (g) = Concentration (mol/L) X Volume (L) X Formula Weight (g/mol) 
The stock solution was then serially diluted to a final volume of 10 ml of full 
growth medium per each concentration, as detailed in Figure 2.2.  
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Figure 2.2: Serial dilutions of 1 molar metformin stock solution.  
 
2.2.3 Quantitative real time polymerase chain reaction (qRT-PCR) 
The expression of transporters potentially involved in metformin-uptake by 
breast cells was studied at the mRNA level using quantitative real time PCR (qRT-
PCR). HepG2 cells were used as a positive control for the transporter proteins 
investigated. The protocol of qRT-PCR was carried out for genes of interest in duplicate 
at least three times on ABI Prism 7900HT sequence detection system. The qRT-PCR 
assay is based on measuring the fluorescence using SYBR Green as a fluorescent 
reporter molecule. The first cycle at which the amplification fluorescence generated is 
called the “Ct” or threshold cycle. The fluorescence intensity increases proportionally 
with each amplification cycle in response to the increased target concentration, and the 
numerical value of the Ct is inversely related to the amount of target in the reaction (i.e. 
the lower the Ct, the greater the amount of target)258.  
2.2.3.1 RNA extraction 
Total RNA from the cultured breast cells was extracted using an RNeasy™ Mini 
Kit and RNAse-free pipette tips according to manufacturer’s instructions. The 
RNeasy™ protocol relies on the properties of RNA binding to silica at different salt and 
buffer conditions and is a column (silica) based extraction technique where the 
guanidine isothiocyanate (GITC) is used to lyse cells and denature proteins, RNases and 
DNases.  
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The cells are first collected by gentle trypsinization using 0.25% trypsin EDTA, 
counted, centrifuged and collected as a cell pellet. Approximately 1x106 cells were then 
lysed in 350 µl of RLT buffer (guanidine isothiocyanate containing lysis buffer), which 
immediately deactivated the RNases, and the sample was homogenized using a 21-
gauge needle and 1ml syringe. 350 µl of 70% ethanol was then added to the 
homogenized sample, to provide optimal RNA-binding conditions, and mixed 
thoroughly by inversion. The lysate was then transferred to a silica-based total RNA 
capture spin column, which was centrifuged at 8000 x g for 15 seconds. The RNAeasy 
silica membrane selectively excludes short RNA molecules of <200 nucleotides and 
thus provides enrichment for mRNA.  
To remove contaminants, 700 µl of the guanidine salt containing washing buffer 
(RW1) was applied to the spin column and centrifuged at 8000 x g for 15 seconds, 
followed by two applications of 500 µl of the RPE buffer to remove any excess traces of 
salt using the same process. The RNA was then eluted into a fresh 1.5 ml reaction tube 
by adding 50 µl nuclease free water and centrifuged at 8000 x g for 1 minute and 
collected. The extracted RNA was then either used immediately or stored at -80°C until 
required. 
2.2.3.2 Assessment of RNA yield and quality  
The quantity and quality of extracted RNA was determined using a Nanodrop 
Lite spectrophotometer. A ratio of ~1.9-2.1 of sample absorbance at 260/280 nm was 
considered pure for RNA samples. 1 µl of sample volume was used to analyse the 
concentration and the purity of the extracted RNA and then a concentration of 50 ng/µl 
was used for the reverse transcription reaction for all cell lines.  
2.2.3.3 Reverse transcription polymerase chain reaction (RT-PCR) 
In order to ensure that any potential genomic DNA contamination was removed 
from the samples prior to complementary DNA synthesis (cDNA), RNAse-free DNAse 
set was used. 50 µl of RNA sample was incubated with 1 µl DNAse I and 5 µl of the 
RNAse-free DNAse 10x reaction buffer for 30 minutes at 37°C. The DNAse reaction 
was terminated by the addition of 5 µl of the stop solution (inactivation enzyme) and 
left for 10 minutes at room temperature.   
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Complementary DNA (cDNA) synthesis was then performed using the High-
Capacity cDNA Reverse Transcription Kit, following the supplier’s instructions. The 
RT-PCR reaction was started by the addition of the RNA template (50 ng in 10 µl) to a 
20 µl reaction mixture of random hexamer primers, reverse transcriptase buffer, dNTP 
mix, RNase inhibitor and MultiScribe reverse transcriptase (Table 2.13). To ensure that 
subsequent PCR amplification was derived from RNA and not genomic DNA or other 
contaminants, a no-RT control (no reverse transcription) was included in every reverse 
transcription experiment259. All components were added into thin-walled 0.5 ml reaction 
tubes on ice. The tubes were then placed in a thermal cycler and the RT-PCR 
programme initiated using the following conditions: 25°C for 10 minutes, 37°C for 120 
minutes, 85°C for 5 minutes and finally kept at 4°C until collected. The yield and 
quality of cDNA synthesized was determined using a Nanodrop Lite spectrophotometer. 
A ratio of ~1.8 of sample absorbance at 260/280nm was considered pure for cDNA 
samples. 
Table 2.13: Components of the reverse transcription master mix  
Reagents Final volume (per 
20-µL reaction) 
Description 
Nuclease-free H2O 4.2 µl For dilutions 
MultiScribe™ Reverse 
Transcriptase, 50 U/µl 
1 µl RNA–dependent DNA polymerase 
which uses single-stranded RNA as a 
template to generate a cDNA strand 
10x RT Buffer, 1.0 ml  2 µl Obtains higher yield of cDNA 
10x RT Random 
Primers, 1.0 ml 
           2 µl 
(0.5 µg/µl) 
Produces short cDNA fragments that 
would convert mRNA to cDNA 
25x dNTP Mix (100 
mM) 
0.8 µl 
(0.5 µg/µl) 
Contains premixed aqueous solutions 
of dATP, dCTP, dGTP and dTTP, 
Extracted RNA  50 ng - 
Total           20 µl 
 
2.2.3.4 Primers validation 
The manufacturer has experimentally validated each of our All-in-One™ qPCR 
primers to yield a single dissociation curve peak and to generate a single amplification 
of the correct size for the targeted gene. Therefore, the primers were not further 
validated.  
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2.2.3.5 Quantitative polymerase chain reaction (qPCR) 
Cycling was performed using ABI 7900HT Thermal Cycler under the following 
conditions: 1x hotstart (enzyme activation) at 95°C for 10 minutes followed by 40 
cycles of amplification: 95°C for 10 seconds (denaturing, causes the intertwined DNA 
strands to separate), 60°C for 20 seconds (annealing, allows the primers to anneal to the 
template of interest), and finally 72°C for 15 seconds (extending, optimal temperature 
for Taq polymerase function). At the end of the last cycle, the temperature was 
increased from 72 to 95°C to produce a melting curve. After completion of the 
amplification cycles, the DNA synthesized can be analysed or used as required. The 
following is a typical reaction mix for qPCR: 
 
The 10 µl reaction mix was transferred into a standard 384-well reaction plate, 
which was then sealed with an optical adhesive film, briefly centrifuged at 2000rpm for 
2 minutes using Sovrall Legend X1 centrifuge and then loaded into the Real-Time PCR 
system.  
2.2.3.6 Data analysis  
The threshold cycle (Ct) values were automatically determined by the ABI 
7900HT PCR system. Relative quantification was used to evaluate the transcript 
expression levels for each respective gene by normalising to GAPDH (∆Ct sample). The 
∆Ct values were calculated using the following equation and these values were 
compared between samples being analysed:  
∆Ct sample = Ct gene of interest– Ct GAPDH gene  
 
 
 
 
 
Reagents Final volume (per 10µL reaction) 
Nuclease-free H2O 3 µl 
SYBR green 5 µl 
Primers                1 µl (0.2 µM) 
cDNA sample 1 µl 
Total 10 µl 
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2.2.4 SDS-PAGE and Western Blot 
To explore the differences in the expression of potential metformin-transporters 
between all cell lines, in an attempt to investigate why they respond differently to 
metformin treatment, cell lysates were collected for Western blot analysis. HepG2 cells 
were used as a positive control for the transporter proteins investigated.  
Western blotting is a widely used analytical technique to detect the presence of 
specific cytoplasmic or cell surface proteins in cell extracts.  It involves several steps 
including sample preparation, sample loading, electrophoresis, protein transfer, antibody 
incubation, and signal detection (Figure 2.3). 
 
 
Figure 2.3:The scheme of Western blot.  
After preparation, the samples are loaded onto the gel and proteins are separated by 
SDS-PAGE according to their molecular weights, and then transferred to a membrane. 
The target protein can be specifically detected using a highly selective primary 
antibody. A secondary antibody can then recognise the primary antibody. In the 
presence of a soluble enzyme substrate, the reaction can be detected by the emitted 
chemiluminescent light (This figure produced using Servier Medical Art: 
http://www.servier.com/Powerpoint‐image‐bank). 
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2.2.4.1 Preparation of cell lysis buffer 
Prior to the preparation of fresh lysis buffer, all stock solutions were kept on ice. 
1 ml of ice-cold radioimmunoprecipitation buffer (RIPA) was mixed with 10 µl of the 
halt protease phosphatase inhibitor cocktail to make up a 1 ml solution (1:100 dilution) 
and kept on ice. The RIPA buffer contains: 5 M NaCl, 0.5 M EDTA (pH 8.0), 1 M Tris 
(pH 8.0), Nonidet P-40 (NP-40), 10% sodium deoxycholate and 10% SDS. 1 ml of 
freshly prepared buffer was used to lyse and extract protein from 106-107 cells.   
2.2.4.2 Preparation of cell extract  
Cell lysis was performed to recover cellular proteins whilst removing cell debris. 
Cells were initially cultured to 70-80% confluence and then cells were incubated in 
serum free media for 24 hours to avoid any cross reactivity between the FBS and the 
antibodies of interest. Cell extracts were generated by discarding the serum free media 
from the flask, washing the cells twice with 10 ml of cold PBS followed by removal of 
the residual PBS to prevent dilution of the final protein extraction and then addition of 1 
ml lysis buffer to each flask. The flasks were placed on ice for 10 minutes with 
continuous movement to allow the lysis buffer to detach the cells from the flask surface. 
A cell scraper was used to scrape any remaining cells off the flask surface thus ensuring 
all the cells were in suspension. The collected cells were then pipetted into pre-labelled 
eppendorf tubes. 25-gauge needles and 1ml syringes were used to suck the suspension 
up and down 10 times to break up the cells, disrupt the cell membranes and release the 
proteins into the solution. Cells were then incubated on ice for 30 minutes in order for 
full lysis to occur and then centrifuged for 10 minutes at 4oC at 17,900 x g to pellet the 
cell debris. The supernatant containing proteins was transferred into a fresh tube and 
stored at - 80oC ready for quantification and usage.  
2.2.4.3 Protein quantification with bicinchoninic acid protein assay 
The bicinchoninic acid protein assay is a colorimetric assay, which enables 
quantification of the protein concentrations in cell lysates. Under alkaline conditions, 
Cu+2 will be reduced into Cu+1 by the proteins. This reduction can be detected by 
bicinchoninic acid, which is highly sensitive and selective for Cu+1.  The reaction 
produces an intense purple colour with an absorbance at 562 nm. The relationship 
between the absorbance and the protein concentration in each sample is almost linear 
allowing determination of unknown protein concentrations from a standard curve. The 
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standard BSA (2 mg/ml) stock solutions were prepared with bovine serum albumin 
(BSA) and diluted to make a final concentration of 0.2 mg/ml (100 µl stock to 900 µl of 
the sample diluent, RIPA buffer). This solution was used to generate different standards 
at known concentrations as shown in Table 2.14. 
Table 2.14: Preparation of different concentrations of protein standards of BSA 
and dH2O.  
The BSA protein standards range from (0-20 µg/ml). From the BSA stock solution (2 
mg/ml) initially a 1:10 dilution with dH2O was performed to obtain a 200 µg /ml stock 
for use in the dilutions shown in the table.  
Standard (µg/ml) BSA (µl of 0.2mg/ml 
working stock)  
dH2O (µl) 
0 0 1000 
2.5 12.5 987.5 
5 25 975 
7.5 37.5 962.5 
10 50 950 
15 75 925 
20 100 900 
 
Cell extracts were assayed for protein concentration prior to SDS-PAGE and 
Western blot, to ensure equal loading of protein/cell line to each well. Protein samples 
from all cell lines were prepared by diluting them into 1ml of dH2O using three different 
dilutions for each cell line to ensure that the absorbance was in the range of the BSA 
standard curve. The BCA working reagent was prepared by mixing 25 parts of reagent 
A (Alkaline tartrate-carbonate buffer), 24 parts of reagent B (Bicinchonic acid  solution) 
and 1 part solution C (Copper sulphate solution) (2.5 ml, 2.4 ml and 0.1 ml 
respectively).  The BCA working reagent was mixed thoroughly until it was light green 
in colour. 
150 µl of the BSA standard and unknown protein sample at different dilutions 
were added in to flat-bottomed 96-well plate in triplicates. 150 µl of BCA working 
reagent was added to each well. The plate was then incubated for 2 hours at 37°C and 
the absorbance read at 562 nm using plate reader spectrophotometer. Linear regression 
analysis was performed using Prism 7.0 software to determine the concentrations of 
protein samples from the BSA standard curve (Figure 2.4) 
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Figure 2.4: BCA standard curve example. The thick line is the linear regression 
curve for the entire set of standard BSA points.  
Absorbance values of unknown samples are then interpolated onto the plot or formula 
for the standard curve to determine their concentrations (performed automatically using 
Graphpad Prism 7 software).  
 
2.2.4.4 Sample preparation and loading 
Samples were prepared by mixing 1 volume of the 2X Laemmli gel-loading 
solution and 1 volume of the protein sample and heating at 950C for 10 minutes. The 2x 
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2.2.4.5 Protein Electrophoresis (SDS-PAGE)  
After protein quantification and sample preparation, proteins were separated 
using gradient pre-cast gels (4-20% Mini-PROTEAN® TGXTM) on a Bio-Rad Mini-
Protean 3 electrophoresis system. The predicted molecular weights for all the 
transporters investigated were between 50-65kDa.  After careful removal of the comb, 
the plate was then placed in the gel running apparatus, making sure that the shorter plate 
was placed towards the centre of the tank, and the tank filled with 1X running buffer (25 
mM Tris-base, 192 mM glycine, 20% methanol) until the wells were covered. The wells 
were rinsed out to ensure that they were free of any loose bits of acrylamide that would 
interfere with clean running of the samples. 20 µg of sample was added to each well, 
and 10 µl of the pre- stained protein marker was loaded in the first well as a reference. 
The gel was run at 100 V initially to allow the proteins to go through the stacking gel 
and then the voltage was turned up to 150 V for about 90 minutes until the tracking dye 
ran off the bottom. 
2.2.4.6 Western blot  
Following the SDS-PAGE, the proteins were then transferred to a PVDF 
membrane using a semidry blotter (Trans-Blot Turbo Transfer System, Biorad). The 
plates were removed from the gel running apparatus and opened carefully. The stacking 
gel was then removed from the resolving gel, which was subsequently washed 2 times 
in transfer buffer for 10 minutes. To create the transfer sandwich, a PVDF membrane 
was cut to suitable size (6.5X8.5 cm2) and activated by placing in 100% methanol for 5 
minutes. The membrane was then rinsed in transfer buffer for another 5 minutes and the 
corner of the membrane was cut for orientation. Four pieces of filter paper were also 
soaked in transfer buffer for 2 minutes. The transfer sandwich (from the bottom to the 
top: 2 filter papers, PVDF membrane, gel, 2 filter papers) was loaded onto the semi-dry 
blotter cassette with air bubbles rolled out at every step (Figure 2.3). For efficient 
transfer, the machine was run for 7 minutes at 2.5 A; up to 25 V; using the pre-
programmed Bio-Rad protocol for mixed molecular weight proteins (5-150 kDa).  Once 
transfer had been confirmed by checking the molecular weight markers had transferred 
onto the membrane, the membrane was incubated in blocking solution (5% non-fat milk 
in 0.05% TBS-Teen) at room temperature for 1 hour to prevent non-specific binding of 
the antibodies. Following blocking, the relevant primary antibody, diluted as previously 
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stated in blocking solution, was added and incubated overnight at 4oC with gentle 
agitation (about 16 hour). The next morning, the membrane was washed three times for 
10 minutes with 0.05% TBST to remove any residual antibodies. 10 ml blocking 
solution containing an appropriate dilution of the relevant horse radish peroxidase 
(HRP) secondary antibody was then placed on the membrane and incubated for 1 hour 
at room temperature, followed by a further three 10 minutes washes with TBST.         
2.2.4.7 Chemiluminescence development 
In the dark room under red light, the membrane was covered with 1ml of the 
enhanced chemiluminescence (ECL) blotting substrate for 5 minutes. The excess ECL 
was discarded and the membrane was wrapped in plastic and placed in a hypercassette 
container. A piece of film was placed over the membrane and exposed for a time 
ranging between 30 seconds and 1 hour depending on the band intensity. Once exposed, 
the film was placed in developing solution with a gentle rocking motion until bands 
were visible. The membrane was then washed in water before placing in the fixer 
solution for 30 seconds to avoid overdevelopment and then washed 5 times in tap water 
and allowed to dry. The exposure time, which is the most important parameter during 
membrane development, was carefully optimised for each antibody to avoid the risk of 
overexposure and/or underexposure, both of which can lead to inaccurate 
quantification.  
2.2.4.8 Stripping and re-probing of membranes 
Following confirmation of protein expression, the membrane was stripped using 
the stripping buffer, to ensure that the primary and secondary antibodies were removed, 
and re-probed for β-actin, which was used as a loading control.  Loading controls such 
as β-actin are required to check that the lanes have been evenly loaded with equal 
quantities of sample, and to ensure proteins are transferred from the gel to the 
membrane with equal efficiency, in order to enable direct comparison of protein 
expression levels between different samples. Beta actin belongs to the actin family of 
proteins, which are expressed in all cell types and involved in cytoskeleton structure and 
muscle contraction. The β-actin sequence is highly conserved and identical across 
species (e.g human, mouse, rabbit), and the relative levels of β-actin are similar between 
different epithelial and cancer cells260.   
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In order to probe for β-actin, after development, the membrane was placed in a 
dish and rinsed with PBS. On a gentle shaker, 5 ml of stripping buffer was added to the 
membrane and kept for 15 minutes at room temperature, to allow the release of the first 
set of probes (i.e. the primary and secondary antibodies) from the membrane. Different 
proteins can now be detected using a second set of specific probes i.e. β-actin. The 
membrane was removed from the stripping buffer and washed 3 times with TBST and 
incubated in 10ml of blocking buffer for an hour at room temperature with shaking. The 
blocking buffer was removed and the membrane was given 3 washes of 10 minutes each 
with TBST. The TBST was discarded and 10ml of the blocking solution containing 1µl 
of anti-β-actin antibody was added and incubated for 2 hours. Afterwards, the 
membrane was washed 3 times for 10 minutes with TBST before the addition of the 
secondary antibody and incubated for 1 hour at room temperature. Following this, the 
membrane was again washed in TBST (4 X 5 minutes) and the expression of β-actin 
established following the membrane development protocol detailed in Section 2.2.4.7. 
2.2.4.9 Analysis of Western blot  
To allow semi-quantitative comparison of protein expression between various 
cell lines and antibodies used, the intensity of the detected bands were calculated as a 
proportion of the relevant β-actin band using ImageJ software; a densitometer 
programme. This allows direct comparison as well as confirming equal loading of the 
protein in the wells. Each of the detected protein bands was represented as a peak, the 
signal of which is proportional to the amount of the protein loaded.  
2.2.5 Immunohistochemical staining for metformin-transporters expression in a 
breast tissue microarray 
2.2.5.1 Principles of immunohistochemistry  
The technique of immunohistochemistry was used to study the expression of 
metformin-transporters in a human breast tissue microarray with progressive changes 
from normal, premalignant and cancer tissues with progressive grades and stages. 
Immunohistochemistry (IHC) is the process of using antibodies to detect antigens 
(proteins) in cells within a tissue section. Therefore this method is used to localize 
specific antigens with labelled antibodies based on antigen-antibody interactions. The 
antibody-antigen binding can be visualized by using an enzyme such as horseradish 
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peroxidase (HRP), which is commonly used to catalyse a colour-producing reaction 
(Figure 2.5). 
 
Figure 2.5: Principles of immunohistochemistry.  
When the horseradish peroxidase (HRP) system is applied for IHC, activation of 
endogenous peroxidases enzymes should be blocked by H2O2 to avoid producing non-
specific binding. The HIER is implemented to breaks the methylene bridges and 
exposes the epitope to allow subsequent binding to the specific antibodies. The 
unlabelled primary antibody binds to the antigen on the tissue section. The Labelled 
secondary antibody binds to the primary antibody. The enzyme attached to the 
secondary antibody acts as a substrate to deposit a coloured product where the antigen is 
located. H2O2; Hydrogen peroxide, HIER; heat-induced epitope retrieval, DAB; 3-
Diaminobenzidene tetrahydrochloride, ABC; avidin–biotin enzyme complex (This 
figure produced using Servier Medical Art: http://www.servier.com/Powerpoint‐image‐
bank). 
 
2.2.5.2 Protocol for immunohistochemistry 
The breast tissue microarrays (TMAs) were stained for the presence of 
metformin-transporters (Table 2.15). Prior to staining, the slides were baked at 600C for 
30 minutes in an oven, deparaffinised to remove the embedding wax and then 
rehydrated. The slides were dewaxed by immersion in 2 changes of xylene for 5 min 
each. Tissues were then rehydrated by immersion in absolute ethanol twice, then 
transfer once through 95%, 70% ethanol respectively for 3 minutes each. 
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Table 2.15: Total number of breast tissue cases from TMA slides used in this 
project  
Tissue type Number of cases 
Normal Tissue 34 
Fibrocystic Disease 12 
Atypical Ductal Hyperplasia (ADH) 11 
Ductal Carcinoma in situ (DCIS) 13 
Invasive Ductal Carcinoma Grade I (IDC-I) 9 
Invasive Ductal Carcinoma Grade II (IDC-II) 38 
Invasive Ductal Carcinoma Grade III (IDC-III) 7 
 
Following rehydration, blockade of endogenous peroxidases was achieved by 
incubating the slides for 30 minutes in 3% hydrogen peroxide (H202) in methanol at 
room temperature. Following incubation, the slides were washed in running water for 5 
minutes. To unmask the antigenic epitope, heat-induced epitope retrieval (HIER) took 
place using the citrate buffer method as follows. 100ml of sodium citrate buffer (10 mM 
sodium citrate, 0.05% Tween 20, pH 6.0) was poured onto the pre-arranged slides in the 
slide rack and incubated at 120 °C in a pressure cooker for 5 minutes. The slides were 
allowed to cool inside the antigen-retrieval solution for 2 hours. This was followed by 
three rinses in TBST of 5 minutes each, with gentle agitation at room temperature.   
To block any non-specific proteins, the tissue slides were incubated for 30 
minutes in 200 µl of blocking solution, consisting of 10% goat serum and 10% casein 
diluted in PBS. At the end of the incubation period, the excess fluid was drained and 
either a negative control or a primary antibody was added to the slides. 2% of blocking 
solution in 200 µl of PBS was applied to negative control slides. An appropriate dilution 
of primary antibodies (Table 2.10) was added to 2% blocking solution in 200 µl of PBS 
and applied to the relevant slide and incubated overnight at 40C.  
The following morning, slides were rinsed for 5 minutes in TBST 3 times with 
gentle agitation.  200 µl of the relevant biotinylated secondary antibody diluted in 2% 
blocking solution and PBS was then added to each slide and incubated for an hour at 
room temperature. While the secondary antibody incubated, the VECTASTAIN® 
avidin–biotin enzyme complex (ABC kit) solution was prepared and left to stand for an 
hour at room temperature. The solution is made up of 2 drops of reagent A and 2 drops 
of reagent B in 5 ml of PBS. 200 µl of this solution was added to each slide and 
incubated for 30 minutes after the secondary antibody had been washed off the slides 
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using three five minute washes of PBS as before. Excess fluid was then removed and 
further 3 rinsing steps in TBST were undertaken.  
The 3-Diaminobenzidene tetrahydrochloride (DAB) substrate was then added to 
the slides. This solution is made up of 2 drops of buffer solution, 4 drops of DAB 
solution, 2 drops of H2O2 in 5ml of ddH2O. Within 10 minutes of adding DAB, slides 
were examined under the light microscopy to assess colour development. Once the 
brown staining could clearly be seen the slides were rinsed in gently running water for 5 
minutes to terminate the actions of the DAB solution.  
Slides were then counterstained by immersion in a bath of Gill’s haematoxylin 
for one minute to stain the nuclei. Again, the slides were rinsed in gently running water 
until the run-off water was clear. The tissues were then dehydrated through 5 changes of 
alcohol (70%, 95%, 95%, 100% and 100%) by incubating for three minutes in each.  
The final step of dehydration was performed by 2 changes of xylene for 5 minutes each. 
Finally, coverslips were secured to the stained tissue slides by using the DPX mounting 
solution. The mounted slides can then be permanently stored at room temperature. 
2.2.5.3 Analysis of immunohistochemical staining 
For the analysis of immunohistochemical staining, various human tissue sections 
were used as a positive control (Table 2.16). The quality control for the staining of all 
tissue sections was provided by Dr. P. Vergani; consultant histopathologist at Royal 
Hallamshire Hospital. A combined score of intensity and percentage of staining was 
performed and the staining was considered positive if greater than 10% of breast 
epithelium was stained brown261. The staining was subjectively scored in order to semi-
quantify the data (Figure 2.6). Based on the intensity of staining from light to dark 
brown the scores were given as the following: 
0= no Staining,  1= weak Staining,  2= moderate Staining,  3= strong Staining 
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Figure 2.6: Immunohistochemical analysis of transporter proteins staining on 
normal breast tissues. 
Representative images of immunoreactive staining, (A) Strong staining. (B) Moderate 
staining. (C) Weak staining. (D) Negative staining. The scale bar=50 µm. 
 
Known protein positive tissues were used as positive controls in each run 
(summarised in table 2.16), negative controls (which had only 2% of goat serum) were 
used to confirm the validity of results.   
  Table 2.16: Positive tissue controls used for optimisation of the IHC assay.  
Transporter protein  Positive control (human tissue sections)  
OCT1 (SLC22A1) Normal kidney and prostate  
OCT2 (SLC22A2) Normal kidney and skin 
OCT3 (SLC22A3) Normal kidney and prostate + colon adenocarcinoma 
PMAT (SLC29A4) Ductal carcinoma tissue section* 
MATE1 (SLC47A1) Normal kidney and prostate tissue sections  
MATE2 (SLC47A2) Normal kidney  
 *The pre-invasive (DCIS) tissue slides were obtained from patients attending the Royal  
Hallamshire Hospital from 1995-2003 (Research Ethics: SSREC 98/137). 
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2.2.6 Assessment of breast cell proliferation and survival 
Four independent methods were used to assess cell proliferation and survival 
which include: MTS assay, cell count and viability assay, BrdU incorporation assay and 
colony formation assay. 
2.2.6.1 MTS cell proliferation assay  
2.2.6.1.1 Principles of the MTS assay  
To evaluate the sensitivity of different cell lines to metformin treatment, the 
MTS proliferation assay (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl) -2-
(4-sulfophenyl)-2H-tetrazolium, inner salt), an in vitro plate-based proliferation assay, 
was used to detect the approximate number of viable cells. The assay is based on the 
reduction of the tetrazolium salt, MTS, to a coloured soluble formazan compound 
mediated by mitochondrial-NADH or NADPH of the viable cells in culture and is 
therefore a measure of the mitochondrial function. The intensity of formazan can be 
quantified by reading the absorbance at 490nm in a 96 well plate reader. The MTS assay 
has the advantages of precision, ease of use, reagent solubility in culture media and 
elimination of the washing step, over the widely used MTT assay). The MTS assay was 
used initially as many previous publications investigating the effects of metformin have 
used either MTS or MTT165, 172. However, as it has been shown that metformin may 
interfere with mitochondrial enzymatic activity262 this may not be the most accurate 
assay for assessing the effects of metformin on cell growth so a simple trypan blue 
exclusion cell counting assay was also employed to confirm the results of the MTS 
assay. 
2.2.6.1.2 Protocol of the MTS assay 
When cells were 70% confluent they were trypsinized, counted and seeded at 
5x103 cell/100 µl/well in 96-well plates. For each experiment, a total of three 96-well 
plates were prepared; one for each time point (24, 48 and 72 hours). Each of the assay 
plates were set up, and then incubated for a period of 24 hours to allow the cells to 
equilibrate and begin to proliferate before discarding the media and adding 100 µl of 
freshly prepared metformin-containing phenol red-free media (6 wells for each 
concentration excluding the wells that contained control cells only and media-only) 
(Figure 2.7). To eliminate the edge effect and maintain the well-to-well consistency 
throughout the entire plate, 150 µl of PBS was used to surround the periphery wells and 
prevent evaporation.  
72 
 
The plates were incubated at 37oC, 95% O2 and 5% CO2 for 24, 48 and 72 hours 
post exposure to metformin. Three hours prior to each time point, 20 µl of MTS reagent 
was added directly to the wells of the relevant plate, the plate wrapped in foil and then 
incubated at 37oC for 3 hours. The MTS reagent is extremely light sensitive, so light 
was turned off in the hood before work started. Assessment of metabolic activity was 
established by measuring the colorimetric changes using absorbance at 490 nm recorded 
using a micro-plate reader. Data were analysed on Microsoft Excel by subtracting the 
background absorbance level of the media-containing wells. The results were 
graphically presented using Prism 7 software. Each experiment was performed at least 3 
times.  
 
 
Figure 2.7: Generalized scheme of the MTS cytotoxicity assay.  
Cells were seeded into 96 well plates and allowed to equilibrate for 24 hours prior to 
metformin exposure for 24-72 hours. MTS reagent was added 3 hourss prior to each 
time point resulting in a coloured formazan product, which was read on the plate reader 
(This figure produced using Servier Medical Art: http://www.servier.com/Powerpoint‐
image‐bank). 
2.2.6.1.3 Optimization of the MTS assay 
Initially, the seeding density for the MTS assay was optimized to avoid one of 
the most common limitations affecting MTS validity, which is cessation of cell growth 
due to depletion of media or cellular confluence during the time course. All cell lines 
were seeded at two different densities (5x103 and 1x104 cell/well) in a 96 well plate in 
the absence of treatment in order to determine the most appropriate seeding density for 
these experiments. At 5000 cell/well, a steady rate of growth was seen in all cell lines 
with very little difference in the growth speed between the premalignant and pre-
invasive cells on one hand and the cancer cells on the other hand, except the T47D cells 
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which were slow growing (Figure 2.8A). At 10000 cell/well, a decrease in the growth 
rate was markedly seen after 48 hours in the premalignant and pre-invasive cells and 96 
hours in the invasive cancer cells (Figure 2.8B). As a result of these data a density of 
5x103 was used, where all cell lines continued to grow throughout the time course of the 
experiment (4 days).  
 
 
Figure 2.8: Optimisation of the MTS assay (n=3).  
(A) Cells were seeded at 5000 cell/well in their assay media, and their proliferation 
measured by MTS assay.  Under these conditions all cell lines continued to grow at 
different rates. (B) Cells were seeded at 10000 cell/well and their proliferation measured 
by MTS assay.  Under these circumstances the premalignant cells slowed their growth 
at 48 hours, while the cancer cells slowed their growth at 72-96 hours depending on cell 
line. Data shown are the mean ± SD of three independent experiments.  
 
2.2.6.2 Viability assay using trypan blue cell counting  
This method is based on the principle that viable cells do not take up trypan blue 
dye whereas non-viable cells do. However, it is important to note if cells are exposed to 
trypan blue for extended periods of time, both viable and non-viable cells may begin to 
take up dye so the assay must be performed promptly. As the results from the MTS 
assay demonstrated that the 72-hours time point was the one at which an effect of 
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metformin was most clearly visible, the following experiment was only performed at 72 
hours. Cells to be assayed were recovered from a culture flask as described in Section 
2.1.2. Cells were counted and the density adjusted to be plated at 5X103 cells/well in a 
12-well plate (triplicate for each metformin concentration + triplicate for the control 
untreated cells). 1 ml of the cell suspension was added to each well and incubated for 24 
hours at 370C, following which the media was discarded and different concentrations of 
metformin were added to each triplicate and incubated for a further 72 hours in a 5% 
CO2 incubator. After 72 hours of treatment, media were collected from each well into a 
corresponding pre-labelled tube. Each well was washed twice with 1ml PBS (also 
collected) before adding 0.5 ml of trypsin. After 2 minutes, the action of trypsin was 
neutralized by addition of 1.5 ml of fresh media, and the entire contents of the well 
(cells, trypsin and media) collected and transferred into the corresponding tube. Each 
well was then washed with 1 ml of media to ensure all cells were removed from the well 
and collected again. The collecting tubes were then centrifuged and the contents were 
re-suspended in 1ml of fresh medium before counting. Viability and total cell counts 
were then detected using TC20™ Automated Cell Counter as described in section 
2.2.1.7. 
2.2.6.3 BrdU (bromodeoxyuridine) proliferation assay 
2.2.6.3.1 Principles of the BrdU assay 
The BrdU cell proliferation assay was employed to detect the incorporation of 5-
bromo-2’-deoxyuridine (BrdU) into cellular DNA during cell proliferation using an 
anti-BrdU antibody. The pyrimidine analogue (BrdU) is incorporated in place of 
thymidine into the newly synthesized DNA of proliferating cells. A BrdU mouse 
monoclonal antibody detects the incorporated BrdU after DNA denaturation; a 
necessary step to improve the accessibility of the incorporated BrdU to the detection 
antibody. The anti-mouse horseradish peroxidase (HRP)-linked antibody can then 
recognize the bound detection antibody. Finally, the HRP substrate, tetra-
methylbenzidine (TMB), can then be added to generate a colour reaction. The intensity 
of the colour is proportional to the quantity of BrdU incorporated into cells, which is a 
direct indication of DNA synthesis and therefore cell proliferation (Figure 2.9).  
75 
 
 
Figure 2.9: BrdU cell proliferation assay principles.  
Cells are incubated with BrdU to allow its incorporation into the newly synthesized 
DNA in place of thymidine. Subsequently, anti-BrdU antibodies are used to detect the 
level of BrdU incorporation, an accurate indicator of cell proliferation (This figure 
produced using Servier Medical Art: http://www.servier.com/Powerpoint‐image‐bank). 
  
2.2.6.3.2 BrdU assay protocol  
5X103 cells were seeded in triplicates for each dose and control in 96 well plates 
in the respective assay media to a final volume of 100 µl/well and incubated overnight 
at 370C.  Three types of controls were used: Blank control, contains only culture media 
without cells or BrdU label; Background control, contains cells without BrdU and a 
positive control contains the untreated cells and the BrdU label. On the following day, 
the media were discarded before adding different doses of metformin to the 
corresponding wells and incubated for 72 hours at 370C. 18 hours before the end of the 
3-day incubation period, 20 µl of diluted BrdU label (diluted to 5-fold according to 
manufacturers instructions) was added to all wells except the blank and background 
controls. On the following day, the media was removed from the wells and the cells 
were fixed in 200 µl of the fixative/denaturing solution. After 30 minutes incubation at 
room temperature, the cells were then washed 3 times with 1X washing solution 
(prepared by diluting the 20X concentrated washing solution in deionised water). 100 
µl/well of the anti-BrdU monoclonal detector antibody (prepared by diluting the 
antibody stock as 1:100 ratio in the supplied antibody dilution buffer) was added and 
incubated for 1 hour at ambient temperature. Each well was then washed three times 
with 1X washing solution before the addition of 100 µl/well of the 1X HRP-conjugated 
Goat Anti-Mouse secondary antibody and incubated for further 30 minutes at room 
temperature.  The three washing steps were repeated for each well, followed by flooding 
the entire plate with distilled water. The water was removed and then 100 µl/well of the 
TMB Peroxidase substrate (tetra-methylbenzidine solution) was added and incubated 
for 30 minutes at ambient temperature in the dark. The population of BrdU positive 
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cells, which are actively synthesizing DNA will be visible as a blue colour with variable 
intensities based on the amount of incorporated BrdU in the proliferating cells. Finally, 
100µl/well of the stop solution (2.5N Sulphuric acid) was added and the change of 
colour, from blue to bright yellow, was recorded immediately at A450 using a micro-
plate reader.  
2.2.7 Cell survival assay  
2.2.7.1 Principles of the clonogenic assay  
The clonogenic assay is a basic tool to study cell survival. It is different from the 
proliferation assays but complementary to them in terms of exploring the mechanism by 
which the cells can respond to an insult; and evaluate whether metformin is working 
differently in the different cell lines.   It determines the ability of the cells to retain their 
reproductive ability, thereby to proliferate indefinitely and to form a large clone in the 
presence of an agent. It also defines the relationship between the dose of the agent used 
and the number of cells that were able to reproduce after drug exposure. Cell death, 
either by necrosis or apoptosis, is not the only parameter that confirms the cytotoxic 
effect of the drugs, because even the living cells with retained ability for DNA and 
protein synthesis are consider dead, if they lose their reproductive integrity and become 
unable to divide and produce colonies263, therefore, a clonogenic assay was employed to 
test this aspect of metformin activity. To assess the differences in reproductive 
capability between the untreated cells and metformin-treated cells (the capacity of cells 
to form a colony of 50 or more cells)264, clonogenic assays were performed using two 
different protocols. Namely, the traditional method whereby cells are treated with 
metformin then washed and placed into the assay in the absence of metformin exposure, 
or the method commonly reported in previous studies172 whereby metformin is present 
in the media throughout the assay (Figure 2.10). Using both methods is important to 
both confirm previous data, and to show whether metformin has a true effect on the 
clonogenicity of the breast cell lines. 
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Figure 2.10: Traditional clonogenic assay setting up. 
 
2.2.7.2 Clonogenic assay on adherent cells (traditional method)  
Breast cancer cells (25x104) were seeded into T25 flasks and incubated 
overnight. After incubation, the cells were exposed to varying concentrations of 
metformin for a further 72 hours (consistent with the proliferation assay time point) 
before they were trypsinized, counted, syringed (to ensure that the suspension is really 
single cells) and plated in triplicates at a density of 50 cells/well. Plates were incubated 
for 10-14 days at 370C at the back of the incubator without moving or replacement of 
media. After this time point when colonies had formed, the cells were fixed in 100% 
ice-cold methanol and incubated for at least 30 minutes in a spark proof freezer. 
Afterwards, the methanol was removed with care (as it is a neurotoxic substance) and 
the cells were stained with 0.25% crystal violet in 40% methanol (0.25g in a mixture of 
40ml methanol and 70ml water; filtered through a funnel and Wattman filter paper). The 
stain was washed off after 10 minutes by immersing the plate several times in tap water.  
Plates were dried at room temperature and colonies consisting of 50 or more cells were 
counted under a light microscope.  
A previously published metformin study172 has used a different protocol where 
cells were trypsinized, syringed and counted, then seeded into the 6-well plates at a 
density of 1000 cells/well and incubated at 370C for 24 hour before replacing the media 
with metformin-containing media. Every 3 days, the media were changed with a fresh 
metformin-containing media. This method was trialled for direct comparison with the 
previous study, but the colonies in the control wells were impossible to count by the end 
of the experiment and so this method was not pursued (Figure 2.11). 
2.2.7.3 Optimization of the plating densities for the clonogenic assay 
In order for a clonogenic assay to yield meaningful data an appropriate seeding 
density must be established that will result in single discrete colonies for counting at the 
end point of the assay (after 2 weeks). Two different methods were trialled with 
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different seeding densities. Alimova and colleagues seeded the cells at 1000 cell per 
well and therefore utilized this protocol but the colonies in the control wells were 
impossible to count and therefore this method was not utilized further (Figure 2.11). 
The traditional method where 100 and 50 cells were seeded per well yielded much 
better results with clear, discrete colonies in the untreated wells at a seeding density of 
50. Therefore, the traditional clonogenic assay protocol was employed to assess whether 
clinically relevant doses of metformin would alter the ability of BC cells to form 
colonies. While clonogenic potential of most cells was readily measured after 72 hours 
of metformin exposure, MCF10A and MCF10AT cells did not form colonies and were 
therefore excluded from clonogenic assays. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11: Plating densities for the clonogenic assay.  
(A) Method adopted from Alimova et al,172.The MCF10A and MCF10AT cells did not 
form colonies at the higher density of 1000cells/well.  (B) Traditional clonogenic assay 
method. Pictures of cells from the control wells in 6 well plates were taken by digital 
camera; Results show that untreated cells in Alimova method were coalesced together 
and difficult to count even under a microscope (4X magnification).  
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2.2.8 DNA cell cycle analysis 
2.2.8.1 Principles of cell cycle analysis  
Quantitation of DNA content in each phase of the cell cycle was evaluated by 
flow cytometry using propidium iodide, a DNA-binding dye. PI binding is proportional 
to the amount of DNA present in the cell. To allow easy access of PI to the cellular 
DNA, cells were fixed and permeabilized using alcohol. Cells in the synthesis phase (S 
phase) will have more DNA than cells in Gap1 phase (G1), and thus will take up more 
dye and will fluoresce more brightly. However, the G1 phase shows up as the largest 
peak as it is the most predominant phase of the cell cycle. The cells in G2 will be 
approximately twice as bright as cells in G1. The G1 → S → G2 → M → G1 cycle is 
schematically shown in figure 2.12. 
 
Figure 2.12: A schematic representation of the cell cycle, including the flow 
cytometric components of each phase.  
Before cell division, the synthesis and duplication of the repository of the cell's genetic 
material, DNA, occurs during “S phase”. G1 represents the gap between mitosis and the 
onset of DNA synthesis where most of the RNA and protein molecules needed for DNA 
replication are synthesized. G2 represents the gap between the completion of DNA 
synthesis and the onset of mitosis where the repair of any DNA damage from the 
preceding cell cycle phases takes place. The G0 cells represent the quiescent cells that 
have yet to enter the cell cycle. Mitosis phase represents cellular division where DNA is 
divided equally between daughter cells. 
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2.2.8.2 Sample preparation 
Cells were serum starved for 48 hours. Serum starvation was used to deplete the 
nutrient availability and therefore induce cell cycle synchronization to accumulate 
the cell population prior to G2/M, after which they were grown at a density of 5x105 
cells in 100 mm culture dishes and were treated with or without metformin (0, 0.3, 1, 
and 5 mM) for 72 hours. The media were collected; the cells were then trypsinized, 
washed twice with cold PBS, and centrifuged with the collected media. 1 ml of 70% 
ice-cold ethanol (made with ddH2O not PBS to avoid protein precipitation on fixation) 
was added drop wise to each pellet while vortexing, to ensure cell fixation and minimize 
clumping. The cells were then maintained at 40C overnight or up to 2 weeks. 24 hours 
before evaluation by flow cytometry, the ethanol was washed off the cells using 2 ml of 
PBS. Cells were centrifuged at 850 x g for 5 minutes and the supernatant was discarded 
with extreme care to avoid cell loss. To ensure that only DNA, not RNA, is stained the 
cells were treated with 50 µl of ribonuclease (from 100 µg/ml RNase stock, 5 µg final 
volume) and incubated at ambient temperature for 30 minutes. For DNA staining, 200 
µl of propidium iodide (from 50 µg/ml stock solution) was added and incubated 
overnight at 40C before being analysed by flow cytometry for DNA content and cell 
cycle stage the next morning.   
2.2.8.3 Flow cytometry analysis 
The majority of dead cells and debris were excluded from the flow cytometry 
data acquisition by thresholding on forward scatter. Single cell populations were 
identified by forward scatter (FS) and side scatter (SS). For each sample, 10000 cells 
were evaluated for PI staining. Cells being evaluated for PI staining were acquired using 
a LSRII model flow cytometer equipped with a laser (488 nm) and a red diode laser 
(640 nm). PI was excited by the 488 nm laser with collection of PI emissions at 564-606 
nm. Cell cycle analysis was carried out using the BD FACSDiva 8.0.1 software (Figure 
2.13).  
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Figure 2.13: A representative cell cycle analysis of untreated MDA-MB-231 cells 
using FACSDiva 8.0.1 software.  
Panel A shows the pulse width (X-axis) vs. pulse area (Y-axis) blot, used to gate on the 
single cell population. Panel B is an example of forward (X-axis) and side scatter (Y-
axis) blot where the gate from panel A is applied to gate out obvious debris. Panel C 
shows the PI histogram plot, where the combined gates are applied (P1 represents the 
subG1 or apoptosis phase).   
 
2.2.9 Scratch wound-healing assay 
One characteristic of tumour spread is the increased migratory ability of tumour 
cells. The inhibition of migration of the invasive and metastatic breast cancer cells by 
the clinically relevant doses of metformin was investigated using the scratch wound-
healing assays.  The scratch wound healing assay is a popular simple and cheap in 
vitro method to study cell migration by “wounding’ a confluent monolayer of cells 
and observing the process of cell migration to close the gap.  
2.2.9.1 Optimization of the scratch wound healing assay 
In order to set up a reliable assay, various experimental conditions in 96-well 
plate needed to be optimised including the seeding density, starvation period prior to the 
assay and the duration of breast cancer cell migration as detailed below, although the 
scratch assay has been previously used for breast cancer cell migration in multiwall 
plates.  
A B 
C 
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2.2.9.2 Optimization of the starvation period 
Serum deprivation is a prerequisite step for the migration assay, as this step 
would synchronize the cells and arrest them at G0 phase of the cell cycle, thus, the cells 
would respond uniformly to metformin treatment.  As a confluent cell monolayer is 
required for this assay, we therefore established whether the cells could maintain an 
adherent monolayer after 48 hours of starvation when compared to cells without 
starvation. We found that the starvation didn’t affect cell attachment to the plate if the 
PBS washing was extremely gentle.   
2.2.9.3 Optimization of the migration time period 
To establish how long the cells take to close a wound made by 200µl pipette tip, 
different time points were required by different cells to migrate to close the gap. When 
confluent monolayers of cells were scratched, the MCF-7, T47D and MDA-MB-231 
cells readily closed the gap at 24 hours. Both MCF10A and MCF10AT cells did not 
migrate over a 3 days time period. Similarly, DCIS.com and MDA-MB-231(BM) cells 
did not migrate after 5 days post scratch (Figure 2.14). Therefore, the cells that did not 
migrate were excluded from the final experiment.  For the final experiment, the treated 
cells were not allowed to migrate for so long so that they will fully close the gap; this is 
to show any difference in migration speed relative to the untreated cells with one time 
point being chosen based on the subsequent optimisation steps (the 24 hours).  
As the gap can potentially be filled by cell migration and cell proliferation, in 
order to avoid cell proliferation masking the effects of metformin on migration, 4 doses 
of mitomycin C (2-20 µg/ml) were added to all cell lines in triplicates for 2-4 hours 
before scratching. Mitomycin C (MMC) is a cell cycle antagonist and DNA synthesis 
inhibitor, a commonly used inhibitor in cell migration assays265. However, mitomycin C 
caused cell death and disruption of cell monolayer at these concentrations and the 
scratch assay could not be performed without a confluent monolayer (Figure 2.15). 
There was a concern that in the absence of any proliferation inhibitory agent the results 
of this assay may be affected by breast cancer cells proliferation masking or enhancing 
the effects purely on migration. Therefore, in order to set up a reliable wound-healing 
assay in absence of mitomycin C, different measures were taken. 
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Figure 2.14: Optimisation of the migration time period. Images were taken at 
different time points post scratch of untreated cells.  
The gap was almost closed by the MCF7, T47D and MDA-MB-231 at 24 hours. The 
MCF10A, MCF10AT, DCIS.com and MDA-MB-231(BM) did not migrate after 72 to 
120 hours post scratch.  
The cells were first synchronized by serum starvation prior to the assay, which 
would bring all cells to a phase of growth and proliferation arrest. Additionally, the EGF 
was removed from the pre-malignant cell assay medium and 1% FBS medium was used 
for the entire assay that may further help in reducing the proliferation over the time 
course of the assay. Furthermore, the assay time was set to be less than the invasive 
cells doubling time. Finally, to ensure that proliferation would not be taking place over 
the time course of the scratch assay, cellular proliferation was measured by MTS assay 
immediately after wounding and 24 hours later (the end point of the assay). This 
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enabled assessment of whether the wound-healing assay would only assess migration 
and not gap closure due to proliferation.  
   
Figure 2.15: A representative picture of the effect caused by different doses of 
mitomycin C on MDA-MB-231 monolayers.  
Cells were treated with 4 different doses of mitomycin C (2, 5, 10 and 20 μg/ml). Cells 
were less confluent and showed evidence of cell death at 2 hours with increased doses 
of mitomycin C. Scale bar represents 100 μm. 
 
2.9.3.4 Control proliferation experiment  
The proliferation results obtained by MTS assay clearly showed that the three 
invasive cell lines did not proliferate over the course of the assay (24 hours), however, 
the viability of the pre-malignant, pre-invasive and the bone-homed cells was markedly 
reduced consistent with the finding observed previously that these cell were unable to 
migrate and close the scratch (Figure 2.16). This might be due to the unfavourable 
culture conditions as the pre-malignant cells are both serum and growth factors 
dependent. Accordingly, the migration of the invasive breast cancer cells was analysed 
at 24 hours following wounding, confident that the majority of scratch closure will be 
due to migration and not proliferation of the cells. 
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Figure 2.16: Control proliferation experiment.  
Cells were seeded into the 96 well plates, left to become confluent, serum starved and 
the scratch generated. Cellular proliferation was then measured immediately and after 
24 hours using the MTS assay and expressed as absorbance at 490nm. Results shown 
are the mean ± SD of three independent experiments. The metabolic activity of the three 
pre-malignant cells was significantly affected at 48 hours; similarly the metabolic 
activity of metastatic bone-homed cells was markedly affected at 24 hours. Meanwhile 
the viability of the three invasive cells was not affected at the 24 hours time point.  
 
2.2.9.5 Wound healing assay protocol 
The ability of the invasive breast cancer cells to migrate into an empty space 
was evaluated by creating a scratch wound in vitro. The MCF7, T47D and MDA-
MB-231 cells were firstly serum-starved for 48 hours. The following day, cells were 
seeded in triplicate in a 96-well plate at a density of 4X104 cells/well for the T47D 
cells and 3X104 for MCF7 and MDA-MB-231 cells in a low serum medium (1% 
FBS), to reduce their ability to proliferate during the assay, and allowed to settle for 4 
hours.  After this time the scratch wounds were created using a sterile 200 µl pipette 
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tip. Cellular debris was removed by extremely gentle washing with PBS before four 
concentrations of metformin were added in 100 µl of low serum medium, with 1% 
FBS medium only as a control. Images of the wounds were captured by a digital 
camera at 0 and 24 hours for the three cells. ImageJ software was used to analyse the 
results. 20 different random distances between the two edges of the wound were 
measured. The percentage of wound closure was calculated using the following 
equation:  
Percentage of wound closure= (!!!) !  × 100 
Where A is the width of initial scratch wound and B is the width of scratch wound at 
time 24 hours (Figure 2.17).    
 
   
Figure 2.17: Calculation of the percentage of wound closure.  
A representative of scratch closure by untreated MDA-MB-231 cells at 0 and 24 hours. 
The edges of the wound are emphasised by the dotted lines. Images were taken using 
Olympus digital camera. 20 points across the gap were assessed for each image. Scale 
bar represents 100 μm. 
 
2.2.10 Mass spectrometry-proteomic analysis  
Two Mass spectrometry-proteomic analysis techniques were performed in this 
project, namely Label free quantification (LFQ) and Spike-in SILAC-based 
quantification (SIS). The details of the methodology used can be found in chapter 5.  
 
 
 A 
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2.2.11 Statistical analysis 
The D'Agostino-Pearson omnibus test was first used to assess normality. This 
test computes the skewness of the data and quantifies how far the distribution is from 
the Gaussian, in terms of shape and asymmetry. It then calculates how far each of these 
values differs from the value expected with a Gaussian distribution, and computes a 
single P value from the sum of these discrepancies. Considering that the very large 
majority of data were not normally distributed, statistical comparisons were carried out 
using the non-parametric tests using Graphpad Prism software 7 for Mac and shown as 
mean ± standard deviation (SD) in all graphs for all replicates.   
Therefore, data were analysed using a non-parametric one-way ANOVA test to 
compare the means of data among each groups followed by Dunnett’s post hoc test for 
multiple comparison. All P values are two- tailed. A P value < 0.05 was considered 
statistically significant.   
Data for the analysis of qRT-PCR, Western blot and immunohistochemistry 
experiments was assessed using the same tests comparing each cell line/tissue to the 
normal non-tumorigenic MCF10A cells/normal breast tissue.     
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3. Chapter 3: Analysis of metformin-transporters 
expression, in vitro 
3.1 Introduction  
Although previous studies have suggested that breast cancer incidence and 
recovery may be influenced by metformin treatment in diabetics, there is still a question 
as to whether metformin will be taken into the cancer cells and gain access to the 
mitochondrial respiratory complex in order to mediate these effects or whether these 
effects are indirect.  Metformin is highly hydrophilic and cannot readily cross the 
impermeable plasma membrane, thus to enter the cell, metformin trafficking across the 
cell membrane must be transporter-mediated124. Four organic cation-transporters (OCTs) 
are actively involved in the cellular uptake of metformin and have been identified as 
putative determinants of metformin’s pharmacokinetics in the main organs such as liver 
and small intestine, namely OCT1-3 and PMAT.  If cancer cells were positive for those 
transporters it would strongly suggest that metformin could accumulate and exert its 
direct effect in these cells. The multidrug and toxin extrusion transporters (MATE1 and 
2) can also mediate cellular extrusion of metformin and contribute to its excretion 
through urine and bile. With this in mind, reduced drug response cannot be solely 
attributed to reduced metformin uptake into cancer cells but also to increased efflux out 
of the cells, which is governed by the presence of two metformin extrusion proteins.  
The expression of metformin transporters has been found to be extremely 
diverse in different tissues266   (Figure 3.1). In diabetic patients, alteration in metformin 
pharmacokinetics, disposition and side effects have been linked to single nucleotide 
polymorphisms affecting the functions of OCT1-2 and MATE1-2138, 267-277, and these 
polymorphisms have also been identified in healthy subjects278.  A detailed description 
of the localization and tissue distribution of these transporters can be found in the 
introduction chapter (section 1.3.2 and table 1.3).  
To date, very little is known about the quantitative expression of metformin 
transporters in breast cancer settings. Only one study, by Cai and collegues279, examined 
whether the expression of metformin transporter mRNAs differ significantly between 
basal and luminal breast cancer cells/tumour tissues. These authors found that the 
expression of cation-selective transporter is critical for the anti-proliferative effect of 
metformin in basal breast cancer cell lines279. However, no comprehensive description 
89 
 
of gene and protein expression in normal, pre-malignant, pre-invasive and tumour breast 
cells and tissues is available, to date.  
 
 
Figure 3.1: Baseline expression of metformin-transporter genes and proteins in 
normal organs and tissues.  
 (A) Transporter gene expression corroborating high level of OCT1, OCT3 and MATE1 
expression in liver across GTEx (Genotype-Tissue Expression) studies with very little 
information about transporter expression in breast tissue. The unit used for reporting 
expression in RNA-seq studies is FPKM (fragments per kilobase of transcript per 
million).  (B) Very little is known about transporter protein expression in the human 
protein atlas and human proteome studies, and it appears that normal breast tissue was 
not assayed in the given studies. Likewise there was no available information about 
PMAT and MATE2 expression in various normal tissues. Data obtained from 
Expression atlas website https://www.ebi.ac.uk/gxa/ (accessed on 15-December-2017). 
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Therefore, to address this gap in knowledge, this study was designed to compare 
the expression of the six important metformin transporter genes and proteins (Table 3.1) 
in our representative in vitro model of breast cancer disease progression and to enable 
testing of the hypothesis that the expression of the solute carrier transporters is critical 
for the direct effect of metformin on breast cells, in the subsequent chapter. 
 
Table 3.1: Metformin transporters  
Import transporters Export transporters 
 SLC22A1 = OCT1 
   SLC22A2 = OCT2 
 SLC22A3 = OCT3 
                  SLC29A4 = PMAT 
SLC47A1 = MATE1 
SLC47A2 = MATE2 
 
In an attempt to mimic the diversity of breast disease and carcinoma that is seen 
in the clinical population of patients, a panel of increasingly transformed breast cell 
lines were chosen to represent the graduated progress and evolution of breast 
carcinogenesis as described by Wellings and Jensen6. In this case, the MCF10A cell line 
was used to represent the non-transformed breast ductal epithelial cells,  MCF10AT 
cells represent pre-malignant hyperplastic ductal epithelial cells and the DCIS.com cells 
represent pre-invasive ductal carcinoma in situ. Three immortalised human invasive 
breast cancer cell lines were chosen to represent a variety of hormone receptors status, 
variable invasive activity and metastatic potential. MCF7 (Luminal A) represents 
tumours with non-invasive and low metastatic potential, T47D (Luminal A) represents 
tumours with low invasive and low to moderate metastatic potential, while MDA-MB-
231 (Basal/Triple negative) represents tumours with highly invasive and metastatic 
capacity280-283. For the sake of better comprehensiveness an end-stage metastatic bone-
seeking cell line (MDA-MB-231(BM)) was also added to the previous spectrum (Figure 
3.2). 
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Figure 3.2: An in vitro model of breast cancer and disease progression.   
 
The major aim of this chapter was to assess which of the metformin transporters 
are present in the different cell lines and whether transporter expression alters with 
increasing severity of the disease.  
More specific aims were to: 
1. Investigate gene expression of the endogenous solute carrier transporters 
SLC22A1, SLC22A2, SLC22A3, SLC29A4, SLC47A1 and SLC47A2 in human breast cell 
lines at various stages of BC disease progression.  
2. Investigate the transporter protein expression in the representative human breast 
cell lines.  
3. Evaluate the transporter expression in human breast tissues of similar 
morphology to the cell lines used.  
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3.2 Methods 
§ In order to investigate the expression of the putative metformin 
transporters in breast cancer, cell lines representing different severities of breast lession 
were cultured as described previously (see section 2.2.1).   
§ To assess the transporter gene expresion, mRNA was extracted from the 
cells (as described in section 2.2.3.1) and then converted to cDNA for use in a 
quantitative real-time polymerase chain reaction (qRT-PCR) (sections 2.2.3.3, 2.2.3.4). 
All the validated metformin-transporter qPCR Primers ID and sequences are listed in 
table 2.8. 
§ To assess the protein expression of the transporters, samples were 
prepared and resolved by SDS-PAGE (section 2.2.4.5), transferred to a PVDF 
membrane (section 2.2.4.6 ) and incubated with the corresponding primary and 
secondary antibodies (listed in table 2.10 and 2.11). The immune-reactivity was 
visualised by chemiluminscence (section 2.2.4.7). The transporter protein expression 
was semi-quantified using the ImageJ programme as described in section 2.2.4.9, then 
normalized to β-actin and presented as the percentage of β-actin expression.   
§ Immunohistochemical staining was performed to further characterize 
metformin-transporters expression in a total of 124 human tissue microarray sections 
per transporter representing a model of breast cancer progression (detailed in table 2.14), 
along with the positive controls listed in table 2.15. IHC was conducted according to 
normal laboratory routines (section 2.2.5.2) with commercially available antibodies 
(tables 2.10 and 2.11) and analysed as detailed in section 2.2.5.3.  
§ Each experiment was performed on at least three occasions and the 
graphs shown are the average of these data.  All statistical analyses were performed 
comparing each cell line/tumour tissue to the non-tumorigenic MCF10A cells/normal 
tissue and the tests used were the non-parametric tests as advised by the Sheffield 
statistical services as detailed in statistical analysis, section 2.2.11. A P-value of <0.05 
was taken to be significant.  
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3.3 Results 
3.3.1 Evaluation of metformin-transporter genes expression in the tumour and 
non-tumour breast cell lines  
In order to evaluate whether the development and progression of breast cancer 
from normal to pre-malignant, pre-invasive, invasive to a metastatic disease would be 
associated with changes in metformin-transporter expression at the gene level, 
quantitative real time polymerase chain reaction (qRT-PCR) was performed on the 
representative cell lines of breast disease progression. HepG2, the human hepatocellular 
carcinoma cell line and a commonly used organotypic cell line for in vitro studies284, 
was used as a positive control for transporter gene expression and GAPDH 
(Glyceraldehyde 3-phosphate dehydrogenase) as an internal control gene.  Consistent 
with the previous literature, the HepG2 cell line expressed all the investigated 
transporter mRNAs284 (Figure 3.3).  
The relative expression of our genes of interest was quantified to determine the 
changes in steady-state mRNA levels across all cell lines and expressed relative to the 
level of GAPDH as an internal control as shown in Figure 3.3.  Both cancer and non-
cancerous breast cell lines were found to express a significant level of metformin-
transporter mRNAs with PMAT being the predominant transporter in both the tumour 
and non-tumour cell lines except the MDA-MB-231 cells where OCT3 was the most 
predominant. MATE1 was the second most highly expressed transporter. OCT1, OCT2 
and MATE2 were the third, fourth and fifth most highly expressed genes (Figure 3.3). 
The pattern of expression of each individual transporter mRNA across all cell lines is 
summarized in table 3.3.  
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Table 3.2: Analysis of metformin transporter gene expression relative to GAPDH 
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OCT1 mRNAs: there was a tendency for the expression to increase slightly with 
increased cellular invasiveness and metastatic potential (P=0.003, One-way 
ANOVA test), however, a post hoc Dunnett’s test revealed no significant 
difference in the expression of OCT1 between the non-tumorigenic MCF10A and 
other cell lines.  
OCT2 mRNAs were shown to have a relatively similar expression level across 
the representative cells of the breast disease spectrum (P=0.1, One-way ANOVA 
test). (Figure 3.3). 
OCT3 mRNA, most cell lines showed a similar level of expression, except the 
metastatic MDA-MB-231 that showed a relatively higher expression compared to 
the normal MCF10A cell (P=0.001, Dunnett’s test). However, OCT3 expression 
was not detectable in MCF7 cell line (Figure 3.3). 
PMAT mRNA was found to present a similar pattern of expression to that of 
OCT1, with no statistically significant difference in the expression across the 
investigated breast cell lines (P=0.05, One-way ANOVA test) (Figure 3.3). 
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MATE1 mRNA expression was unchanged between the normal, pre-malignant 
and pre-invasive cell lines whereas it was slightly decreased in MCF7 and MDA-
MB-231 and slightly increased in T47D and MDA-MB-231(BM) cell lines 
(P=0.008, One-way ANOVA test). However, these differences between the 
tumorigenic cell lines and MCF10A cells were not significant (Figure 3.3). 
MATE2 mRNA analysis showed a slight increase in the expression with 
increased cellular atypia and invasiveness in the MCF10AT, DCIS.com and 
MCF7 cell lines compared to the normal MCF10A cell line. However, the 
expression was slightly reduced to a level similar to the MCF10A cells in the 
T47D, MDA-MB-231 and MDA-MB-231(BM) cell lines (P=0.004, by One-way 
ANOVA test).  However, none of the pairwise comparisons to the normal cell 
line as a control were significant. 
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Figure 3.3: Expression profiling of the cation-selective transporters OCT1-3, 
PMAT, MATE1 and MATE2 mRNAs in various human breast cell lines.  
Relative gene expression was determined by qRT-PCR and normalized to GAPDH. 
HepG2 cells were used as a positive control and GAPDH as an internal control gene. 
Values represent the mean of 3 duplicate repeats and error bars are SD. Cell line marked 
with an asterisk (*) indicates undetermined transporter expression in all biological 
replicates. For statistical analysis the cells were compared to the non-tumorigenic 
MCF10A cell as a control. P<0.05 was considered significant. ***P<0.001. For raw 
data, see Supplementary material CD (S1). 
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3.3.2 Evaluation of metformin-transporter proteins in the tumour and non-tumour 
breast cell lines  
To evaluate whether the transporter gene expression observations were 
translated to the protein level, Western blot analysis was carried out and protein 
expression of all cell lines was analysed and compared to the non-tumorigenic MCF10A 
cells. The cell lysates from three biological replicates per cell line were tested 
independently for the expression of human OCT1 (molecular weight 61kDa), OCT2 
(molecular weight 63kDa), OCT3 (molecular weight 61kDa), PMAT (molecular weight 
58kDa), MATE1 (molecular weight 62kDa), MATE2 (molecular weight 61kDa) and 
normalized to β-actin (molecular weight 42kDa). The results showed that the human 
hepatocellular carcinoma cell (HepG2), used as a positive control, expressed all the 
tested transporter-proteins in the cell lysates284. The percentage expression of band 
densities against β-actin in the above experiments was graphically plotted in figure 3.6. 
Semi-quantification densitometry was not possible for MATE2 due to non-detectable 
bands.  
In the non-tumorigenic and pre-malignant human breast epithelial cells 
(MCF10A and MCF10AT), there was a strong expression of OCT1, OCT2, PMAT and 
MATE1; with PMAT being the predominant transporter followed by MATE1, OCT1 
and OCT2 respectively. There was no expression of either OCT3 or MATE2 in these 
cell lines (Figures 3.4 and 3.5).  
The pre-invasive DCIS.com cells demonstrated a strong expression of OCT2, 
PMAT and MATE1 but only minimal positivity for OCT1 and no expression of OCT3 
and MATE2. A similar pattern of expression was found in the invasive MCF7, T47D, 
the metastatic MDA-MB-231 and the bone homed MDA-MB-231(BM) cells, with 
MDA-MB-231 being the only cells to express OCT3 protein (Figure 3.4). 
There was not generally a good correlation between the gene and protein 
expression pattern for most transporters. OCT1 and PMAT proteins expression do not 
reflect the gene expression, while PMAT protein expression was elevated in the pre-
invasive, invasive and metastatic breast cancer cells (P<0.0001, by One-way ANOVA 
test), OCT1 protein expression was reduced in these cells (P<0.0001, One-way 
ANOVA test) (Figure 3.5). No significant difference was observed in OCT2 and 
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MATE1 expression between all cell lines (P=0.33 and P=0.2 respectively, by One-way 
ANOVA test) (Figure 3.4), which is in agreement with gene analysis results.  
The expression of OCT3 and MATE2 proteins was not detectable in all cell 
lines except the MDA-MB-231 cells, which expressed a significant level of OCT3 
protein. This observation was not consistent with the gene expression data where these 
transporters were expressed at a higher level (Figure 3.4 and 3.5).  
	
 
Figure 3.4: Representative cropped Western blots of transporter expression in 
normal, pre-malignant, pre-invasive, invasive, bone-homed breast cell lines and 
hepatoma cell control (HepG2).   
The images represent the expression of metformin transporter proteins (OCT1-3, PMAT 
and MATE1-2) and their corresponding molecular weights are indicated in brackets. β-
actin (42kDa) served as a loading control for comparison of expression levels for all 
proteins tested. 20 μg of proteins (total cell lysate) were loaded into each lane. For full 
images of the three independent experiments, see Supplementary material CD (S2).   
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Figure 3.5: Representative Western blot analysis of metformin-transporter 
proteins expression (OCT1-3, PMAT and MATE1-2) by all breast cell lines.  
The intensity of the different bands were determined by densitometry, normalized to β-
actin, plotted as the percentage of β-actin expression and expressed as mean±SD from 
three independent experiments. For statistical analysis cells were compared to the non-
tumorigenic MCF10A cells as a control. ***P<0.001 and ****P<0.0001. 
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3.3.3 Analysis of metformin-transporter expression in human breast tissues 
Having determined the levels of metformin-transporter genes and proteins 
expression in the representative cell lines of breast cancer progression, 
immunohistochemical staining was performed to determine whether the transporters 
are expressed in human breast tissues of similar morphology to the cell lines. To 
correlate the findings of this experiment with the results of qRT-PCR and Western blot 
analysis, sections with fibrocystic disease were also analysed to represent the source 
from which the immortalized MCF10A cells were derived and to investigate if there is 
a difference in expression between them and the completely normal epithelial cells. 
The different grades of invasive ductal carcinoma (IDC I-III) were analysed and plotted 
separately owing to the fact that the degree of differentiation is a better clinical 
representative of disease severity rather than the tumour subtype (grade I, II and III 
represent well, moderately and poorly differentiated tumours, respectively). It is worth 
noting that there was no metastatic breast tissue available for use in this study.  
Each tissue microarray slide was stained for metformin-transporters and scored 
under light microscope to evaluate the intensity and quantity of staining as described in 
section 2.2.3.3. Examples of the grades of staining intensity are shown in the materials 
and methods chapter figure 2.6. The pattern of staining in the ductal epithelial and 
tumour cells was observed to be uniformly membranous and cytoplasmic, occasionally 
nuclear (based on slides examination with higher magnification lenses). There was no 
staining observed in the surrounding stromal cells. Analysis is presented as the 
percentage of each tissue type scoring 0, 1, 2 or 3 for intensity of stain of the relevant 
metformin-transporter, as shown in figure 3.6. A proportion of the scoring was 
confirmed by a histopathologist (Patricia Vergani) and double assessed by another 
scorer (Nashwa Shesha). The kappa coefficients for inter-observer error scores were 
OCT1, 0.93; OCT2, 0.84; and OCT3, 0.95, PMAT, 0.89; MATE1, 0.83 and 0.91 for 
MATE2, showing a high level of agreement.  
Moderate to strong membranous and cytoplasmic expression of OCT1 was 
detected in 70% of normal ductal epithelial cells. This was significantly reduced to 40 
% in the non-tumorigenic fibrocystic disease sections (FCD), 58% in the pre-malignant 
atypical ductal hyperplasia (ADH) and 69.3% in ductal carcinoma in situ (DCIS). 
Statistical analysis indicated that the expression of OCT1 decreased in disease 
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compared to normal breast epithelial cells (P<0.004, One-way ANOVA test) with post 
hoc test indicating that invasive carcinoma had a significantly reduced expression 
compared to normal epithelial cells (P=0.0001, Dunnett’s test) (Figure 3.6). 
High levels of OCT2 expression were seen with moderate to strong membranous 
and cytoplasmic staining in 100% of ductal epithelial cells in normal breast, 80% in the 
non-tumorigenic epithelium (Fibrocystic disease), 90% in the dysplastic epithelium 
(ADH) and 85% in the pre-invasive ductal carcinoma cells (DCIS). The expression did 
not change significantly with increasing severity until invasive ductal carcinoma where 
it decreased significantly to 20% compared to normal breast epithelial cells (P=0.002, 
Dunnett’s test) (Figure 3.6 and 3.7). The observation that there was no statistical 
difference in the normal, pre-malignant and pre-invasive breast tissues stained for OCT2 
expression is in agreement with both gene and protein cell line expression results.  
Moderate to strong expression of OCT3 was identified within the cytoplasm and 
membrane of 37% of normal ductal epithelium, 42% of fibrocystic disease and 33% of 
ADH tissues. Similarly, moderate to strong expression was also detected in 31% and 
40% of DCIS and grade-I IDC cells, respectively. 85% of the grade-III IDC cells 
stained negative for OCT3. There was no statistically significant difference between 
tissues stained for OCT3 expression across the range of normal to grade I IDC, even 
though there was a small tendency of decreased strong staining intensity with increased 
lesion severity (Figure 3.6 and 3.8). Results presented here correlate well with the gene 
expression findings but not with the non-detectable proteins on Western blot. 
Moderate to strong PMAT cytoplasmic and membranous expression was seen in 
83% of the normal breast epithelium with a significant decrease in expression to only 
20% of fibrocystic disease tissues compared to normal breast epithelial cells (P=0.0001, 
Dunnett’s test) and 60% of ADH. Moderate to strong expression was also observed in 
the cytoplasm of 100% of DCIS cells while 60% and 40% of grade I-II invasive 
carcinoma cells expressed PMAT and this was significantly reduced to 10% in grade III 
IDC compared to normal breast epithelial cells (P=0.0001, Dunnett’s test) (Figure 3.6). 
Although tissue expression of PMAT did not correlate with gene expression in terms of 
being the predominant transporter in all cell lines, PMAT is expressed in all stages at 
different degrees in both cell lines and tissues. 
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There was moderate to strong expression of MATE1 in the cytoplasm and 
membranes of 100% of epithelial cells in normal breast ducts and this expression 
reduced slightly but non significantly in fibrocystic disease sections (90%) and in ADH 
(66%), whereas it was 100% in DCIS and then 80-71% among the progressive grades of 
invasive ductal carcinoma tissues from I to III respectively. This is also consistent with 
gene and protein expression findings (Figure 3.8 and 3.9).  
There was generally weak cytoplasmic expression of MATE2 in 36% of the 
normal breast ductal epithelium and atypical ductal hyperplasia. Moderate to strong 
expression was only observed in 41% of fibrocystic disease sections. The weak 
expression was significantly decreased with increasing lesion severity (P= 0.0009, One-
way ANOVA test); with no expression detected in grade-III invasive ductal carcinoma 
cells (Figures 3.9). The very low to no expression pattern of MATE2 in different breast 
tissues is consistent with the protein expression findings.  
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Figure 3.6: Expression of metformin transporters OCT1-3, PMAT and MATE1-2 
in a spectrum of breast tissue lesions.  
Percentages of staining intensity in different cases with varying epithelial/tumour cell 
transporter expression. There is a significant decrease in the expression of some uptake 
transporters, such as OCT2 and OCT3, with increased severity and grade of invasive 
ductal carcinoma. Low expression of MATE2 transporter was evident among most 
types of breast tissues.  Normal: Normal breast tissue, FCD: Fibrocystic disease, ADH: 
Atypical ductal hyperplasia, DCIS: Ductal carcinoma in situ; IDC: Invasive ductal 
carcinoma grade I-III.  
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Figure 3.7: Examples of metformin uptake transporters staining (OCT1 and OCT2) 
in human breast tissues.  
The images show sections of a range of breast tissues, which are positively or 
negatively stained for OCT1 and OCT2. Membranous and cytoplasmic staining of 
ductal and tumour cells indicate positivity (scale bar: 50 μm) 
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Figure 3.8: Examples of metformin uptake transporters staining (OCT3 and 
PMAT) in human breast tissues.  
The images show sections of a range of breast tissues, which are positively or 
negatively stained for OCT3 and PMAT. Membranous and cytoplasmic staining of 
ductal and tumour cells indicate positivity (scale bar: 50 μm). 
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Figure 3.9: Examples of metformin extrusion transporters staining (MATE1 and 
MATE2) in human breast tissues.  
The images show sections of a range of breast tissues, which are positively or negatively 
stained for MATE1 and MATE2. Membranous and cytoplasmic staining of ductal and 
tumour cells indicate positivity (scale bar: 50 μm). 
 
106 
 
4.4 Discussion   
Previous studies have suggested that OCT1 and OCT2 expression is highly restricted 
to liver and kidney respectively, whereas OCT3 was found to be more widely distributed 
across several human tissues, and the efflux transporters MATE1-2 are predominantly 
expressed in the kidney266, but not according to the Genotype-Tissue Expression (GTEx) 
project and RNA sequencing (RNA-seq) results mentioned earlier in this chapter. The present 
study is the first comprehensive evaluation of all these putative metformin transporters in 
breast epithelial and cancer cells. To our knowledge, none of the previous investigators have 
examined metformin transporter expression using human breast tissue specimens and there is 
no published literature investigating the expression profile of metformin-transporters in the 
MCF10A, MCF10AT, DCIS.com, T47D and MDA-MB-231(BM) cell lines. 
In the present study, three techniques have been used to investigate the expression of 
the solute carrier transporters (OCT1-3, PMAT, and MATE1-2) in human breast cell lines 
(using qRT-PCR and Western blot) and tissues (using immunohistochemistry).  
Our results showed that the expression of metformin transporters varies across the 
different cell lines and tissues and provide convincing evidence that at least one importer and 
one exporter is present on each cell line and in each tissue.  These data therefore suggest that 
metformin could act on all cell lines and in all breast cancer tissues. However, the 
immunohistochemistry data seem to suggest that there is a decrease in expression of all of the 
transporters in stage III breast cancer, suggesting that metformin may be transported to a 
lesser degree into these tissues and have less beneficial effects in patients with advanced 
breast cancer. 
We firstly aimed to determine metformin transporter expression in human breast cell 
lines and explore whether there is a differential expression between malignant and non-
malignant cells. We found that all cell lines expressed all candidate cation-selective 
transporter genes. However, at the protein level, OCT1 and PMAT were the predominant 
transporters in the normal and pre-malignant cells while PMAT was the predominant 
transporter in the pre-invasive and invasive malignant cells. OCT2 and MATE1, which are 
involved in metformin uptake and excretion respectively, were abundantly expressed in all 
cell lines. OCT3 appears to be important for metformin uptake by the triple-negative cells as 
these were the only cells expressing this transporter. However, although the pre-malignant 
and malignant cells expressed low level of PMAT and OCT1 respectively, this does not 
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exclude the possibility that they might have an important role in metformin uptake too. 
Therefore, the data in this chapter suggests that metformin transport is multi-transporter 
dependent in breast cell lines.  
Quantitative RT-PCR was used to identify the cell lines with high, low or no 
expression of OCTs and MATEs genes in order to explore potential correlation with 
metformin response, as described in the next chapter. Thus, to quantify the relative 
expression difference between samples in all biological replicates (n=3), comparative Ct 
measurements were used. The Ct value (the threshold cycle) indicates the cycle at which the 
fluorescent signal first shows significant difference with respect to the background where a 
lower Ct value means greater expression and vice versa. In our study, OCT1-3, PMAT and 
MATE1-2 were amplified between 14-29 cycles, which indicates high expression of these 
genes. The findings presented here add to and expand the previous study by Cai and 
colleagues as it is currently the only published study which investigated the transporter 
expression in a panel of 13 basal and luminal breast cancer cell lines including MCF7 and 
MDA-MB-231279. However, in contrast to our findings they suggest that the expression of 
most transporter mRNAs was negligible in MCF7 cells while we showed a sufficient amount 
of expression of all investigated transporter mRNA except OCT3 in this cell line. We have 
also reported the same finding that multiple transporters are expressed by the MDA-MB-231 
and showed for the first time that the OCT2 and PMAT uptake transporter genes were also 
expressed in a significant amount.  Generally, the normalized gene expression values in the 
Cai et al. study were relatively lower than our expression values and their data were 
normalized to the 18s as a reference gene, which might be a possible reason for the 
discrepancy in the results. In addition, variation in the results obtained by different 
laboratories using the same cell lines, may also be attributed to genotypic drift caused by high 
passage number, or cross-contamination with another cell line285. In this study, fresh cells 
(bought from the ATCC) with low passage number were used to overcome this limitation 
including the non-tumorigenic MCF10A and the three invasive breast cancer cell lines.   
Metformin transporter gene expression have also been previously demonstrated in a 
study that used a panel of cancer cell lines including colorectal, pancreatic, lung, prostate, 
liver and cervical carcinomas. This study detected a relatively low and uniform expression of 
OCT1-2 and higher variability in OCT3 and MATE1-2 expression among the cancer cell 
lines with OCT3 showing the highest overall expression286. Generally, the pattern of 
transporter genes expression seen in the breast cancer invasive cell lines in this study is 
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different, suggesting a low expression of OCT2, high expression of OCT1 and PMAT,  and 
variability in OCT3, MATE1-2 expression, indicating that the breast cancer cell lines are 
likely to react in a different way to other cancer cells in response to metformin. However, the 
gene expression findings of this study are generally in concordance with the microarray data 
published in the cancer cell line encyclopedia, which indicates high expression of PMAT and 
MATE1 genes, and a low expression of OCT1-3 and MATE2 genes across breast cancer cell 
lines (includes MCF7, T47D and MDA-MB-231)287.  
One of the possible limitations of the RT-qPCR approach is improper use of the 
internal control gene where careful normalization is an essential step for accurate 
quantification of mRNA levels. To avoid these issues in this study GAPDH was used as a 
normalizing gene, as it has been identified previously as the most stable reference gene, along 
with ACTB gene (β-actin), in both basal (MDA-MB-231) and ER+ (MCF7 and T47D) as 
well as MCF10A cell lines288, 289. Furthermore, variation of GAPDH mRNA expression 
within the same tissue, such as breast tissue, was also demonstrated to be relatively small 
when compared to other housekeeping genes290. Indeed, the GAPDH Ct values in this chapter 
strongly suggest the stability of GAPDH expression in all cell lines investigated (see 
supplementary material CD, S1).  Although the compact error bars observed in this 
experiment minimize the possibility that a significant expression of metformin transporters 
was obscured by outlying results, as only duplicates of three biological replicates were used, 
the data may potentially be improved by repeating the experiment with more replicates but 
time constraints prevented this.  
Indeed, the detection of the transporter expression at mRNA level provides a good 
indication of their presence or absence in a given biological sample. However, a good 
correlation between the mRNA transcript level and the protein level does not always exist in 
the same tissue, therefore, the confirmation of expression is required at the protein level291. 
Additionally, protein expression is expected to correlate better with transporter function than 
mRNA expression and so Western blot analysis was performed to establish transporter 
protein expression in these cell lines.  
Using Western blotting, OCT1, OCT2, PMAT and MATE1 proteins were all detected 
in the cell lysates of all the cell lines. In contrast the extrusion protein, MATE2, was not seen 
in any of the cells at the protein level and OCT3 expression was only detected in the MDA-
MB-231 cells (Figure 3.6). To confirm that the results were not a consequence of absent or 
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unequal protein loading, β-actin was used as a loading control where the presence of 
equivalent bands confirmed equal protein loading. Generally, there was no exact 
correspondence between the transporter gene and transporter protein expression in the human 
breast cell lines analysed, however, the OCT2, PMAT and MATE1 gene and protein 
expression have all followed similar patterns.  This poor correlation between the gene and its 
relevant protein level can be attributed to several different reasons, including post-
translational modification involved in translating the mRNA into protein, the stability of the 
mRNA, low level of protein expression, differential in vitro half-lives of the proteins and 
protein modification. Interestingly, our findings of transporter protein expression by MDA-
MB-231 cell are consistent with the Cai et al. study (including OCT1, OCT3 and MATE1) 
and in addition showed for the first time that OCT2 and PMAT uptake proteins are also 
highly expressed by MDA-MB-231 cells. In contrast to the finding by Cai and colleagues that 
expression of all transporter proteins was undetectable in the MCF7 cell line, this study 
showed for the first time that MCF7 cells actually abundantly express OCT1-2, PMAT, 
MATE1 but not OCT3 and MATE2. The investigators in Cai study have obtained their 
MCF7 cells from their local tissue culture facility, while the MCF7 cells used in this project 
were freshly bought from the ATCC, this can explain the remarkable difference in the 
expression data between the two studies. It is well known that MCF7 cell lines used by 
various laboratories may exhibit a fundamental difference in their biological properties, 
despite having a similar karyotype, and this difference is related to the number of passages 
and the culturing conditions before storage292, 293. 
  Previous studies have shown that high expression of OCT3 was associated with 
increased intracellular concentration of metformin and improved cellular response in terms of 
inhibition of proliferation in breast279 (MDA-MB-231) and prostate (LNCaP) cancer cell 
lines286. OCT3 expression was also shown to be a critical determinant of metformin uptake in 
breast cancer cells where metformin uptake was negligible in the OCT3-deficient BT20 cells 
and high in OCT3-competent MDA-MB-231 cells279. In contrast, positive expression of 
MATE2 correlated with resistance to antineoplastic activity of metformin in some cancer cell 
lines such as prostate (LNCaP) and small cell lung cancer (A549) cells286. This correlation 
was in the expected direction given the role of OCT3 and MATE2 as metformin importer and 
exporter respectively. Our findings might suggest that the transporters identified in other 
cancers may not be as relevant for metformin action in breast cancer where OCT3 appears to 
be the least likely to be involved while other transporters such as PMAT and OCT2 are more 
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likely to be involved in metformin translocation into the invasive and metastatic cancer cell 
lines and MATE1 in the extrusion of the drug, however, further cellular uptake experiments 
should be performed before such a conclusion can be reached. 
Finally this chapter investigated transporter expression in the non-tumour and tumour 
breast tissues using immunohistochemical staining, a reliable method of testing for protein 
expression status in breast cancer patients. To date, little is known about the expression and 
localization of metformin transporters in human breast tissue and this was the first study to 
explore this. OCT1-2, PMAT and MATE1-2 proteins were predominantly localized to the 
plasma membrane but also found in the cytoplasm and intracellular organelles of the ductal 
epithelial and tumour cells but not the stromal cells.  Generally, there is a consistency in 
expression data between the normal and the fibrocystic disease tissues with a few 
discrepancies, which might be explained by the difference in the number of tissue sections 
analysed (n=34 and n=12, respectively). The results obtained from breast tissue 
immunostaining suggest that, OCT1 is down-regulated with increased disease severity, 
MATE1 is highly expressed, while OCT3 and MATE2 are the least expressed, which 
correlate well with the protein expression study of the cell lines.  All breast tissue subtypes 
abundantly expressed OCT2, however, Western blotting revealed no change in the expression 
of OCT2 among the cell lines while the immunostaining showed down-regulation of the 
expression with increased stage of BC disease. Unlike the cell line expression findings, 
PMAT tissue expression was reduced with advanced stages of the breast cancer disease.  
The data might suggest a possible role for OCT1-3, PMAT and MATE1 in breast 
tissue response to metformin; however, this remains inconclusive unless further uptake 
studies are performed. The data also demonstrate a clear pattern of decreasing OCTs and 
PMAT expression with an increasing severity of breast disease, with grade III having the 
lowest. This suggests that metformin may be transported into breast cells at all stages of 
cancer progression, but least at stage III and therefore if a patient has stage III cancer they are 
less likely to respond to metformin, and analysis of the transporter expression would be 
necessary to identify patients who are likely to respond to metformin treatment. Although it 
would be interesting to identify the hormonal receptor status of the different grades of IDC 
tissue section used in our study, they were all commercially available TMAs and this data 
was not available. To date there are no studies that have looked at a correlation between 
breast cancer stage and metformin response in established disease.  
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The expression of OCTs and MATEs genes in human breast tumour tissues, and their 
corresponding adjacent normal and non-malignant tissues has been previously assessed using 
RT-qPCR. In the three tissue types examined in this study, OCT3 and PMAT genes were the 
predominant transporters expressed using PCR279.  The study also detected a lower 
expression of OCT1 and MATE1 genes and negligible expression of the OCT2 and MATE2 
genes. Similarly to the protein immunohistochemistry results presented here, the analysis of 
OCT1, OCT3, PMAT and MATE1 gene expression revealed a down regulation of these 
transporters in all the breast tumour tissues analysed compared to the adjacent non-malignant 
tissues, although this decrease was not statistically significant. However, considering that the 
RT-PCR and immunohistochemistry techniques are totally different (targeting RNA and 
proteins respectively), the results, although similar, are not fully comparable, which may 
explain some of the subtle differences between them.  Sample size and preparation are also 
likely to make a difference.  
To complement this work, future experiments might include a mass spectrometry 
analysis to determine the relative importance of how the expression of these transporters can 
affect intracellular uptake of metformin. This would be followed by a knockdown experiment 
of these transporters to determine whether this would alter sensitivity to metformin (in terms 
of proliferation) and metformin uptake.  Moreover, it remains to be determined whether the 
transporter expression would change with prolonged exposure to metformin and hence this 
could be a mechanism of acquired resistance. However, due to time and money constraint 
these experiments were not performed.  
To conclude, in this study, OCTs, PMAT and MATE1 were all detected in normal, 
pre-malignant, pre-invasive and invasive human breast cell lines and tissues. These findings 
suggest that multiple transporters are likely to be involved in metformin transport in breast 
cell lines and tissues and there might be an overlap between them. Therefore, metformin is 
likely to enter and leave all the breast cells in our model of breast disease, as the majority of 
our cell lines are positive for at least one influx and one efflux transporter. Furthermore, data 
in this chapter have demonstrated that there is an altered expression of metformin transporters 
in disease states, with the majority decreasing with increasing lesion severity. The next 
chapter will now investigate whether clinically relevant doses of metformin will be 
efficacious in these models of increasing severity of breast disease. The data will also identify 
whether there is a correlation between transporter expression and metformin response in these 
cells.  
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4. Chapter 4: Evidence of anti-Cancer effects of clinically 
relevant doses of metformin, in vitro 
4.1 Introduction 
Recently, the bench-to-clinic scenario for metformin as a potential treatment for non-
diabetic breast cancer patients has received considerable critical attention. Population-based 
observational studies indicate that metformin might reduce breast cancer risk and mortality in 
diabetic patients. Metformin might protect against breast cancer indirectly by ameliorating 
insulin resistance and systemic glucose homeostasis. Alternatively, metformin might directly 
target breast cancer cells through a series of events resulting in decreased protein translation, 
inhibition of cell proliferation and increased apoptosis 
Indeed, a considerable number of preclinical studies have also suggested a wide range 
of anti-cancer effects of metformin, including the inhibition of cell proliferation, cell cycle 
progression and apoptosis in vivo and in vitro cell line model systems of various breast cancer 
subtypes, and have attempted to identify the potential mechanisms of action. Moreover, 
considerable attention has been paid to the role of altered metabolism in breast cancer and the 
ability of metformin to significantly affect several metabolic pathways that suggests that it 
could be effective at preventing the development and progression of this disease. However, 
an important shortcoming of most previous in vitro studies is the use of supra-
pharmacological doses of the drug and supra-physiological glucose concentrations in culture. 
Consequently, the clinical relevance of the data obtained using doses higher than 10mM 
metformin has been questioned with growing concerns that the inhibitory effects seen with 
higher metformin doses are likely to be off-target effects which are not reflective of in 
vivo events; this remains a contentious issue which limits the translation of published 
preclinical data into the clinical setting.  
Despite the wealth of information presented in chapter one, we are still far from a 
clear, consistent picture that could support the rational for metformin to be used in either 
breast cancer prevention or treatment.  Additionally, there is still a concern that not all breast 
cancer cell lines responded to metformin treatment, so it could therefore potentially be more 
effective on specific subtypes of breast cancer such as luminal A, and as yet it is not clear 
why some respond while others do not. What is clear is that metformin does have a great 
impact on breast cancer growth both directly and indirectly in vitro, at least at supra-
physiological doses.  
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The data in the previous chapter demonstrated that there is at least one importer and 
one exporter protein on each breast cell type that could potentially allow metformin to 
accumulate in the non-tumour and tumour breast cells, suggesting that metformin would 
directly enter the cells and has the potential to enter the mitochondrion where it can inhibit 
complex 1, which would result in growth and survival inhibition of the breast cells.  In 
addition, the previous observations from the literature that metformin inhibits the growth and 
proliferation of breast cancer cells in culture, suggests that the antineoplastic action of 
metformin could be mediated, at least in part, through a direct effect on cancer cells. 
Therefore, this project tests the hypothesis that clinically relevant doses of metformin would 
inhibit the growth and survival of breast cancer cells. Accordingly, our panel of increasingly 
malignant cell lines would be expected to demonstrate potential variability in their response 
to the clinically relevant doses of metformin, due in part to the heterogeneity in their OCTs 
and MATEs metformin transporter expression.  
As data on the effect of the therapeutically relevant doses of metformin on breast 
cancer is extremely limited, this study aimed to assess the direct anti-proliferative and 
cytotoxic effects of metformin at increasing doses including those which are clinically 
relevant plasma doses (0.03-0.3 mM) close to those found in the plasma of type 2 diabetic 
patients treated with this drug, potential tissue accumulated doses (1 mM and 5 mM), as well 
as using higher concentrations corresponding to the toxic supra-pharmacological doses (10 
mM and 20 mM) in certain assays to confirm the previous literature, against a panel of breast 
cell lines.  The cell lines were chosen as a representative sequence in the tumourigenesis of 
breast cancer, with cell lines corresponding to non-tumorigenic (normal epithelial), 
hyperplastic tissue, in situ carcinoma, 3 molecular subtypes of invasive carcinomas (with 
different hormonal status) and the fully bone-homed metastatic breast cancer cells in order to 
mimic a more clinically relevant breast cancer model system, in vitro. The luminal cell lines 
A (MCF-7 and T47D) have molecular signature of epithelial phenotype, while the basal cell 
line (MDA-MB-231) is molecularly mesenchymal-like. It is hoped that this will be useful in 
identifying any subpopulation that are more responsive to metformin treatment.  
This work therefore aimed to provide insight into whether metformin may act as a 
chemotherapeutic drug in different breast cancer subtypes by affecting cell viability, 
metabolic activity, DNA replication and cell cycle and migration at clinically relevant doses 
in vitro. Additionally, the work in this chapter aimed to see whether there is a possible 
correlation between the sensitivity to metformin and metformin-transporter expression.  
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4.2 Methods  
§ In order to investigate the effects of the clinically relevant doses of metformin 
in breast cancer, cell lines representing different severities of breast lession were cultured 
as described previously in section 2.2.1.                   
§ MTS assay was used to assess the effect of the pharmacologically relevant 
doses of metformin on the metabolic activity of breast cells, following the protocol in 
section 2.2.6.1.2.   
§ Trypan blue exclusion assay was used to investigate the effect of the clinically 
relevant doses of metformin on viability and total cell count of the breast cells, as in 
section 2.2.7.2. 
§ BrdU incorporation assay, a DNA synthesis–based cell proliferation assay, 
was used to explore the effect of the clinically relevant doses of metformin on the 
proliferation of breast cells, following the protocol in section 2.2.8.4.  
§ Clonogenic assays were used to assess the influence of the clinically relevant 
doses of metformin on cell survival and reproductive capabilities, following the protocol 
in section 2.2.7.2. 
§ Flow cyotometry analysis was used to explore the effect of metformin on cell 
cycle progression as detailed in sections 2.2.8.2 and 2.2.8.3. 
§ Wound healing scratch assay was used to assess the effect of metformin on the 
migration of breast cancer cells following the protocol in section 2.2.9.4. 
§ Each experiment was performed on at least three occasions and the graphs 
shown are the average of these data.  Statistical analysis was performed with advice from 
the Sheffield statistical services and the tests used were the non-parametric tests as 
detailed in Statistical analysis, section 2.2.11, and a P-value of <0.05 was taken to be 
significant. 
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4.3 Results  
4.3.1 Comparison of growth rate between tumour and non-tumour breast cell lines 
Before assessing the anti-proliferative effect of metformin on different cells, cellular-
growth curves for all cell lines were established to compare the growth patterns and rates 
between different human mammary cells and define the baseline growth characteristics of 
cells. Proliferation was quantitated and expressed as population-doubling time. Cell line 
population doubling times (PDTs) were determined by plating 2×104 cells of three biological 
replicates as triplicates in a 6-well plate in their respective assay media. Four plates per cell 
line were counted at 24, 48, 72 and 96 hours after plating and cellular proliferation was 
analysed by counting the viable cell number. The PDT for each cell line was calculated using 
the following equation (doubling time computing tool at http://www.doubling-
time.com/compute.php was employed):   
Doubling time=
duration× log 2
log(FinalConcentration) - log(InitialConcentration)
 
 
 
Where "log" is the logarithm to base 10 (as automatically calculated). 
 
The growth curves, illustrated in figure 4.1, showed that the malignant cells divided at 
a slower rate than normal, premalignant and pre-invasive cells and population-doubling time 
values of malignant cells were more heterogeneous than those of the normal cells. Our 
findings demonstrate that the MCF10A and MCF10AT cell lines had the highest growth rate 
and T47D cells were the slowest; PDTs were 19.02 hours, 19.12 hours and 45.87 hours, 
respectively. For the rest of cell lines, the doubling time was in the following order: 
DCIS.com (21.19 hours) > MDA-MB-231(BM) (36.49 hours) > MDA-MB-231 (37.15 
hours) > MCF7 (40.26 hours), PDTs are summarized in table 4.1.  
It should be noted that the media in which MCF10A, MCF10AT and DCIS.com were 
growing contains more growth stimulatory factors than the media in which the breast cancer 
cells were grown, which may account for some of the differences seen.  
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Figure 4.1: The growth curves of normal, premalignant, pre-invasive, invasive and the 
fully bone-homed human breast cells.  
The numbers of viable cells were counted for 4 days. Data represent the mean±SD of three 
independent experiments. 
 
Table 4.1: Summary of the cell lines used in this chapter and their population doubling 
times (PDTs)  
Cell line  Classification  PDT 
(hours) 
PDT from the 
ATCC website 
MCF10A Non-tumorigenic normal epithelium  19.02 16 hours 
MCF10AT Pre-malignant ductal hyperplasia 19.12 Not available 
DCIS.com Pre-invasive ductal carcinoma in situ 21.19 Not available 
MCF7 Invasive BC, luminal A 40.26  38 hours 
T47D Invasive BC, luminal A 45.87 43 hours 
MDA-MB-231 Invasive BC, Claudine low (triple 
negative) 
37.15 38 hours 
MDA-MB-231(BM) Metastatic bone-seeking  36.49 Not available 
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4.3.2 Assessment of the anti-metabolic effect of metformin using MTS assays 
Initially, in order to compare our findings with those of the literature152, 173, 294, the 
post-treatment cellular viability and metabolic activity were assessed using the colorimetric 
MTS assay. Following assay optimisation (section 2.2.6.1.3), the anti-proliferative effect of 
metformin was then evaluated by treating all cell lines with increasing concentrations (0.03-
20 mM). Cellular responses in terms of metabolic activity were measured at 3 time intervals 
(24, 48 and 72 hours) (Figure 4.2).  
Following 72 hours of treatment, the clinically relevant doses of metformin did not 
inhibit the proliferation of the invasive breast cancer cell lines, but significantly reduced the 
cellular metabolic activity of the pre-invasive MCF10A (by 11.8% of the untreated control), 
MCF10AT (by 8.3% of the untreated control) and DCIS.com (by 41.6% of the untreated 
control) cells at a dose equal to or greater than 0.03 mM (P<0.001, P<0.001 and P<0.0001, 
Dunnett’s test, respectively, compared to the untreated controls), the same effect was 
observed at 0.3 mM in the metastatic bone-homed cells (by 20% of the untreated control) 
(P=0.01, Dunnett’s test, compared to the untreated control).  
A significant inhibition was only achieved at 20 mM concentration resulting in 19% 
(P=0.01), 13% inhibition (P=0.04) and 10% (P=0.03) in the MCF7, T47D and MDA-MB-231 
cells respectively; assessed using the Post hoc Dunnett’s test compared to the untreated 
controls. Percentages of inhibition are summarized in Table 4.2. 
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Figure 4.2: Clinically relevant concentrations of metformin reduced the viability of the non-tumorigenic (MCF10A), premalignant 
(MCF10AT) and pre-invasive (DCIS) cells.  
Cellular metabolic activity was measured using the MTS assay and the percentage of cell viability was calculated relative to control wells (no 
treatment) designated as 100% viable cells. Metformin inhibited all the pre-malignant and pre-invasive cell lines in a significant dose dependent 
manner achieving significance at 0.03 mM and 0.3 mM in the metastatic bone-derived cells. The metabolic activity of the three invasive cells was 
inhibited at 20 mM. The values are presented as mean ± standard deviation (SD) from three independent experiments.  
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   Table 4.2: Analysis of the inhibition in cellular metabolic activity following 72 hours of metformin treatment 
 Percentages of inhibition P-values IC50 
 
Cell line 
Clinically relevant  
doses 
Potential tissue 
accumulation 
doses 
  Supra-
pharmacological  
(Toxic) doses 
One-way 
ANOVA 
test 
Post hoc Dunnett’s 
test 
 
0.03mM 0.1mM 0.3mM 1mM 5mM 10mM 20mM 
MCF10A (11.8%) (14.7%) (16%) (20.6%) (24.5%) (24.6%) (25%) P<0.001 Achieved 
significance at 0.03 
mM (P=0.001) 
>20mM 
MCF10AT (8.3%) (11.4%) (9.3%) (9.7%) (41%) (70.2%) (75.5%) P<0.003 Achieved 
significance at 0.03 
mM (P=0.002) 
5.7mM 
DCIS.com (41.6%) (46.4%) (45.3%) (49.7%) (61.7%) (63.2%) (63.1%) P<0.001 Achieved 
significance at 0.03 
mM (P=0.0001) 
1.8mM 
MCF7 (0.9%) (2.3%) (3.5%) (3.3%) (3.9%) (5.2%) (19.7%) P<0.01 Achieved 
significance at 10 
mM (P=0.01) 
>20mM 
T47D (0.8%) (0.8%) (3.1%) (3.7%) (6%) (4.4%) (13.7%) P<0.05 Achieved 
significance at 10 
mM (P=0.03) 
>20mM 
MDA-MB-
231 
(4.3%) (4.9%) (10%) (9.5%) (7.7%) (8.8%) (10.6%) P<0.05 Achieved 
significance at 20 
mM (P=0.04) 
>20mM 
MDA-MB-
231(BM) 
(0.2%) (4%) (20%) (20.5%) (19.3%) (23.2%) (25.3%) P<0.002 Achieved 
significance at 0.3 
mM (P=0.01) 
>20mM 
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4.3.3 The effects of metformin on viable cell numbers and viability as assessed by 
trypan blue exclusion assay 
As the MTS assay relies on the activity of mitochondrial dehydrogenase and there 
is some evidence that metformin may alter the activity of mitochondrial enzymes295, the 
data needed confirming in an alternative assay.  Using a trypan blue exclusion assay it 
was possible to both confirm the MTS assay data and to evaluate whether clinically 
relevant doses of metformin have an effect on both on both the viability and viable cell 
counts 72 hours after treatment. This time point was used, as this is the point at which 
maximum inhibition was seen in the MTS assay for all cell lines.  
The data clearly demonstrate a significant decrease in cell number in all cells lines 
in a dose dependent manner (Figure 4.3A and Table 4.3) as assessed by the One-way 
ANOVA test.  The reduction in viable cells count was significant at doses equal to or 
greater than 0.03 mM (P=0.0001, Dunnett’s test, compared to the untreated controls) in 
MCF10A, MCF10AT, DCIS.com (to 42%, 58% and 78% of the untreated controls, 
respectively) and achieved significance at 0.3 mM in T47D, MDA-MB-231 and its bone-
homed variant cells to 19%, 36% and 39% of the untreated controls respectively 
(P=0.0001, Dunnett’s test, compared to the untreated controls) (Table 4.3). In contrast the 
MCF7 cells only achieved significant inhibition in cell number (36% of the untreated 
control) when treated with 5 mM metformin (P=0.0001, Dunnett’s test, compared to the 
untreated controls).  
However, unlike in the MTS assay, among cancer cells the invasive T47D, MDA-
MB-231 and the fully bone-homed cells were responsive to the highest dose in the 
clinically relevant doses range, namely 0.3 mM, as well as to the potential tissue 
accumulation doses of metformin (1-5 mM). MCF7 cells have also significantly 
responded to a dose of as low as 5 mM.  The results from all other cells were in line with 
the MTS assay.  
Interestingly the pre-malignant and pre-invasive cell lines showed a clear dose 
dependent inhibition in cell viability at all doses (Figure 4.3B), achieving significance at 
0.03 mM (P=0.0001) in the MCF10AT and DCIS.com and 0.1 mM (P=0.0001) in the 
MCF10A cells; assessed by post  hoc Dunnett’s test compared to the untreated controls.  
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In contrast, there was only a slight reduction in the viability of the invasive breast 
cancer cells in response to metformin treatment.  Indeed, T47D cells were the most 
responsive showing a significant inhibition in viability in response to 5 mM metformin 
treatment  (P=0.0001), whereas MCF7 and MDA-MB-231 cell viability was only 
significantly affected at the highest tested dose; 20 mM (P=0.0012). In contrast the 
viability of the fully bone-homed cells was not significantly affected at any tested dose 
(P=0.109); Dunnett’s test compared to the untreated controls (Figure 4.3B). Percentages 
of inhibition are summarized in Table 4.3.  
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Figure 4.3: Clinically relevant doses of metformin reduce the growth and viability of 
the premalignant cells and suppress the proliferation of invasive cells without 
affecting their viability.  
Cells were treated with increasing doses of metformin and the cell number and viability 
established following 72 hours of treatment. (A) The growth inhibitory effect of 
metformin was noticeable at lower doses than the MTS assay in all cancer cells. 
MCF10A, MCF10AT and DCIS.com cellular proliferation were inhibited at the lowest 
dose of 0.03 mM. (B) In contrast to the invasive cells, in which the effect on viability was 
limited, the viability of MCF10A, MCF10AT and DCIS.com was significantly reduced at 
0.03 mM (P=0.0001; Dunnett’s test). Data is presented as mean ± SD of the viable cell 
counts and percentage of viability from three independent experiments.   
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Table 4.3: Analysis of the reduction in viable cells number following 72 hours of metformin treatment 
 Percentages of inhibition P-values IC50 
 
Cell line 
Clinically relevant  
doses 
Potential tissue 
accumulation 
doses 
  Supra-
pharmacological  
(Toxic) doses 
One-way 
ANOVA 
test 
Post hoc Dunnett’s test 
 
0.03mM 0.1mM 0.3mM 1mM 5mM 10mM 20mM 
MCF10A  (42.2%) (52.4%) (56.8%) (67.7%) (74.3%) (80.2%) (86.8%) P<0.001 Achieved significance at 
0.03 mM (P=0.0001) 
0.05mM 
MCF10AT  (58.2%)  (74.6%) (90.4%) (91.4%) (94.4%) (96.71%) (96.8%) P<0.001 Achieved significance at 
0.03 mM (P=0.0001) 
<0.03mM 
DCIS.com  (78.0%)  (82.4%) (82.9%) (83.2%) (88.8%) (100%) (100%) P<0.0001 Achieved significance at 
0.03 mM (P=0.0001) 
<0.03mM 
MCF7  (1.6%)  (0.8%) (1.3%)  (3.5%) (36.5%) (37.3%) (48.4%) P<0.003 Achieved significance at 5 
mM (P=0.0001) 
>20mM 
T47D  (1.7%)  (4.3%) (19.7%)  (41.7%) (48.7%) (58.6%) (68.0%) P<0.001 Achieved significance at 
0.3 mM (P=0.002) 
5.7mM 
MDA-MB-
231 
(0.7%) (2.0%) (36.3%) (45.2%) (67.9%) (80.93%) (81.12%) P<0.0001 Achieved significance at 
0.3 mM (P=0.0001) 
1.4mM 
MDA-MB-
231(BM) 
(2.5%) (0.8%) (39.1%) (38.7%) (44.7%) (60.8%) (80.5%) P<0.0001 Achieved significance at 
0.3 mM (P=0.0001) 
7.8mM 
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4.3.4 The effects of metformin on DNA replication activity of the breast cells as 
measured by the BrdU assay  
As the MTS assay measures metabolic activity and the trypan blue exclusion 
assay simply measures cell number and viability, it was decided to use the BrdU 
incorporation assay to measure DNA replication as a further measure of proliferation, 
again after 72 hours treatment with increasing doses of metformin. The change in 
DNA synthesis was calculated by comparing BrdU signals of metformin-treated cells 
to that of the BrdU-labelled control untreated cells. 
Proliferation of cell lines as measured using the BrdU assay was significantly 
inhibited in a dose dependent manner (Figure 4.4). Metformin treatment of the 
immortalised normal breast epithelial cells (MCF10A) resulted in a significant 
inhibition at a dose of 0.3 mM achieving 37% inhibition. In contrast the pre-
malignant, MCF10AT, and pre-invasive, DCIS.com, cells were more sensitive to 
metformin treatment, achieving significance at 0.1 mM (34.4%, P=0.0019) and 0.03 
mM (36%, P=0.0001), respectively; assessed by Dunnett’s test compared to the 
untreated controls. The less invasive breast cancer cell lines were less sensitive with 
inhibition achieving significance at 1 mM (MCF7 = 43.3%, P=0.0008; T47D = 41%, 
P=0.0018, Dunnett’s test, compared to the untreated controls). In contrast the highly 
aggressive MDA-MB-231 and the metastatic bone-homed variant MDA-MB-
231(BM) cells were more sensitive with significance seen at lower doses; 0.3 mM and 
0.03 mM, respectively (26.2%, P=0.0024 and 27.6%, P=0.004, respectively, 
Dunnett’s test, compared to the untreated controls) (Table 4.4).  
However, metformin at concentrations of 10-20 mM inhibited BrdU 
incorporation by 71%–90% in MCF10A, MCF10AT, MCF7, MDA-MB-231(BM) 
and T47D (Figure 4.4). Metformin at 20 mM inhibited 65% and 47% of the 
DCIS.com and MDA-MB-231 cells proliferation.  
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Figure 4.4: Experimentally relevant doses of metformin significantly reduced the 
proliferation in all cell cultures after 72 hours of treatment.  
Cell proliferation was evaluated by BrdU incorporation assay. Three individual 
experiments were performed in triplicates. Graphs represent the percentage of BrdU 
positive cells relative to the BrdU-labelled control cells. The data are expressed as 
mean ±SD. Metformin inhibited all cells lines in a significant dose dependent manner 
achieving significance at 0.1 mM in the pre-malignant and pre-invasive cells and 1 
mM in invasive cells and 0.1 mM in the metastatic bone-derived cells.  
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     Table 4.4: Analysis of the inhibition in BrdU incorporation in breast cells following 72 hours of metformin treatment 
 
 
 Percentages of inhibition P-values IC50 
 
Cell line 
Clinically relevant  
doses 
Potential tissue 
accumulation doses 
  Supra-
pharmacological  
(Toxic) doses 
One-way 
ANOVA test 
Post hoc Dunnett’s 
test 
 
0.03mM 0.1mM 0.3mM 1mM 5mM 10mM 20mM 
MCF10A (20.3%) (28.5%) (37.6%) (50.8%) (62.6%) (71.7%) (75.0%) P<0.002 Achieved significance at 
0.3 mM (P=0.001) 
0.97mM 
MCF10AT (2.9%) (34.4%) (37.6%) (37.1%) (43.7%) (72.13%) (80.36%) P<0.001 Achieved significance at 
0.01mM (P=0.0019) 
6.1mM 
DCIS.com (36.0%) (47.1%) (53.6%) (51.7%) (52.9%) (53.2%) (65.2%) P<0.0001 Achieved significance at 
0.03 mM (P=0.0001) 
0.29mM 
MCF7  (14.4%)  (17.0%)  (17.9%)  (43.3%)  (55.4%)  (72.1%)  (83.9%) P<0.002 Achieved significance at 
1 mM (P=0.0008) 
4.1mM 
T47D  (19.0%)  (28.9%)  (31.6%)  (41.4%)  (76.9%)  (86.15%)  (90.02%) P<0.005 Achieved significance at 
1 mM (P=0.01) 
2.5mM 
MDA-MB-
231 
(11.9%) (15.4%) (26.3%) (30.3%) (30.3%) (35.5%) (47.5%) P<0.001 Achieved significance at 
0.3 mM (P=0.0024) 
>20mM 
MDA-MB-
231(BM) 
(27.6%) (40%) (52.4%) (68.8%) (73.8%) (77.62%) (77.8%) P<0.0001 Achieved significance at 
0.03 mM (P=0.004) 
0.91mM 
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4.3.5 Assessment of the anti-survival effect of metformin using clonogenic assays  
As previous studies have used clonogenic assays to investigate the effects of 
high doses metformin on the ability of the breast cancer cells to form colonies, it was 
decided to study the ability of the breast cancer cells to form colonies after exposure 
to the pharmacologically relevant doses of metformin using a traditional clonogenic 
assay. In this assay cells were exposed to various concentrations of metformin for 
72hrs before being collected by gentle trypsinization and seeded onto the assay plates 
and incubated for 14 days before they were stained with crystal violet and the number 
of colonies counted. It should be noted that while the majority of the cell lines readily 
formed colonies, MCF10A and MCF10AT cells did not form colonies in the absence 
of treatment and were therefore not able to be investigated in these assays. 
Metformin induced a significant reduction in colony formation in a dose-
dependent manner in all cell lines tested (Figure 4.5). In contrast to the data seen with 
the cell counting assays, the clinically relevant doses of metformin induced a 
significant reduction of the reproductive capability of all invasive cell lines (P 
<0.0001, by One-way ANOVA test). At 0.03 mM, all cell lines lost a significant 
percentage of their reproductive ability; DCIS.com (by 57% of the untreated control, 
P<0.0001), MCF7 (by 39% of the untreated control, P<0.0019), T47D (by 48% of the 
untreated control, P<0.0001) and MDA-MB-231 (by 37.4% of the untreated control, 
P<0.0116), MDA-MB-231(BM) (by 44.7% of the untreated control, P=0.0008) 
measured by Dunnett’s test.  
At higher doses (10-20 mM) the colony formation ability was markedly 
impaired and frequently no colonies were observed (reduced to <5% as compared to 
the controls in all cell lines) (Figure 4.5).  
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Figure 4.5: Metformin is able to significantly suppress colony formation at the lowest concentration of 0.03 mM in all cell lines tested.  
The bar graphs represent the mean of 3 independent experiments +/- SD. P-value of each dose versus control was measured by Dunnett’s test. 
Representative pictures of the crystal-violet stained colonies were taken on day 14 using a digital camera. ***P<0.001 and ****P<0.0001.   
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4.3.6 The effects of metformin on cell cycle progression in breast cells 
As the different assays described demonstrated an inhibition in proliferation in 
all the cell lines, flow cytometric cell cycle analysis was performed to determine 
whether the results of these proliferation assays were a reflection of cytostatic or 
cytotoxic effects due to cell cycle arrest or apoptosis. Since the inhibition of cellular 
proliferation may be mediated by the regulation of cell cycle, we examined the effect 
of three doses of metformin (0.3, 1 and 5 mM) on cell cycle perturbations; these were 
the doses that were significant in all the cell lines in most of the assays and represent 
both plasma and tissue achievable doses of metformin.     
Compared with untreated controls, more cells had accumulated in G0/G1 phase 
in MCF10A, DCIS.com, MCF7, T47D and MDA-MB-231 cell lines after 72 hours of 
metformin treatment in a dose dependent manner; the higher the dose the more cells 
accumulated (98%, 94%, 98%, 97%, 80% at 5 mM compared to 91%, 80%, 78%, 
70%, and 73% in the control cells; P<0.0001, respectively), as shown in figures 4.6 
and 4.7. 
In contrast, a significant reduction in the number of cells present in the G0/G1 
phase was observed in MCF10AT cells at all tested concentrations (67%, 61% and 
66% at 0.3, 1 and 5 mM, compared to 74% in the control untreated cells, P<0.0001) 
and there was a significant accumulation of cells in the G2/M phase at all tested doses 
(27%, 34% and 25%, compared to 21% in the control untreated cells, P<0.0001), as 
shown in figure 4.6.  
In contrast to the other cell lines the MDA-MB-231(BM) cells did not show a 
consistent pattern with the number of cells in G0/G1 phase increased significantly 
when treated with 5 mM metformin (97%, compared to 73% in the control untreated 
cells, P<0.0001), but significantly reduced alongside a significant increase in the 
number of cells in G2/M phase at the 0.3 and 1 mM doses (23% and 26.6%, 
respectively, compared to 21% in the control untreated cells ; P<0.0001), as shown in 
figure 4.7.   
There was no significant change in the number of S phase cells throughout all 
concentrations in all cell lines tested, suggesting that the cells were arrested at either 
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G0/G1 or G2/M phase. Importantly there were no cells in the sub-G1 phase indicating 
that the tested concentrations did not induce cell apoptosis. 
 
 
 
Figure 4.6: Metformin induced cell cycle arrest in the premalignant and pre-
invasive breast cells.  
Cells were treated with 0.3, 1 and 5 mM of metformin for 72 hours, stained with PI, 
and analyzed by flow cytometry. Stacked bar graphs represent the percentage of cells 
in each cell cycle phase for MCF10A, MCF10AT and DCIS.com cells respectively. 
Histograms represent the distribution of cells in each cell cycle phase; P1 represents 
the Sub-G1 or apoptosis phase. Data are presented as the means ±SD from three 
independent experiments.  
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Figure 4.7: Metformin induced cell cycle arrest in the invasive and fully bone-
homed breast cancer cells.  
Stacked bar graphs represent the percentage of cells in each cell cycle phase for 
MCF7, T47D, MDA-MB-231 and MDA-MB-231(BM cells respectively. Histograms 
represent the distribution of cells in each cell cycle phase. Data are presented as the 
means ±SD from three independent experiments.   
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4.3.7 Assessment of the anti-migration effect of metformin as measured by in 
vitro scratch wound healing assay  
To investigate the effects of the clinically relevant and potential tissue 
accumulation doses of metformin on cell migration; an important part of the 
metastasis pathway, a wound-healing assay was performed.  As discussed in section 
2.2.9, it was only possible to perform this experiment in the non-aggressive MCF7, 
less invasive T47D and the highly aggressive MDA-MB-231 human breast cancer 
cells, as the other cell lines did not migrate in this assay (Section 2.2.9.3).  
Cells were incubated with different concentrations of metformin and their 
ability to fill the scratch by migration assessed over 24 hours (Figure 4.8).  In all the 
cell lines where migration occurred, metformin doses equal to or greater than 0.03 
mM caused a significant, concentration-dependent inhibition in migration, with the 
exception of the MDA-MB-231 cells where inhibition became significant at 0.3 mM 
but not 0.03 mM.  The T47D cells showed a 50% inhibition in migration following 
0.03 mM metformin treatment, while MCF7 cells showed a 37% decrease in 
migration at the same dose; compared to the untreated control cells.  The migration 
ability of the highly metastatic MDA-MB-231 cells was reduced to 47% at 0.3 mM, 
compared to the untreated control cells. At the highest dose tested, 5 mM, the 
inhibition ranged between 50% for MCF7 cells and 60% for T47D and MDA-MB-
231 cells. 
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Figure 4.8: The migration of invasive breast cancer cells is reduced by metformin 
treatment.  
Cell migration was detected by wound scratch assay. In all cell lines, untreated cells had 
completely closed the gap by 24 hours. The quantitative effect of metformin treatment on 
wound closure at 24 hours was used to compare cell motility, represented by the bar 
graphs. Cell migration was calculated and expressed as the percentage of migration 
relative to the untreated control cells. Statistical significance of differences was assessed 
by Dunnett’s test. Values are presented as means ± SD of three independent experiments, 
***P<0.001 and ****P<0.0001. Representative wound closure images from three 
experiments are shown. The photographs represent images obtained at zero time, and at 
24 hours after scratch formation.  
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4. Discussion  
To date, despite strong evidence from in vitro studies supporting the role of 
metformin in treating most, if not all, molecular subtypes of breast cancer, there is no 
consensus regarding which molecular subtype would, more likely, respond better than 
others. The data demonstrate variability in proliferation and cytotoxic sensitivity 
between breast cancer cells in response to different concentrations and different 
exposure time-points. However, when reviewing the literature it becomes increasingly 
obvious that all the evidence about the cytotoxic effect of metformin in pre-clinical 
studies was obtained by exposing the in vitro cultured cells to supra-pharmacological 
concentrations of metformin (5-50 mM)156, 176, 177, 179, 243, 296. Therefore, the anti-
proliferative effect seen at these supra-clinical doses might be considered as a general 
response to metformin toxicity with no clinical value. In order to understand the 
anticancer mechanism of this anti-diabetic drug, it is important to clarify whether 
metformin can exert direct effects on breast cancer cells at the recommended clinical 
doses (850-2250 mg).  
In the present study, six in vitro techniques have been used to evaluate the 
effects of clinically and experimentally (probable tissue accumulation concentrations) 
relevant doses of metformin244, 248, 249 on the proliferation, survival, cell cycle 
progression and migration of various breast cell lines. Metformin was tested at 
concentrations within the therapeutic range (0.03-0.3 mM) that were 10-100-fold 
lower than those used in most previous reports in order to overcome the limitations of 
those studies, as well as using higher concentrations (10-20 mM), in certain assays, to 
confirm the previous literature. 
To account for the variability in cell culture and to enable comparison between 
groups of cell lines we used the same assay media for all the non-transformed, pre-
malignant and pre-invasive cells (MEGM). Similarly, all the invasive and metastatic 
breast cancer cells were assayed in the same media (RPMI-1640).  
Our finding that the invasive malignant breast cells doubled, on average, more 
slowly than the non-transformed, premalignant and pre-invasive cells, may appear 
surprising.  However, a number of previous in vitro studies have shown very 
similar growth rates to the data shown in our study255, 297. This increase in growth 
potential is conferred by the presence of human epidermal growth factor and cholera 
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toxin in the Mammary Epithelial Cell Growth Medium (MEGM) used to grow the 
MCF10A, MCF10AT and DCIS.com cells.  The addition of EGF, hydrocortisone and 
insulin supplements to the MEGM assay medium is known to stimulate the growth 
and proliferation of the mammary epithelial cells298, 299. In addition, cholera toxin is 
also known to increase the intracellular cyclic adenosine monophosphate (cAMP) 
levels caused by continuous stimulation of adenylate cyclase in the mammary 
epithelial cell culture system, which has a growth stimulatory effect300-302. The 
heterogeneity of the doubling time values among the invasive malignant cells may 
indicate a high degree of individuality between the breast cancer subtypes, and are 
consistent with previous studies showing that T47D cells grow more slowly than 
MCF7, which grow more slowly than MDA-MB-231 cells303, 304.  
MTS, trypan blue and BrdU incorporation assays of viability and proliferation 
One cellular metabolic assay employed in this chapter was the MTS assay to 
measure the cytotoxic/static effect of metformin exposure in different breast cell lines 
for comparison with the previous literature. In addition two alternative independent 
measures of viability/proliferation, that of trypan blue exclusion and BrdU 
incorporation, were used to directly compare the measurements obtained by MTS, as 
there is a theoretical risk that metformin may falsely lower the measure of viability 
due to mitochondrial effects which may influence the MTS results252, 295. MTS assay 
measures cellular metabolic activity of various dehydrogenase enzymes such as 
NAD(P)H-dependent oxidoreductases found in the mitochondria of cells by 
measuring the reduction of a tetrazolium component (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) to yield 
a formazan product. As metformin is thought to potentially affect this and other 
mitochondrial enzymes, data from the MTS assay may be lowered as a result of this, 
rather than a decrease in the number of metabolically active cells305, and may 
therefore underestimate the cell viability. However, the tetrazolium ring is not only 
cleaved in the mitochondria, but it may also cleaved in the presence of non-
mitochondrial pyridine nucleotide-dependent enzymes306, this suggests that, despite 
the theoretical concerns, MTS assay might still be used as a relevant metabolic 
measure of metformin activity.  In addition to the MTS assay, the BrdU assay, which 
measures replicating DNA in the proliferating cells, and would not be similarly 
affected by metformin exposure, was also utilised. Similarly, the trypan blue 
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exclusion assay was utilized, but in this case as only one time point was assessed (72 
hours), it was used as a measure of viability, and not specifically cellular 
proliferation. Trypan blue is a dye that is excluded from viable cells due to an 
impermeable intact plasma membrane307.   
In the MTS assay, metformin demonstrated a time and dose dependent 
reduction in the metabolic activity to a greater or lesser extent after 72 hours of 
treatment. Interestingly our data demonstrate that actually the pre-malignant and pre-
invasive cells (MCF10AT and DCIS.com) may be more responsive to metformin 
treatment than the invasive cancer cells.  This is an interesting finding that has 
potential implications for clinical use of this drug. However, there is no previous 
literature to compare these results to, and it may simply be a result of these cells 
proliferating faster than the other cell lines in the absence of metformin treatment 
(Figure 4.1), and therefore being more metabolically active in the first place. Further 
work is required to assess whether proliferation rate will dictate how well cells 
respond to metformin.   
A significant effect was observed at 72 hours following 20 mM metformin 
treatment in all the invasive cell lines.  With regard to MCF7 cells, our findings 
correlate well with previous studies using both MTT180 and MTS172 assays which 
reported the same effect at the same concentration and the same time point. However, 
the literature has reported inconsistent results from experiments using MDA-MB-231 
cells, when assessing the effectiveness of metformin as a direct anti-cancer agent. In 
our MTS assay, although our data demonstrate similar findings to those reported by 
Wang and collegues294,  reported the same effect at 20 mM concentration  after 72 
hours, they are inconsistent with the majority of in vitro work that have reported that 
the MDA-MB-231 cells were the more responsive to the cytotoxic effects than other 
breast cancer cells152, 176, 296 using the same assays. For example, Liu and 
colleagues152, using MTS assay, reported a significant inhibition of metabolic activity 
at a dose as low as 10 mM from a range of 1-40 mM. However, in our assay we did 
not observe a difference between the three invasive cell lines in response to 
metformin. This is surprising as there was no obvious difference in the protocol used 
for this assay, so it may be due to confluence of the cells prior to the experimental set 
up (i.e. were they in the exponential phase of growth or the lag phase).  
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Additionally, a recent study has recently investigated the effects of clinically 
and experimentally relevant doses (6-30 µM and 1000-5000 µM) of metformin using 
MTT assay308, and showed that the reduction in both the proliferation and metabolic 
activity was observed at the clinically relevant doses in the MCF7 cells and at the 
experimental relevant concentrations at the MDA-MB-231 after 24 hours of 
treatment. However, in our assay we have neither observed an inhibitory effect at the 
24 hours time point nor a positive effect at the mentioned concentrations after 72 
hours of drug exposure. This may be attributed to the difference in the protocol as 
they serum starved the cells prior to the assay.  
Data from the trypan blue exclusion assay further confirms the proliferation-
curtailing activity of metformin after 72 hours of exposure. Consistent with the MTS 
data, the clinically relevant concentrations of metformin were able to reduce the 
survival of all the pre-malignant and pre-invasive cells. Our results demonstrate for 
the first time, a significant inhibitory effect on the premalignant, pre-invasive, T47D, 
triple negative cells and its bone homed variants at the therapeutic doses of 
metformin. Additionally, the MCF7 cell line has also responded to the potential tissue 
relevant dose of 5 mM, which although higher than the other cell lines, is lower than 
the previously reported doses in the literature.  
 The viable cell counts of T47D, MDA-MB-231 and its bone-homed variant 
cells were significantly reduced at 0.3 mM, whereas the MCF7 required higher doses, 
within the experimentally relevant range, for inhibition (5 mM).  These data are in 
line with a study by Queiroz and colleagues who treated MCF7 cells for 24, 48 and 72 
hours with single dose of metformin (10 mM) and also reported a significant 
inhibition of cellular growth and proliferation180. In contrast to our data, a similar 
study by Zhuang and co-workers who used a single drug concentration (8 mM) for 3 
days, demonstrated that the MDA-MB-231 were the least responsive to metformin 
treatment when compared to MCF7 and T47D173. However, it was not clear in their 
protocols if they have renewed the metformin-containing medium every 24 hours or 
not as it has been recently suggested that medium renewal can block the anti-
proliferative effect of metformin even if a low glucose-containing medium was used. 
This is because the glucose concentration in the medium is likely to be markedly 
reduced during a 72-hours experiment if the medium was not renewed, and therefore 
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the sensitivity to metformin under these conditions is likely to increase. The other key 
determinant of cellular response to prolonged metformin treatments besides the 
medium renewal protocol is the cell density that can also determine metformin 
sensitivity. Low cellular density cultures can be resistant to metformin treatment even 
if medium is not renewed, while high-density cultures consume more nutrients and 
have elevated rate of glucose consumption, which in turn sensitizes the cells to 
metformin action due to earlier glucose depletion309.  
Despite the sensitivity of all the invasive and metastatic cells to doses lower 
than the supra-pharmacological doses (10-20 mM) previously reported, in terms of 
the cell number, survival data indicate that the viability of invasive cells was not 
affected even at 20 mM. In general, the viability data points towards cytostatic but not 
cytotoxic effects of metformin against the invasive and metastatic cells. However, 
there was a significant cytotoxic effect on all premalignant and pre-invasive cells, 
observed at all the clinically relevant doses, suggesting that these cells are more 
sensitive to metformin treatment. Since the viable cell count was significantly reduced 
at lower doses in all cells than that of the MTS assay, it appears that the MTS assay 
overestimated cell viability and/or failed to accurately detect the reduction in invasive 
cancer cells number at all tested concentrations. Therefore, an additional proliferation 
assay would potentially be beneficial to validate the MTS and trypan blue exclusion 
assay results, and therefore BrdU incorporation into all cells was measured (Figure 
4.4).  
After 72 hours treatment, incorporation of BrdU was reduced significantly by 
the clinically relevant doses in the premalignant, pre-invasive and the fully bone-
homed cells. All the experimentally relevant concentrations of metformin also altered 
BrdU incorporation in all the pre-invasive, invasive and the fully bone-homed cells. 
To our knowledge, there has been no previous work in the literature using the BrdU 
assay to compare our data with.  Collectively, as shown in figures 4.2, 4.3 and 4.4, the 
proliferation measured after 72 hours in the presence of 0.03-20 mM metformin is not 
significantly different between the three assays for the normal, pre-malignant and pre-
invasive cells. However, the results were very different between the MTS and the 
other two assays, supporting our use of three different assays to evaluate the effects of 
the clinically relevant concentrations of metformin and suggesting that the MTS assay 
might not be the relevant assay to be used when evaluating the anti-proliferative effect 
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of metformin where the direct and off-target effects of metformin can result in 
over/underestimation of cell viability. This can be attributed to the ability of 
metformin to work as a weak mitochondrial “poison”, an effect that has been recently 
shown to be enough to reverse the resistance to tamoxifen in MCF7 cells, where the 
mitochondrial activity was responsible for the development of tamoxifen resistance 
and the use of metformin to block mitochondrial function and reversed this effect310. 
Additionally, there is also the possibility that presence of phenol red in the assay 
medium interfered at the wavelength most suitable for the MTS formazan 
measurement, and this may have affected published results in the literature.  This was 
excluded in the present study as a phenol red free media were used for this assay. 
Metformin and breast cells survival  
As all the previous data demonstrated that metformin inhibited cell growth a 
clonogenic assay was employed as an alternative method to study the effect of 
metformin on the survival of the pre-malignant, pre-invasive, invasive and metastatic 
breast cancer cells. This method involved treating the cells with metformin once, then 
seeding them in fresh media without metformin and not changing the media during 
the 14 days period. In all the breast cancer cell lines, the lowest dose of metformin 
(0.03 mM) had a significant effect on colony forming ability. Unlike our approach, all 
previous studies performed the assay by exposing the cells to fresh metformin-
containing media every 72 hours for 14-21 days172. Data from previous literature 
using a wider range of supra-pharmacological doses (2, 10 and 50 mM) for 21 days 
have shown that concentrations as low as 2 mM and 5 mM inhibited colony formation 
in MCF7 and MDA-MB-231 respectively152, 172 which are in agreement with the data 
presented in this chapter. The clonogenic ability of T47D and the fully bone homed 
triple-negative cells in response to metformin has not been studied before. Thereby, 
we demonstrate here for the first time that colony-forming ability was markedly 
impaired by the clinical relevant doses of metformin and no colonies were observed at 
the potential tissue accumulation doses in the DCIS.com, MCF7, T47D and MDA-
MB-231 and MDA-MB-231(BM) cell lines, confirming the previous proliferation 
data.  As the clonogenicity is a property that frequently correlates with 
tumorigenicity, neither the MCF10A nor the MCF10AT were able to form colonies, 
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which is in agreement with the literature that states they cannot form colonies unless 
they are induced to produce colonies by expression of strong oncogenes311.  
Metformin and cell cycle progression in breast cells  
As the data in this chapter clearly show that proliferation is affected by 
metformin in all the cell lines and the effect was dose and cell line dependent, flow 
cytometry was used to characterize the cell cycle progression and establish whether 
metformin caused cell cycle arrest. The data indicate that both clinically and 
experimentally relevant doses of metformin arrest the cell cycle in the G0/G1 phase, 
thus inhibiting the proliferation of the pre-invasive and invasive breast cancer cells, 
suggesting that the growth inhibitory effects of metformin on the all cell lines tested 
might be caused by induction of cell cycle arrest rather than cell death. A different 
pattern of cell cycle arrest was observed in the MCF10AT and MDA-MB-231(BM) 
cells with cells accumulating mostly in the G2/M phase.  These data are in agreement 
with previous studies, which demonstrated that the anticancer property of metformin 
is a consequence of cell cycle perturbation and that exposure to metformin induced 
cell cycle arrest in G0/G1 and G2/M phases in different cancer types, including breast 
cancer. Indeed, several studies reported similar pattern of cell cycle arrest in the 
invasive breast cancer cells (MCF7 and MDA-MB-231) at supra-pharmacological 
concentrations172, 173, 179, 180 although none of the studies have looked at 
pharmacologically relevant concentrations. As several other studies have 
demonstrated that the effects of metformin on cell cycle were mediated by the 
activation of AMPK and inhibition of mTOR signalling pathway in several human 
cancer cell lines including the breast177, 182, 185, 188, 190, 296, 312, 313, we have not further 
evaluated the mechanism of action as the main focus of this project was to confirm 
the end result and explore if the phenotypic effect would occur at lower doses than 
those previously investigated. It is noteworthy however that although there was no 
sub-G0 cell population suggesting that metformin did not induce apoptosis, future 
studies could include flow cytometric analysis using annexin-V to confirm the 
absence of cell death; by measuring both apoptosis and necrosis.   
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Metformin and tumour cell migration 
 
Cellular migration is a crucial initial stage in the breast cancer metastatic 
process which is associated with a loss of cell–cell adhesion, increased migration as 
well as invasion of cancer cells. This study demonstrated that clinical and potential 
tissue accumulation doses of metformin suppressed the migration of the three invasive 
breast cancer cell lines (MCF7, T47D and MDA-MB-231). This finding suggests that 
the clinical doses of metformin might be considered in preventing the invasion and 
metastasis of some subtypes of malignant breast tumours. Our findings might add to 
and expand the results of a recent study by Zhang and colleagues where metformin 
treatment for 48 hours significantly inhibited the migration of MCF7, T47D and 
MDA-MB-231 at a concentration of 5 mM, 10 mM and 20 mM314. However, our 
findings are not directly comparable with Zhang’s study where a different migration 
assay was used, namely the Boyden transwell chamber, as well as prolonged time 
points (48 hours) and supra-pharmacological doses of metformin.  
Our findings that the non-tumorigenic mammary epithelial cells (MCF-10A), 
the hyperplastic MCF10AT and the pre-invasive DCIS.com do not migrate is in line 
with their reported lack of invasive and metastatic capacity and their expression of 
high levels of the epithelial biomarker E-cadherin315-318. At the same time, cells with 
the highest colony-forming ability such as MDA-MB-231 are characterized by low 
expression of E-cadherin, which promote their migratory and invasive capacity. 
Furthermore, the inability of the bone-homed cells to migrate is consistent with a 
previous report showing that the MDA-MB-231(BM) cells exhibited significantly 
decreased migration in a wound-healing assay compared with the parental MDA-MB-
231 cells suggesting that the alterations between the parental and bone-homing 
variants of MDA-MB-231 cells are likely to be clinically relevant to breast cancer 
patients256. 
In conclusion, the data show for the first time that metformin treatment at 
clinically relevant doses inhibits proliferation via cell cycle arrest in breast epithelial 
cells, hyperplastic, pre-invasive (DCIS.com), invasive and metastatic breast cancer 
cells regardless of their receptor status and aggressiveness.  
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These data therefore give further support to the theory that metformin can 
directly affect the phenotype of human breast cancer cells. Moreover, the data 
demonstrate that metformin can inhibit migration of the invasive breast cancer cells, 
suggesting that metformin may potentially inhibit breast cancer invasion and 
metastasis. Interestingly, unlike other commonly used therapeutic drugs, metformin 
does not appear to exhibit a direct cytotoxic effect against the breast cancer cells, 
although it does against the pre-malignant cell line. 
The data also suggest a strong effect against the pre-malignant and the pre-
invasive cells, a finding that might correlate well with the findings arising from the 
observational studies in diabetic populations showing lower incidence of breast 
cancer in patients on long-term metformin treatment.  However, in order to confirm 
this a transgenic mouse model would need to be employed whereby mice are treated 
with metformin from an early age and the age of onset of mammary cancer is 
established compared to those which are not treated.  
To correlate between cellular response to metformin and the expression of 
cation-selective transporters, this study demonstrated that the triple negative BC cells 
(MDA-MB-231) express all the relevant transporters but is still less responsive to the 
effect of clinically relevant doses of metformin when compared to the DCIS.com; the 
most responsive cell line in all our in vitro assays in which PMAT was the 
predominant influx transporter; suggesting that metformin action does not solely rely 
on the transporter expression and its intra-cellular accumulation but several other 
factors are involved in the differential response, which include genetic variability, the 
dosage used, duration of treatment and the presence of competent LKB1/AMPK 
pathway in these cells; AMPK pathway was reported to be incompetent in the MDA-
MB-231 due to an intrinsic deficiency in LKB1 kinase thus attenuating the anti-
proliferative effect of metformin206.  The data also emphasize that one needs to use 
caution in choosing a relevant in vitro cell model for investigating anticancer efficacy 
of metformin whose uptake is transporter-mediated and its action is LKB1-dependent.  
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However, another interesting extension to the assays used in this chapter is by 
culturing the breast cancer cells in 3D (eg spheroids constructed from immortal breast 
cell lines) and determine how this will impact on toxicity and other data. Once this 
was achieved, the IC50 for metformin can be determined to evaluate whether the 
values obtained using 3D spheroids could be compared with those obtained in vitro in 
the classical proliferation assays used and with in vivo observations published 
elsewhere in the literature. This would represent a more clinically relevant assay; than 
the in vitro assays used in this project, to screen the effect of the clinically relevant 
doses of metformin.  
In this chapter, we found that the parental MDA-MB-231 cells and its 
metastatic bone-homed variant were the most sensitive to the clinical doses of 
metformin of the invasive cell lines, however, the pre-invasive and pre-malignant cell 
lines were more sensitive.  Although the ductal carcinoma in situ (DCIS) represents 
20–25% of all breast neoplastic lesions, it is currently cured by complete surgical 
resection and the majority of the pre-cancerous and pre-invasive lesions will never 
progress to an invasive disease. In contrast, the triple negative breast tumours are 
more aggressive and harder to treat. Also, they are more likely to spread and recur and 
therefore identifying a new better treatment for these patients may be advantageous 
and is urgently needed. Thus, the next chapter will now focus on these cells (MDA-
MB-231 and MDA-MB-231(BM)) in particular to profile the global proteomic 
response to metformin treatment.  
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5. Chapter 5: Comparative proteomic analysis of 
differentially-expressed proteins in response to metformin 
in metastatic breast cancer cell lines 
5.1 Introduction 
Data presented in the previous chapter demonstrate that although the clinically 
relevant doses of metformin were more efficacious against the normal epithelial, pre-
malignant and pre-invasive cell lines, the triple negative MDA-MB-231 cells and 
their bone-seeking variant were the most sensitive of the invasive breast cancer cell 
lines to the anti-proliferative effect of these doses. Our data also suggest that the 
effects of metformin on parental MDA-MB-231 are distinct from the bone-homing 
metastatic cells. Indeed, metformin inhibits the migration of the wild-type triple-
negative cells and reduces the number of viable cells as well as the BrdU-labelled 
cells at the highest dose in the clinically relevant range (0.3 mM), whereas the bone-
homing cells were more responsive to doses as low as 0.03 mM and 0.1 mM in the 
cell counting and BrdU assays respectively. Metformin also induces G1 and G2 cell 
cycle arrest without apoptosis in the wild-type and the bone-homing cells 
respectively, at 0.3 mM. However, both cells were equally responsive to the lowest 
dose of 0.03 mM in the clonogenic assay. This indicates that both cells are 
differentially responding to metformin exposure.  
Triple-negative/basal breast cancers (TNBCs) occur in a minority of patients 
compared with other molecular subtypes of breast cancer (15%), however, despite this 
fact triple-negative tumours are particularly aggressive and result in a 
disproportionately high morbidity and mortality due to their rapid proliferation rate, 
high metastatic potential and frequent chemo-resistance319-321. While triple negative 
cancers fail to express oestrogen, progesterone or HER-2 receptors, they express basal 
cytokeratins and the epidermal growth factor receptor (EGFR) and have a 
predominant subpopulation of stem-like cells or mesenchymal features and the latter 
feature would enhance tumour cell dormancy and therapeutic resistance322. TNBCs 
are also known for some unique features, which include p53 mutations, activation of 
the cell surface receptor tyrosine kinase EGFR, up-regulation of interleukin-6 (IL6) 
expression and janus kinase-2/signal transducer and activator of transcription 
3 (JAK2/STAT3) signalling pathways, as well as their dependence on both aerobic 
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and anaerobic glycolysis to derive energy and sustain cell growth (the Warburg 
effect)323, 324.  
Distant relapse remains a substantial risk for patients with all types of BC, 
with >75% of advanced breast cancer patients developing bone metastasis, resulting 
in skeletal complications which have a major negative impact on survival and quality 
of life, as well as incurring a high economic burden. Bone targeted agents such as the 
bisphosphonate drugs including zoledronic acid, and monoclonal antibody-based 
therapeutics (e.g Denosumab), have reduced the incidence of skeletal-related events 
(SREs) within BC patients, however these treatments are not without side-effects and 
only a proportion of patients will benefit325-327. In contrast to bone metastasis that 
occurs more frequently in patients with ER-positive tumours, lung metastasis; the 
second most frequent site for BC relapse, is more frequently diagnosed in patients 
with ER-negative tumours. Thus far, there remains a significant unmet clinical need 
to develop effective, safe and more specific systemic therapy options for the 
prevention and treatment of metastatic bone and lung spread, and in particular for the 
development of biomarkers that will predict those patients at highest risk of 
developing relapse. Current technological advances in the fields of genomics, 
proteomics and metabolomics approaches can potentially provide a major 
contribution to meeting this need by identifying novel target molecules as well as new 
therapeutic options.      
Although the anti-cancer properties of metformin have been well-studied and 
it is now well known that metformin acts on cell metabolism and supresses breast 
cancer cell proliferation by a number of different mechanisms, including cell-growth 
inhibition mediated via effects on IGF1 and downstream PI3K/AKT/AMPK 
signalling pathways, other mechanisms may also occur, including direct modulation 
of protein synthesis. To date there have been few studies of the global proteomic 
effects of metformin within TNBC. To our knowledge no previous attempt has been 
made to explore the global proteomic effects of metformin exploring whether 
metformin plays a potential therapeutic role in BC metastasis particularly to bone and 
lung.  
Therefore, we hypothesize that metformin might have a potential anti- 
metastatic effect within breast cancer via differential targeting of signalling pathways, 
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or altering protein expression differentially between the wild-type triple negative and 
the two aggressive end-stage bone- and lung-derived breast cancer cell lines. 
In this project, we had a useful opportunity to test our hypothesis by 
comparing the effects of metformin on the proteome of the relevant metastatic breast 
cancer cell models. This work has potential to not only identify possible biomarkers 
of metformin action but also to identify possible drug targets of interest within breast 
cancer metastatic spread. The spike-in SILAC method is suitable for this type of 
experiment and this method has been successfully used before for proteomics-based 
identification of biomarkers of bone-metastasis within the laboratory of Professor 
Janet Brown256, 328-330.  The major aim of this study was to identify additional unknown 
mechanisms by which metformin impacts metastatic breast cancer cell lines and to 
validate these changes by Western blot in metformin treated and untreated cells.  
A three-cell line experiment was conducted utilising three biological replicates 
of each cell-type using heavy SILAC-labelled parental MDA-MB-231 as an overall 
control. 
5.2 Methods 
5.2.1 Label-free quantification (LFQ) proteomics  
An initial small-scale pilot experiment testing the effect of both the clinically 
relevant (0.3 mM) and the potential tissue accumulated (5 mM) doses of metformin 
on the 'parental' MDA-MB-231 (PCC) cells and the fully bone-homed variant (MDA-
MB-231(BM)) was carried out using a label-free quantification method. This small 
experiment was designed to assess any evidence of change in protein expression 
profiles in response to the different metformin doses to establish whether or not a 
subsequent proteomics experiment should be based on the clinically relevant or the 
potential tissue accumulated dose of metformin. The proposed larger proteomics 
experiment involved the use of the 'spike-in' SILAC method analysing PCC, bone- 
and lung-homed breast cancer cell types with and without the chosen dosage of 
metformin to enable comparison of protein expression across multiple replicates. For 
the initial pilot experiment, the following samples were generated, without sample 
mixing or isotopic labelling, where the cells were treated with the stated doses of 
metformin for 72 hours. 
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• PCC no drug (control) 
• PCC + 0.3 mM of metformin 
• PCC + 5 mM of metformin 
• MDA-MB-231(BM) no drug 
• MDA-MB-231(BM) + 0.3 mM of metformin 
• MDA-MB-231(BM) + 5 mM of metformin 
 
Samples were run into the top of a 4-20% SDS-PAGE gradient gel (For a 
maximum 20 minutes running time), to concentrate the protein samples into one tight 
band, in order to aid subsequent buffer exchange steps. The samples were then 
digested and processed as per figure 5.1 (Sample preparation workflow, without the 
heavy and light-labelled mixing step) and figure 5.2 (Experiment 1), the extracted 
tryptic peptides were sent for mass-spec analysis and label-free quantification (using 1 
μg of peptide injections per run and duplicate injections performed for each sample to 
ensure greater confidence with the MS-based identifications and quantifications). Dr. 
Caroline Evans operated the mass spectrometer in a data dependent acquisition mode 
(DDA) as follows: liquid chromatography (LC) peptide separation was coupled online 
to MS using a data-dependent LFQ method on a Q Exactive™ HF hybrid quadrupole-
Orbitrap mass spectrometer. Full-scan MS spectra (375-1500 m/z) were acquired at a 
resolution of 120,000 after accumulation to an automated gain control (AGC) target 
value of 1e6 or maximum injection time of 60 ms. MS2 spectra were obtained at a 
resolution of 30,000, with an AGC target value of 1e5 or maximum injection time of 
60 ms. Higher-energy C-trap dissociation (HCD) was performed with a normalised 
collision energy of 27 and an underfill ratio of 2%. Dynamic exclusion was set to 20 
s, charge state screening was enabled and unassigned charge states and singly charged 
precursors were excluded. MS performance was verified by running complex cell 
lysate quality, 400ng Hela protein digest (Pierce, P/N 88328 for quality control). The 
downstream data analysis steps were performed as described in the data analysis 
workflow in figure 5.1.   
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Figure 5.1: Schematic workflow of the mass spectrometry method.  
Illustration of the experimental procedures: sample preparation and data analysis 
workflow. 
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5.2.2 SILAC-based quantitative proteomics 
Metastatic variants of the human triple negative breast cancer cell (TNBC) 
line MDA-MB-231 which home to bone (BM) or lung (LM) produced by repeated 
intra-cardiac injection within an immunocompromised mouse257, were used alongside 
the parental MDA-MB-231 (PCC) cells. The parental PCC cells and the different 
metastatic variants were then used to explore differences in the proteomes between 
metformin-treated and untreated cells, and to identify any differences to metformin 
treatment between the cell lines. The idea is that analysis of the cellular proteomes 
would allow to infer network information that may complement the previous work in 
this thesis on the efficacy of metformin, the expression of metformin transporters, and 
any published literature on cellular mechanisms of action of metformin in triple 
negative breast cancer and their metastases.   
Based on preliminary data from our small-scale experiment (Section 5.3.1.2), 
a 5 mM concentration of metformin was chosen as the validated test concentration. 
To account for any technical and biological variability within the cell system studied, 
for each cell type, three aliquots of a frozen stock were revived and cultured 
independently. Differential protein expression between the three independent cultures 
of these three cell lines was quantified by concentrating the proteins present within 
cell-lysates using SDS-PAGE followed by in-gel tryptic digestion and protein 
identification using an orbitrap-mass spectrometer (gel-LC-MS/MS) (Figure 5.1, 
Sample preparation workflow).  
Comparative quantitative analysis of global-protein expression between the 
replicate cultures was facilitated by use of the spike-in-SILAC (SIS) method328, 329, 
since it offers accurate and sensitive quantification of protein expression between 
replicate samples via the use of a spike-in heavy-labelled internal standard sample. 
Spike-in SILAC is also a cost-effective way to enable comparison of the 5 treatment 
combinations in 3 biological replicates. The use of triplicate biological repeats is a 
common approach used within the proteomics analysis of cell-lines as these display 
lower variability than patient-derived biological samples such as blood and urine. We 
analysed 15 samples in total, each containing 50 microgram of total protein pooled 
from each group (i.e. 25 μg of control (P-SIS) protein and 25 μg of metformin treated 
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protein). Three independent cultures from each of the cell lines/treatment 
combinations of 2-6 were used, as listed below (See figure 5.2 for the experimental 
setup).  
1. P-SIS  Parental cell line cultured in ‘heavy’ SILAC medium 
2. PCC+5 mM of Metformin  Parental cells treated with metformin 
3. BM Bone-homed variant of MDA-MB-231 
4. BM+5 mM of Metformin  Bone-homed variant of MDA-MB-231 (treated) 
5. LM Lung-homed variant of MDA-MB-231 
6. LM+5 mM of Metformin  Lung-homed variant of MDA-MB-231 (treated) 
 
All cell lines (except P-SIS) were grown in standard “light; isotopically 
normal” (Lys0) (SILAC-control) medium containing 10% dialyzed FBS, 2 mM L-
glutamine, 0.1mg/mL streptomycin and 0.2U/ml penicillin. The parental cell line 
(PCC) was grown in “heavy” SILAC medium Containing 13C and 15N-labelled 
variants of Lysine and Arginine, 10% dialyzed FBS, 2 mM L-glutamine, 0.1mg/mL 
streptomycin and 0.2U/ml penicillin, for at least six cell-doublings prior to use, so that 
the cells fully incorporated the labelled amino acids. When the cells have been 
passaged this way they are ready for treatment with metformin for 72 hours. 
 
After metformin exposure, the protein samples were prepared in standard 
RIPA lysis buffer, homogenized and cleared of nuclei and cellular debris by 
centrifugation as described previously (Section 2.2.8), and assayed for protein content 
using the BCA protein assay kit. Protein extracts thus prepared were mixed with the 
heavy-labelled PCC-protein sample and the proteins from each of the light labelled 
samples forming a 1:1 mix (Summarized in table 5.1). The protein samples were then 
reduced with 10 mM dithiothreitol (DTT) (0.1 M final concentration) for 5 minutes at 
60°C. Reduced cysteines were then alkylated with 50 mM iodoacetamide (IAA) (10 
mM final concentration) by incubation for 30 minutes at room temperature in the 
dark, as the IAA is light sensitive.  
The combined samples were run on a 4-20% SDS-PAGE gradient gel for 
approximately 45 minutes until the dye front reached the end of the gel. The gels were 
briefly stained with colloidal coomassie-G250 brilliant blue gel-stain for the shortest 
amount of time which allowed protein visualization, and then the concentrated gel-
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bands from each lane were individually excised into 5 equal slices with a scalpel and 
each slice cut into cubes (approximately 1mm3). All gels were kept hydrated with 
distilled water to prevent shrinkage during cutting.  
The proteins within the cubes obtained from each gel slice were once again 
reduced with DTT and alkylated with IAA to ensure complete reaction followed by 
extensive gel-destaining with 50 mM ammonium bicarbonate, 50% (v/v) acetonitrile 
(ACN) and vortexed briefly, to get rid of the negatively charged coomassie blue dye 
that can interfere with trypsin digestion, followed by gel-dehydration with 
acetonitrile. The reduced, alkylated, destained and dehydrated gel-cubes were then 
subjected to overnight tryptic digestion using a 1:25 trypsin:protein ratio.  
The following day peptides were extracted twice from the gel cubes using 
sequential treatment with 1% (v/v) formic acid (FA) and acetonitrile and the 
combined extracts dried down for mass-spectrometric analysis using a speedvac 
concentrator. The dried down peptides were stored at -80°C. Individual samples were 
then analysed using the orbitrap-mass spectrometer using triplicate injections of each 
sample.  
Table 5.1: An illustration of the sample mixing.   
Five cell line/treatment combinations samples prepared by mixing with an equal 
concentration of the spike-in SILAC control cell protein.  
Sample 
number 
Heavy-labelled sample 
(25 microgram) 
Light-labelled sample 
(25 microgram) 
1.  SILAC-labelled PCC   PCC+ 5mM metformin 
2.  SILAC-labelled PCC Untreated BM 
3.  SILAC-labelled PCC BM+ 5mM metformin 
4.  SILAC-labelled PCC Untreated LM 
5.  SILAC-labelled PCC LM+ 5mM metformin 
6.  SILAC-labelled PCC   PCC+ 5mM metformin 
7.  SILAC-labelled PCC Untreated BM 
8.  SILAC-labelled PCC BM+ 5mM metformin 
9.  SILAC-labelled PCC Untreated LM 
10.  SILAC-labelled PCC LM+ 5mM metformin 
11.  SILAC-labelled PCC   PCC+ 5mM metformin 
12.  SILAC-labelled PCC Untreated BM 
13.  SILAC-labelled PCC BM+ 5mM metformin 
14.  SILAC-labelled PCC Untreated LM 
15.  SILAC-labelled PCC LM + 5mM metformin 
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Dr. Caroline Evans performed the mass spectrometry as follows: A U3000 
nano-flow high performance chromatography system (Thermo, Hemel Hempstead, 
UK) was employed with peptide separation using a 50cm C18 reverse-phase 
analytical column (Thermo Easy-spray P/N ES803) at 40 0C. A 300μm i.d x 5cm trap 
column packed with C18, 5μm, 100 A ̊ particles (LC Packings P/N 160454) was used 
for sample loading. The buffers used were loading buffer (97% (v/v) water, 3 % (v/v) 
acetonitrile with 0.1% (v/v) trifluoroacetic acid (TFA)), buffer A (100% (v/v) water, 
0.1% (v/v) FA) and buffer B (80% (v/v) acetonitrile, 20% (v/v) water with 0.1% (v/v) 
FA). Peptides were eluted over 3-10% buffer A for 30 minutes, then 10 to 50% buffer 
B gradient over 75 minutes for a total run time of 105 minutes.  
The mass spectrometer was operated in a data dependent acquisition mode 
(DDA) as follows: LC peptide separation was coupled online to MS using a data-
dependent Top15 method on a Q Exactive™ HF hybrid quadrupole-Orbitrap mass 
spectrometer (Thermo Scientific, Bremen, Germany). Full-scan MS spectra (375-
1500 m/z) were acquired at a resolution of 120,000 after accumulation to an 
automated gain control (AGC) target value of 1e6 or maximum injection time of 60 
ms. MS2 spectra were obtained at a resolution of 30,000, with an AGC target value of 
1e6 or maximum injection time of 60ms. Higher-energy C-trap dissociation 
(HCD) was performed with a normalised collision energy of 27 and an underfill ratio 
of 2%. Dynamic exclusion was set to 20 seconds, charge state screening was enabled 
and unassigned charge states and singly charged precursors were excluded. MS 
performance was verified by running complex cell lysate quality; 400 ng Hela protein 
digest (Pierce, P/N 88328 for quality control). 
5.2.3 Data analysis and statistical methods 
Proteins within the final data set were prioritized as follows: proteins were 
selected which had at least 1 razor and unique peptide within all 5 samples in a 
replicate (i.e the 5 gel slices of each individual lane); this ensures high quality mass-
spectrometric protein identifications across each sample set to be analysed. A razor 
peptide is a peptide that has been assigned to the protein group with the largest 
number of total peptides identified, if unique, the razor peptide only matches to this 
single protein group and if not unique, the razor peptide will only be a razor peptide 
for the group with the largest number of peptide IDs. 
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Proteins were then selected based upon a significant fold change within the 
light labelled cells compared to the heavy-labelled PCC-cells (light labelled / PCC = 
1.5-fold or greater for increased expression or 0.7-fold or lower for decreased 
expression); these are standard cut-offs used to define up and down-regulated proteins 
within discovery proteomic experiments (reference).  
The LFQ-intensity of the light peptide in each sample was normalized to 
the intensity of the identical heavy-labelled peptide spiked in as an internal standard 
within the sample, for the LFQ experiment the LFQ-intensity of the treated samples 
were normalized to the intensity of the control untreated samples. Upon Log2 
transformation of these normalised LFQ-intensities a two-tailed parametric t-test was 
used to assess the statistical significance of any difference in expression observed 
across the three replicate injections of each sample. Proteins which survived these 
tests with a statistically significant difference in log2-LFQ-Intensity between 
metformin-treated bone or lung metastatic cell lines and the heavy-labelled control 
cell line (PCC), were assessed for relevance in breast cancer and/or bone/lung 
metastasis using published literature. The relevant protein candidates were then taken 
forward for verification by Western blotting (Figure 5.1, Data analysis workflow). 
5.2.4 Determination of the labelling efficiency with heavy-SILAC-labelled MDA-
MB-231  
In order to test the quantitative accuracy of mass spectrometry for 
quantification of SILAC- labelled proteins, it was necessary to determine the 
percentage incorporation of heavy L-13C615N4-arginine and L-13C615N2-lysine into 
proteins synthesized in the MDA-MB-231 parental cell line, an important quality 
control step for checking the efficiency of cell labelling. Proteins from control MDA-
MB-231 cells grown in labelling medium were tested for efficiency of incorporation 
of stable isotope-labelled amino acids after 6 doublings (following the same sample 
preparation and data analysis workflow in figure 5.1). We found that within all 
proteins the proteins identified from whole cell lysates significantly greater than 93% 
levels of label incorporation were achieved. However, the fact that some very stable 
proteins have slow turnover within the cell and their replacement by heavy-labelled 
versions during the SILAC-labelling may not have been complete may account for the 
7% poorly labelled proteins found. 
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Figure 5.2: Schematic depiction of the experimental setup and subsequent workflow used for proteomic analysis of cell lines of interest.  
Two separate experiments were conducted in the current study. In experiment 1, proteins from cells grown in standard culture media were 
extracted, concentrated briefly on 1D 4-20% gradient gel, digested, and subsequently analysed by LC-MS/MS. In experiment 2, proteins were 
extracted from both heavy-labelled spike-in SILAC standard and the light-labelled cells for comparison. Proteins from cells grown only in 13C6 
15N4-Arginine and 13C6-Lysine containing medium, were mixed 1:1 (25 μg:25 μg) with proteins extracted from the cell lines of interest.  Each 1:1 
protein sample mix was separated according to molecular weight by 1-DE SDS-PAGE.  The entire 1-D gel lane was fractionated into five equal 
‘slices’, and the proteins within each slice were digested using trypsin before peptides were extracted from the gel matrix.  The five-peptide 
samples for each 1:1 protein mix were subsequently analysed using mass spectrometry (MS). PCC: Parental MDA-MB-231 cell line, BM and 
LM bone and lung-seeking metastatic cell lines.   
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5.3 Results  
5.3.1 Metformin action- label free quantification; proteomics pilot-experiment 
5.3.1.1 Label free quantification’s data correlation and quality check  
Prior to protein identification and quantification by MaxQuant the mass-spec 
RAW files were first analysed via the RawMeat software package (freeware: 
http://rawmeat.software.informer.com/2.0/). RawMeat is used to compare the LC-MS run 
quality so poor or aberrant runs can have samples re-injected. Key parameters from the 
RawMeat analysis include “TopN” (the number of MS/MS scans triggered during each 
MS time window and thus the number of co-eluting peptides which the mass 
spectrometer can attempt to sequence and quantify). Next, RAW files were then analysed 
using MaxQuant for spectral alignment, normalization, peak matching, protein-
identification and label-free quantification. MaxQuant-analysis provides many data 
outputs. The stated label-free quantification (LFQ) value for each identified protein was 
used as this is considered to be the most robust, quality controlled and normalized value 
for protein quantification provided by the analysis software. Once the LFQ-intensities 
were log2-transformed and valid protein entries were filtered for number of unique and 
razor peptides, the degree of correlation was estimated between the different samples to 
illustrate the reproducibility of the replicate samples and to eliminate possible outliers.  
Then the outputted “ProteinGroups”.txt file from MaxQuant was analysed using 
the Perseus software package for statistical analysis of samples in terms of their group 
behaviour and large-scale data structure, including output of histograms, heat maps and 
hierarchical clustering identification (freeware available from the MaxPlanck Institute; 
http://www.biochem.mpg.de/5111810/perseus). The results of this quality check are 
presented in figure 5.3.   
In this pilot study, none of our samples had to be re-injected. The three different 
bone-homing samples cluster together, as do the PCC samples (Figure 5.3B), but not to 
the same extent (Figure 5.3A). The data were normally distributed (Figure 5.3C) and 
meet the assumption of the parametric test, therefore, the parametric t-test was used to 
statistically compare between the groups (Figure 5.3C). The scatter plot (Figure 5.3D) 
shows the relationship between two quantitative variables measured for the same 
replicate. The values of one variable appear on the horizontal axis, and the values of the 
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other variable appear on the vertical axis. Each individual in the data appears as a point 
on the graph. The correlation r values are all around 0.9, which indicates a strong, 
positive, linear relationship between the variables. Generally, all the quality check 
parameters of the duplicate samples suggest good reproducibility as well as good data 
quality.  
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Figure 5.3: Reproducibility assessment of the label-free quantification data.  
(A) A dendrogram shows clustering of the replicates from the bone-homed cells (BM) 
(red), while the PCC replicates (blue) have clustered separately, indicative of underlying 
cell type-specific differential protein expression. (B) Unsupervised hierarchical clustering 
based on label-free quantification of duplicate samples with all identified proteins; data 
from all contributing peptides were used to calculate protein abundance. Protein 
abundance values are indicated colorimetrically for each protein in each sample; 
indicating a good correlation of proteins expression; red = high, black = mean value, 
green = low. (C) LFQ-intensity plots for each sample. In each case the curve is symmetric 
at the centre suggesting that the mean, mode and median are all equal and indicates a 
normal distribution within all samples, (D) Representative scatter plots of all correlated 
LFQ-intensities for peptides quantified within pairwise sample comparisons. Intensities 
from paired samples; of the median of the duplicate, show inter-sample correlation, units 
of X- and Y-axes both represent LFQ intensities. LFQ intensities represent: LFQ-1: 
PCC+no drug, LFQ-2: PCC+0.3 mM, LFQ-3: PCC+ 5mM, LFQ-4: BM+no drug, LFQ-5: 
BM+ 0.3mM, LFQ-6: BM+ 5mM.  
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5.3.1.2 Proteins identified and candidate selection  
A total list of 4070 proteins were identified and quantified within the complete 
output data set from MaxQuant, however, this figure is before data-filtering for reverse 
hits, proteins which do not have at least 1 razor + unique peptide in all samples analysed, 
potential contaminants and components of the serum used within the cell-culture media. 
Upon removal of proteins which did not satisfy these filters 2909 proteins remained 
which had ≥2 razor + unique peptides per ID (of which ≥1 was a unique peptide). A full 
list of proteins detected is provided in the supplemental CD table S5.  Within these output 
proteins, 44 proteins were down-regulated with metformin when used at both 
concentrations in both cell-types. This number of proteins reduced still further to 27 
proteins when a 1.5-fold change cut-off was applied (comparing between the untreated 
and 5 mM treated cells). 112 proteins were differentially regulated depending upon the 
cell type i.e. these proteins were up-regulated with metformin in the bone-homed BC cell 
line and down-regulated with metformin within PCC. Further filtering of these 
differentially regulated proteins returned 4 proteins when a 1.5-fold change cut-off was 
applied. In a similar way, looking for differentially regulated proteins between PCC and 
BM cells, 53 proteins were down-regulated with metformin in the bone-homed BC cell 
line and up-regulated with metformin within the parental cell line. This number of 
proteins reduced to 3 proteins when we applied the 1.5-fold change cut-off.   
Several criteria were taken into consideration when selecting potential candidates 
for further validation, such as the fold difference with metformin treatment in both the 
PCC and BM cell lines, relative to the untreated cells (>1.5 fold for up-regulation and 
<0.71-fold for down-regulation), statistical P-values (P<0.05 by the parametric t-testing 
or Dunnett’s test as appropriate) and mean normalized LFQ-intensity values. The 
potential candidates were also assessed on the basis of their likely biological relevance to 
breast cancer initiation, progression and/or metastasis using published literature. 
Additionally, the commercial availability of the antibodies was also investigated and 
taken into account when selecting candidates for further analysis.  
In total 34 candidate proteins were selected which demonstrated alterations in 
expression level that were potentially of interest. Table 5.2 summarizes the key proteomic 
results. Proteins in the “Up and Down proteins” categories are the proteins up- or down-
regulated in both cell lines by increasing metformin dosage (green highlighted) and 
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differentially up- or down-regulated by metformin within the two cell lines (blue and 
pink highlighted) with increasing doses of metformin. The fold changes listed in the last 
two table columns are the ratios of protein level with 5 mM metformin compared to 
untreated controls. Proteins of interest with significant alterations in their quantifications, 
and more than 2 unique + razor peptides (of them at least 1 razor peptide) in both 
duplicates all are bold highlighted. 
 These proteins include members that differed in terms of their direction of 
change in protein abundance between the parental (PCC) and bone-homed (BM) cells, or 
showed similar changes in both cell types (using both concentrations of metformin).  
Taken together, these considerations led to the selection of 5 prioritized proteins 
for further validation by Western blotting. These proteins are: tumour necrosis factor 
alpha-induced protein 8 (TNFAIP8), growth factor receptor-bound protein 2 (GRB2), 
signal transducer and activator of transcription 3 (STAT3), translocator protein (TSPO) 
and calmodulin.  
However, it is noteworthy that most of the protein-abundance effects observed 
within this study were subtle, there was no strong on or off effect between the treated and 
untreated samples using both concentrations of metformin as reflected by the protein-
expression fold-differences, and this seems to be the case for the majority of proteins 
identified (Table 5.1). This may be because most of metformin effects on signalling 
pathways are exerted via phosphorylation and not via global proteomic changes.  For this 
reason, the 5 mM dose of metformin was chosen as the optimal dosage for the large-scale 
proteomics experiment, namely the SILAC-based quantification experiment. The choice 
of this dose was also based on the fact that the cells were more sensitive to this dose of 
metformin but their viability was not affected (as shown in the proliferation assays used 
in Chapter 4). Since this concentration of metformin was not yet cytotoxic, we can 
therefore rule out the possibility of radical alteration in protein levels that could be linked 
to the toxicological responses. The 72-hour time point was also chosen based on the 
previous proliferation and cell cycle assays where the effect of metformin was most 
notable.  
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Table 5.2: Proteins identified as significantly differentially expressed within the parental MDA-MB-231 PCC cell-line and its bone     
homed  (BM) variant from pilot the Label-free quantification (LFQ) study.  
Proteins here are progressively up- or down- regulated with increasing metformin dose and have a least a 1.5-fold increase (or 0.71-fold 
decrease) between the untreated cells and cells treated with 5 mM metformin. Fold change (FC) was calculated by comparing mean normalized 
LFQ intensity values between samples. Status indicates the direction of the differential expression and in which cell types: PCC= Parental MDA-
MB-231, BM = bone homing cells. Entry refers to UniProt entry http://www.uniprot.org/.  
 Entry Protein names Biological Function Status FC in 
PCC+5mM 
FC in  
BM+5mM 
1.  Q06481 Amyloid-like protein 2 Cellular protein metabolic process, G-protein coupled receptor 
signalling pathway, post-translational protein modification 
Down in PCC & BM 0.59 0.50 
2.  P63165 Small ubiquitin-related modifier 1 DNA repair, positive regulation of calcium-transporting ATPase 
activity, positive regulation of proteasomal ubiquitin-dependent 
protein catabolic process, positive regulation of protein complex 
assembly, protein stabilization  
Down in PCC & BM 0.58 0.57 
3.  P63165 Small ubiquitin-related modifier 1 DNA repair, positive regulation of calcium-transporting ATPase 
activity, positive regulation of proteasomal ubiquitin-dependent 
protein catabolic process, positive regulation of protein complex 
assembly, protein stabilization  
Down in PCC & BM 0.58 0.57 
4.  Q9BTT0 Acidic leucine-rich nuclear phosphoprotein 32 
family member E 
Histone exchange, nucleocytoplasm transport and regulation of 
apoptosis 
Down in PCC & BM 0.56 0.55 
5.  Q13283 Ras GTPase-activating protein-binding protein 
1 
Negative regulation of canonical Wnt signalling pathway Down in PCC & BM 0.56 0.54 
6.  Q15021 Condensin complex subunit 1 Cell division, chromosome separation, meiotic and mitotic 
chromosome condensation.  
Down in PCC & BM 0.54 0.50 
 
7.  Q8NBT2 Kinetochore protein Spc24 Cell division and sister chromatid cohesion Down in PCC & BM 0.51 0.56 
8.  P40763 Signal transducer and activator of 
transcription 3 
Acute phase response, cell proliferation, cytokines-mediated 
signalling pathway, energy homeostasis, glucose 
homeostasis, growth hormone receptor signalling, negative 
regulation of apoptosis, positive regulation of cell 
proliferation, negative regulation of glycolytic process, 
positive regulation of ATP biosynthesis, regulation of cell 
cycle and mitochondrial membrane permeability 
Down in PCC & BM 0.47 0.51 
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Table 5.2: continued (legend on previous page)    
9.  P04637 Cellular tumour antigen p53 Tumour suppressor, positive regulation of cell cycle arrest and 
intrinsic apoptotic signalling pathway, autophagy and cellular 
response to DNA damage 
Down in PCC & BM 0.47 0.54 
10.  P02794 Ferritin heavy chain; N-terminally processed  Cellular iron homeostasis, negative regulation of cell proliferation 
and immune response 
Down in PCC & BM 0.46 0.59 
11.  P00403 Cytochrome c oxidase subunit 2 ATP synthesis coupled electron transport  Down in PCC & BM 0.46 0.57 
12.  O00217 NADH dehydrogenase iron-sulfur protein 8  Mitochondrial respiratory chain Complex I assembly, mitochondrial 
electron transport and response to oxidative stress 
Down in PCC & BM 0.46 0.54 
13.  Q8TCF1 AN1-type zinc finger protein 1 Zinc ion binding Down in PCC & BM 0.46 0.56 
14.  Q9BQ69 O-acetyl-ADP-ribose deacetylase MACROD1 Cellular response to DNA damage Down in PCC & BM 0.45 0.55 
15.  P35222 Catenin beta-1 Androgen receptor signalling pathway, regulation of apoptosis, cell 
adhesion, cell differentiation, epithelial to mesenchymal transition, 
negative regulation of   angiogenesis, negative regulation of cell 
death and proliferation, positive regulation of I-kappaB kinase/NF-
kB signalling, positive regulation of MAPK cascade, positive 
regulation of osteoblast differentiation 
Down in PCC & BM 0.44 0.48 
16.  P62158 Calmodulin Negative regulation of ryanodine-sensitive calcium-release 
channel activity, calmodulin-calcium complex stimulate 
kinases and phosphatases enzyme. 
Down in PCC & BM 0.43 0.41 
17.  P33993 DNA replication licensing factor MCM7 DNA replication initiation, cellular proliferation, response to DNA 
damage and G1/S transition of mitotic cell cycle 
Down in PCC & BM 0.43 0.41 
18.  O60493 Sorting nexin-3 Protein transport and regulation of Wnt pathway Down in PCC & BM 0.40 0.56 
19.  P50454 Serpin H1 Collagen biosynthesis  Down in PCC & BM 0.40 0.58 
20.  P45974 Ubiquitin carboxyl-terminal hydrolase 5 Protein ubiquitination and deubiquitination Down in PCC & BM 0.39 0.57 
21.  P49327 Fatty acid synthase (FASN) Fatty acid biosynthetic process, acetyl-CoA metabolic process, 
fatty-acyl-CoA metabolic process, positive regulation of cellular 
metabolic response and regulation of cholesterol biosynthesis  
Down in PCC & BM 0.38 0.58 
22.  O75607 Nucleoplasmin-3 rRNA processing and transcription Down in PCC & BM 0.37 0.51 
23.  Q96PU8 Protein quaking mRNA processing and stabilisation, positive regulation of gene 
expression and long-chain fatty acid synthesis.  
Down in PCC & BM 0.34 0.40 
24.  P07339 Cathepsin D  Proteolysis, autophagy protein catabolic process involved in the 
pathogenesis of breast cancer 
Down in PCC & BM 0.31 0.50 
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Table 5.2: continued (legend on previous page)     
25.  Q56VL3 OCIA domain-containing protein 2 Unknown function Down in PCC & BM 0.30 0.40 
26.  Q5JRX3 Presequence protease, mitochondrial Degradation of mitochondrial transit peptides after their cleavage  Down in PCC & BM 0.29 0.56 
27.  Q9P0S9 Transmembrane protein 14C Heme biosynthesis  Down in PCC & BM 0.26 0.56 
28.  P62993 Growth factor receptor-bound protein 2 Cell-cell signalling, cell differentiation and migration, EGFR 
signalling pathway, ERbB2 signalling pathway, insulin 
receptor signalling pathway, regulation of MAPK cascade, 
phosphatidylinositol-mediated signalling, signal transduction 
in response to DNA damage 
UP in PCC & down in 
BM 
1.76 0.40 
29.  P56134 ATP synthase subunit f, mitochondrial ATP biosynthesis, mitochondrial ATP synthesis and coupled 
proton transport 
UP in PCC & down in 
BM 
1.60 0.71 
 
 
30.  P30536 Translocator protein Anion transport, cell proliferation, contact inhibition, heme 
biosynthesis, negative regulation of ATP metabolic process, 
negative regulation of TNF production, positive regulation of 
apoptosis and necrotic cell death, positive regulation of 
calcium ion transport, positive regulation of reactive oxygen 
species metabolic process, regulation of cholesterol 
transport, regulation of steroid biosynthesis and metabolism, 
response to progesterone and testosterone 
UP in PCC & down in 
BM 
1.55 0.48 
31.  Q9NPA0 ER membrane protein complex subunit Carbohydrates binding  UP in BM & down in 
PCC 
0.58 1.83 
32.  Q96TC7 Regulator of microtubule dynamics protein 3 Negative regulator of apoptotic process, cell differentiation and 
calcium ion homeostasis 
UP in BM & down in 
PCC 
0.55 1.50 
33.  O95379 Tumour necrosis factor alpha-induced 
protein 8 
Negative mediator of apoptosis and play a role in tumour 
progression 
UP in BM & down in 
PCC 
0.51 1.79 
34.  Q96A33 Coiled-coil domain-containing protein 47 Calcium ion homeostasis, osteoblast differentiation UP in BM & down in 
PCC 
0.50 1.65 
 
 
 
 163 
5.3.1.3 Global pathway regulation in response to metformin treatment  
In addition to the analyses performed to select candidate targets for further 
verification, all the proteins identified in Table 5.2 were uploaded into STITCH chemical 
association network (http://stitch.embl.de/) to characterize metformin’s global effects on 
protein levels, cellular pathways and to identify possible direct and indirect interactions 
between the target proteins. The Uniprot identifiers of the 33 proteins identified in table 
5.2 were uploaded to the STITCH website and up to 15 interaction networks were 
generated when the species was restricted to human only.  
The output from the STITCH website allows examination of the biological, 
cellular and molecular functions represented, predicts upstream regulators of target 
proteins, as well as putative networks of interaction for specific molecules of interest. 
Moreover, by exploring the potential of the KEGG pathways; Kyoto Encyclopedia for 
Gene and Genome (which is a reference database for pathway mapping, representing up 
to date knowledge on the molecular interactions, reaction and relation networks for 
metabolism, cellular processes, human diseases and drug development) more can be learnt 
about metformin’s actions on the global protein network within the two cell-types.  
At least 14 proteins from the panel formed more than 7 interactions within the 
network (Figure 5.4). Thus the identified proteins have more interactions among 
themselves than would be expected for a random set of proteins of similar size, drawn 
from the genome. Such enrichment indicates that these proteins are at least partially 
biologically connected as a group, and may function together. The majority of the highly 
interconnected proteins are down-regulated in one or both of the metformin conditions 
(compared to untreated cells). In this network, most of our candidate proteins selected 
were centred on the epidermal growth factor receptor (EGFR). EGFR is known as an 
upstream transmembrane regulator, the phosphorylation of which can initiate an 
intracellular signalling cascade linked to versatile cellular responses including cell 
proliferation, differentiation, adhesion, migration, anti-apoptotic survival mechanisms and 
induction of angiogenesis. EGFR can also mediate several downstream signalling 
pathways including the MAPK and PI3k/Akt signalling pathways. Furthermore, at least 3 
of the candidate proteins (STAT3, GRB2 and TSPO) were also connected to TP53 
(tumour protein p53); which acts as a tumour suppressor in several tumour types by 
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inducing growth arrest or apoptosis depending on the cell type and physiological 
circumstances. 
The main molecular and cellular functions identified as differentially regulated 
were cell growth and proliferation, cell migration, intracellular signal transduction, cell-
to-cell communication, regulation of metabolic processes, DNA replication, cell cycle, 
cell death and apoptosis, response to insulin, protein binding, enzyme binding, response to 
stress, protein phosphorylation and membrane transport. The first nine of these were 
consistently the top functions identified in all treated groups. The biological functions for 
each individual protein identified are listed in table 5.2. 
The major canonical KEGG pathways identified were: focal adhesion, pathways in 
cancer, apoptosis, insulin and insulin-like growth factors signalling, EGFR signalling, 
ErbB signalling, PI3K-Akt signalling, JAK-STAT signalling and MAPK signalling 
pathways (Figure 5.5). Other less statistically significant pathways related to Ras, FoxO, 
oestrogen, growth hormone, HIF-1 and calcium signalling have been also identified. 
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Figure 5.4: Networks identified by STITCH analysis and the patterns of interaction 
between the proteins up and down-regulated by metformin, with non-connected 
nodes removed.  
Protein-protein interactions are displayed in confidence view. Each coloured circle 
represents a node; the node refers to when the protein is making or receiving a 
connection. The edges between the nodes that represent protein-protein associations 
reflect the reliability and confidence of the interaction evidence; thicker lines represent 
stronger associations. In the network image, most of the identified proteins have an 
established confident link with each other in the interaction network. Standard 
nomenclature gene name abbreviations were used to annotate individual proteins (this can 
be searched on www.Uniprot.org for more details). Red arrows highlight the proteins 
chosen for further analysis. 
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Figure 5.5: Metformin modulates key biological processes and pathways in 
metastatic breast cancer cells.  
A bar graph shows the biological (BP) and KEGG pathways significantly overrepresented 
in hyper-activated and inactivated proteins (Benjamin Hochberg FDR<0.05) following 
exposure to 5 mM of metformin in the MDA-MB-231 (PCC) and the bone-homing MDA-
MB-231(BM) cells. In the x-axis, the false discovery rate of each category is plotted.  
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5.3.1.4 Verification of protein expression for selected targets using Western blotting  
In order to confirm that the mass spectrometry results were consistent and 
accurate, the differential expression of the selected proteins was assessed in cell lysates of 
three biological replicates of the parental cell line, MDA-MB-231, along with the bone 
(BM) and lung homed (LM) metastatic cell lines. These lysates were prepared for the 
large-scale proteomics experiment and in parallel employed within the Western blotting 
verification. Similar to the pilot experiment, both the clinically relevant dose (0.3 mM) 
and the potential tissue accumulated dose (5 mM) of metformin were used.  
These experiments verified decreased TNFAIP8 expression (P<0.002, One-way 
ANOVA test) (Figure 5.6 and 5.7) in response to both 0.3 mM and 5 mM metformin in 
the wild type PCC (to 70% and 56% of untreated value, P=0.04 and P=0.003 by 
Dunnett’stest, respectively) and lung-metastatic (LM) cells (to 78% and 32% of untreated 
value, P=0.004, P=0.001, respectively, assessed by Dunnett’stest). In contrast, decreased 
TNFAIP8 expression was only observed with the 5 mM dose (34% of untreated value, 
P=0.002, Dunnett’stest) in the bone-homed variants. Generally, the level of TNFAIP8 
expression by the untreated parental and bone-homed cells lines was relatively similar and 
slightly higher in the lung-homed cells.  
Treatment with metformin markedly increased GRB2 expression in the wild-type 
cells by 60% and 200% of untreated control value, in 0.3 mM and 5 mM treated samples 
respectively (P=0.002, by Dunnett’s test). In contrast, metformin at its highest dose of 5 
mM profoundly down-regulated the expression of GRB2 (by more than 99% compared to 
untreated controls) within both the bone- and lung-homed cells respectively (P=0.0001, 
Dunnett’s test). The 0.3 mM concentration also down-regulated GRB2 expression in the 
BM cells by 50% compared to untreated controls, and in the LM cells by 99% compared 
to untreated cells (P=0.001 and P=0.0001, Dunnett’s test, respectively) (Figure 5.6 and 
5.7). The level of GRB2 expression was very low to undetectable in the parental MDA-
MB-231 control cells, but much more expressed, and to a similar level in the metastatic 
bone and lung homing cells.  
STAT3 expression was down-regulated to less than 50% of its expression in the 
untreated control cells (P=0.0002, Dunnett’s test) in all cell lines at all tested 
concentrations (P<0.0001, One-way ANOVA test) and not expressed in the lung homed 
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cells treated with 5 mM of metformin (P=0.0001, Dunnett’s test) (Figure 5.7). However, it 
was clearly noticeable that the untreated cells do not abundantly express STAT3, although 
the level of expression was relatively similar in the parental and bone-homed cells lines 
and markedly lower in the lung-homed cells (Figure 5.6). 
Translocator protein expression (TSPO) was slightly increased in the wild type 
cells treated with 5 mM of metformin to 20% (P=0.04, Dunnett’s test) and significantly 
reduced in the bone homed cells to 67%, and 71% of the untreated control cells, P=0.001, 
Dunnett’s test, with 0.3 mM and 5 mM metformin treatment respectively. The expression 
of TSPO by lung homed cells was similarly significantly reduced at to 67%, and 70% of 
the untreated control cells, P=0.001, Dunnett’s test, with 0.3 mM and 5 mM metformin 
treatment respectively. The levels of TSPO expression were relatively the same in the 
metastatic bone and lung-homed cells and slightly lower in the parental control cells 
(Figure 5.6 and 5.7).   
Inconsistent with mass spectrometry result, no change in the expression of 
calmodulin was observed in both parental and lung-homing cells after metformin 
treatment (P=0.7, P=0.9, respectively, by One-way ANOVA test). However, calmodulin 
expression was significantly down-regulated to 34% of the untreated controls at 0.3 mM 
in the lung homed metastatic cells and not expressed at all when cells were treated with 5 
mM metformin (P=0.0001, Dunnett’s test) (Figure 5.6 and 5.7). Generally, the level of 
calmodulin expression was relatively similar in the untreated parental and bone-homed 
cells lines and markedly higher in the lung-homed cells.  
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Figure 5.6: Representative cropped Western blots of target protein expression 
(TNFAIP8, GRB2, STAT3, TSPO and calmodulin).  
The expression was tested within the wild type MDA-MB-231 (PCC) cells and its bone 
(BM) and lung homed (LM) variants treated with 0.3 mM and 5 mM of metformin. The 
images represent the expression of the candidate proteins (TNFAIP8, GRB2, STAT3, 
TSPO and Calmodulin), their corresponding molecular weights are indicated in brackets. 
β-actin (42kDa) served as a loading control of expression levels for all proteins tested. 20 
μg of protein total cell lysate of untreated and treated cells were loaded into each lane. (-) 
= Untreated cells, 0.3 and 5 are metformin doses in mM. For full images of the three 
independent experiments, see Supplementary materials CD (S3).      
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Figure 5.7: Representative Western blot analysis of target protein expression 
(TNFAIP8, GRB2, STAT3, TSPO and Calmodulin).  
The expression was tested within the wild type MDA-MB-231 (PCC) and its bone (BM) 
and lung homed  (LM) variants treated with 0.3 mM and 5 mM of metformin. The 
intensity of the relevant bands were determined by densitometry and normalized to β-
actin, then plotted as the percentage of β-actin expression and expressed as mean±SD 
from each of the three independent experiments of three biological replicates. Treated 
cells from each group were compared to the untreated cells as a control. *P<0.05, 
**P<0.01, ***P<0.001 and ****P<0.0001.  
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5.3.2 Spike-In SILAC (SIS)-labelled proteomics quantification: first run  
Having successfully identified some interesting proteins using a label-free 
mass spectrometry method, we decided to run a large-scale Spike-in SILAC 
comparison (experiment 2, Figure 5.2) in an attempt to identify a larger number of 
proteins for future analysis and to more fully understand the effect of metformin on 
these cells. Unfortunately, analysis of the data from the first 50 samples run on the 
mass-spectrometer out of a total of 75 samples revealed two issues, one of which was 
high levels of trypsin peptides relative to cellular-protein released peptides, and, the 
second, more worryingly, was a significant polymer contamination. Both of these 
issues were detrimental to the sensitivity of protein detection and very adversely 
impacted the overall quality of the eventual dataset. Therefore, we were unable to run 
the remaining 25 samples.  
Evidence of the polymer contamination is shown in the screen shot of the data 
in figure 5.8. When these files were run through the MaxQuant software the total 
numbers of proteins quantified and identified in the samples before any filtering of the 
data were 1365 and 1367 in the first and last 5 gel slices respectively. This is 
considerably lower than the 4070 proteins quantified in the first preliminary analysis. 
The drop in the number of proteins can be clearly attributed to the building up of the 
polymer within the samples which supresses the signals via peak-suppression. This 
prevents the detection of lower abundance proteins. Therefore, due to failure at this 
stage, preparation of the whole dataset after ordering all the fresh reagents and 
plasticware to eliminate any possible source of polyethylene glycol (PEG) 
contamination was repeated. The 44 Da PEG-like polymer trace was subsequently 
identified as originating from a commercial detergent used by the bottle-washing 
facility at the University of Sheffield.   
 172 
 
Figure 5.8: Example of an LC-MS/MS-spectrum showing the separation pattern 
of polyethylene glycol (PEG)-like detergent.  
The spectrum is dominated by a series of m/z values with equidistant peaks; 44Da 
apart; which is typical for PEG and PEG-like molecules. Each peak in the grey 
highlighted area (within the red box) section represents the ethoxy structure, which 
indicates PEG contamination.  
 
5.3.3 SILAC-based proteomics analysis of the repeat dataset 
5.3.3.1 Method  
For a full description of the SILAC-based experiment used in here, please 
refer to section 5.2.2. 
5.3.3.2 Quality-check and sample correlation 
Comparison of the repeat samples set was performed to ensure consistency 
across the experiment and eliminate any possible outliers (Following the steps 
mentioned in section 5.3.1.1). 
Cluster analysis of the PCA (principle component analysis) of cell lines with 
and without treatment showed that only the 3 samples of bone-seeking cells treated 
with metformin had fully clustered together. In the other cells with and without 
treatments, two of the three samples were closely related but one sample of each 
group was separate (Figure 5.9A). When an unsupervised hierarchical clustering was 
constructed, the data showed a very similar pattern of distribution to the PCA 
clustering (Figure 5.9B) with most groups having one sample that was not as closely 
associated. All distributions of proteins were normal and not bimodal and therefore a 
parametric statistical test was used to analyse the data (Figure 5.9C). For 
representative scatter plots of all aligned intensities from paired samples please refer 
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to Supplementary materials CD (S4). The correlation r-measures are mostly between 
0.5 and 0.8, which indicates a moderate to strong, positive, linear relationship 
between the variables. However, a few r-values are 0.3 or less suggesting a weak 
relationship. Overall, the quality check assessment suggested that the reproducibility 
of our data is reasonable enough for some further analysis.  
 
 
 
Figure 5.9: Reproducibility assessment of the SILAC-based quantification data.  
(A) A dendrogram shows clustering of the replicates of the three cell lines/treatment 
combinations. (B) Unsupervised hierarchical clustering based on Spike-in SILAC 
quantification of triplicate samples with all identified proteins; Protein abundance 
values are indicated colorimetrically for each protein in each sample; indicating the 
correlations of protein expression red = high, black = mean value, green = low. (C) 
LFQ-intensities are normally distributed within all samples. P0 in the B and C graphs 
refers to the parental cells (PCC), BM: bone-homing cells, LM: lung-homing cells.   
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5.3.3.3 Inter-group comparison and candidate selection; proteins detected 
exclusively in either parental, bone or lung homed cells 
Data were analysed using the aforementioned workflow in figure 5.1, with all 
data taken through RawMeat, MaxQuant and Perseus. Initially 4731 proteins were 
identified within the complete data set which was reduced to 2827 proteins identified 
following the removal of all proteins with < 1 unique + razor peptide across all 
samples. Next, this was further reduced to 2728 proteins following the removal of all 
reverse database hits. Finally, the identified proteins were assessed for the presence of 
at least 1 unique peptide/ID suggesting high quality protein identifications, resulting 
in a final protein number of 2651 (an excel spread sheet of the raw data is included, 
see Supplementary materials S5). Two complimentary approaches were taken towards 
the identification of the targets of interest: 
1. Using the light / heavy (L/H) ratios: if there’s a significant L:H ratio across 
all three replicates, that protein will be taken forward as interesting in our comparison 
of interest as having been increased or decreased compared to the PCC-untreated 
control cells in three biological replicates.  
2. The reciprocal of the H/L ratios was determined, and then the log2 
transformation of the L:H ratio was obtained, followed by the use of a parametric t-
test to work out significant differences in the Log2-LFQ-intensity values between 
chosen cell-line/treatment pairs. Next, a check for the appropriate number of unique 
and unique + razor peptides across all replicates within both the heavy (H) and light-
labelled (L) form of each protein of interest was performed.    
When applying these tests and filters, an initial list of 44 proteins of potential 
interest was generated. However, closer examination revealed that 34 of them had at 
least one sample with zero LFQ-intensity value or they did not pass the 1.5-fold 
change cut off point within one of the triplicate samples. This resulted in only 10 
proteins being identified as being consistently up-regulated with metformin treatment 
in one of the cell types (Table 5.3). However, unlike the pilot study, no down-
regulated proteins were identified in this experiment.  
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Table 5.2: Proteins identified as significantly differentially expressed within the parental MDA-MB-231 (PCC) and its bone (BM) and 
lung (LM) homed variant cell lines. 
Proteins here are progressively upregulated in protein expression and have at least a 1.5-fold increase between the heavy-labeled untreated cells 
(PCC) and cells treated with 5 mM of metformin (PCC, BM and LM). Fold change (FC) was calculated by comparing mean normalized LFQ 
intensity between samples. Status indicates the direction of the differential expression and in which cell type it occurs: PCC= Parental MDA-
MB-231, BM = bone homing BC cells and LM= lung homing BC cells. Entry refers to UniProt entry http://www.uniprot.org/. 
 Entry Protein names Biological functions Status FC 
1.  P02794 Ferritin heavy chain Cellular iron homeostasis, immune response and negative   regulation of 
cell proliferation 
Up in BM 4.13 
2.  P08133 Annexin A6 Apoptotic signalling pathway, ion transmembrane transport, 
mitochondrial calcium ion homeostasis and regulation of muscle 
contraction 
Up in BM 4.09 
3.  H0YM23 Ankyrin repeat domain-
containing protein 17 
(Fragment) 
RNA binding Up in PCC 7.37 
4.  O75208 Ubiquinone biosynthesis 
protein COQ9, mitochondrial 
Mitochondrial electron transport Up in PCC 4.30 
5.  O75607 NADH dehydrogenase iron-
sulfur protein 2, mitochondrial 
rRNA processing and rRNA transcription Up in PCC 2.20 
6.  O75323 Protein NipSnap homolog 2 ATP biosynthetic process, negative regulation of ATP citrate synthase 
activity, oxidative phosphorylation, positive regulation of high voltage-
gated calcium channel activity 
Up in PCC 1.98 
7.  O75438 NADH dehydrogenase 1 beta 
subcomplex subunit 1 
Mitochondrial electron transport and mitochondrial respiratory chain 
complex I assembly 
Up in PCC 1.64 
8.  P50579 Methionine aminopeptidase 2 N-terminal protein amino acid modification, peptidyl-methionine 
modification, protein processing, aminopeptidase and 
metalloexopeptidase activity 
Up in LM 31.39 
9.  P29034 Protein S100-A2 Endothelial cell migration Up in LM 16.58 
10.  P13645 Keratin, type I cytoskeletal 10 (Contaminant protein) Skin cornification and keratinization Up in LM 1.62 
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The following proteins are of tentative interest but they have one replicate with zero LFQ-intensity 
Or they have not passed the 1.5 cut-off point in one of the triplicate samples 
11.  B7Z574 Calpastatin Endogenous calpain (calcium-dependent cysteine protease) inhibitor; involved 
in the proteolysis of amyloid precursor 
Up in BM 2.64 
12.  O14933 Ubiquitin/ISG15-conjugating 
enzyme E2 L6 
Cellular protein metabolic process, SG15-protein conjugation and modification-
dependent protein catabolic process 
Up in BM 2.43 
13.  Q92522 Histone H1x Nucleosome assembly Up in BM 2.27 
14.  O43237 Cytoplasmic dynein 1 light 
intermediate chain 2 
ER to Golgi vesicle-mediated transport, microtubule cytoskeleton 
organization and sister chromatid cohesion 
Up in BM 2.16 
15.  P21912 Succinate dehydrogenase iron-
sulfur subunit, mitochondrial 
Aerobic respiration, respiratory electron transport chain, succinate metabolic 
process and tricarboxylic acid cycle 
Up in BM 2.08 
16.  P51970 NADH dehydrogenase 1 alpha 
subcomplex subunit 8 
Mitochondrial electron transport and mitochondrial respiratory chain complex I 
assembly 
Up in BM 1.97 
17.  Q9BRP8 Partner of Y14 and mago Exon-exon junction complex disassembly, nuclear-transcribed mRNA catabolic 
process and positive regulation of translation 
Up in BM 1.89 
18.  P31040 Succinate dehydrogenase 
flavoprotein subunit, mitochondrial 
Anaerobic respiration, mitochondrial electron transport, oxidation-reduction 
process, succinate metabolic process and tricarboxylic acid cycle 
Up in BM 1.66 
19.  B4DJ81 NADH-ubiquinone oxidoreductase 
75 kDa subunit, mitochondrial 
ATP synthesis coupled electron transport Up in BM 1.65 
20.  P17252 Protein kinase C alpha type Positive regulation of angiogenesis and blood vessel endothelial cell migration, 
apoptotic signalling pathway, cell adhesion, ERB2 signalling pathway, 
intracellular signal transduction, positive regulation of cell migration, adhesion, 
mitotic cell cycle and regulation of insulin secretion 
Up in BM 1.50 
21.  Q9P0J0 NADH dehydrogenase 1 alpha 
subcomplex subunit 13 
Negative regulation of intrinsic apoptotic signalling pathway, cellular response to 
interferon-beta, mitochondrial electron transport, respiratory chain complex I 
assembly, negative regulation of cell growth, positive regulation of cysteine-type 
endopeptidase activity, positive regulation of protein catabolic process 
Up in BM 1.48 
22.  Q9Y3B7 39S ribosomal protein L11, 
mitochondrial 
Mitochondrial translational elongation and termination, ribosomal large subunit 
assembly 
Up in BM 1.47 
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Table 5.3: Continued (Legend on the previous page) 
23.  P10515 Dihydrolipoyllysine-residue 
acetyltransferase component of 
pyruvate dehydrogenase 
complex, 
Regulation of acetyl-CoA biosynthetic process from pyruvate, glucose metabolic 
process, pyruvate metabolic process, tricarboxylic acid cycle 
Up in BM 1.34 
24.  P49588 Alanine--tRNA ligase, cytoplasmic Alanyl-tRNA aminoacylation for protein translation, negative regulation of neuron 
apoptotic process and tRNA modification 
Up in BM 1.33 
25.  Q8N183 Mimitin, mitochondrial Cellular respiration, mitochondrial respiratory chain complex I assembly, 
negative regulation of insulin secretion involved in cellular response to glucose 
stimulus and respiratory electron transport chain 
Up in BM 1.32 
26.  P35221 Catenin alpha-1 Actin filament organization, apical junction assembly, epithelial cell-cell 
adhesion, establishment or maintenance of cell polarity, negative regulation of 
cell motility, negative regulation of extrinsic apoptotic signalling pathway, 
positive regulation of extrinsic apoptotic signalling pathway in absence of 
ligand and response to oestrogen 
Up in BM 1.27 
27.  H0YEB6 Sjoegren syndrome/scleroderma 
autoantigen 1 (Fragment) 
Cell cycle, cell division, mitosis 
 
Up in PCC 13.75 
28.  O75170 Serine/threonine-protein 
phosphatase 6 regulatory subunit 
2 
Regulatory subunit of protein phosphatase 6 (PP6); involved in the regulation of 
phosphoprotein phosphatase activity 
Up in PCC 4.86 
29.  O75251 NADH dehydrogenase iron-sulfur 
protein 7, mitochondrial 
Mitochondrial electron transport and mitochondrial respiratory chain complex I 
assembly 
Up in PCC 2.05 
30.  O75381 Peroxisomal membrane protein 
PEX14 
Microtubule anchoring, negative regulation of protein binding, negative 
regulation of sequence-specific DNA binding transcription factor activity and 
peroxisome organization 
Up in PCC 1.69 
31.  O75394 39S ribosomal protein L33, 
mitochondrial 
Mitochondrial translational elongation and termination Up in PCC 1.65 
32.  O75436 Vacuolar protein sorting-
associated protein 26A 
Intracellular protein transport, regulation of macroautophagy, retrograde 
transport (endosome to Golgi) and Wnt signalling pathway 
Up in PCC 1.67 
33.  O75475 PC4 and SFRS1-interacting 
protein 
Nuclear transport, positive regulation of transcription from RNA polymerase II 
promoter and response to oxidative stress 
Up in PCC 
34.  O75477 Erlin-1 Negative regulation of cholesterol and fatty acids biosynthetic processes Up in PCC 1.58 
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Table 5.3: Continued (Legend on the previous page) 
 
35.  O75569 Interferon-inducible double-
stranded RNA-dependent protein 
kinase activator A 
Cellular response to oxidative stress, immune response, negative regulation of cell 
proliferation, positive regulation of intrinsic apoptotic signalling pathway, protein 
phosphorylation and protein stabilization 
Up in PCC 1.53 
36.  P04350 Tubulin beta-4A chain Ciliary basal body-plasma membrane docking and regulation of G2/M transition of 
mitotic cell cycle 
Up in PCC 1.53 
37.  P05976 Myosin light chain 1/3, skeletal 
muscle isoform 
Cardiac muscle contraction Up in PCC 1.52 
38.  Q13867 Bleomycin hydrolase Homocysteine catabolic process, protein polyubiquitination, proteolysis, response 
to drug and toxic substance 
Up in LM 1.52 
39.  O43396 Thioredoxin-like protein 1 Cell redox homeostasis and cellular response to oxidative stress Up in LM 1.51 
40.  Q9H1E3 Nuclear ubiquitous casein and 
cyclin-dependent kinase substrate 
1 
Cellular glucose homeostasis, double-strand break repair, positive regulation of 
insulin receptor signalling pathway and regulation of DNA replication 
Up in LM 1.51 
41.  P16989 Y-box-binding protein 3 3'-UTR-mediated mRNA stabilization, cellular hyperosmotic response, cellular 
response to tumour necrosis factor, negative regulation of intrinsic apoptotic 
signalling pathway in response to osmotic stress, negative regulation of 
necroptotic process, negative regulation of skeletal muscle tissue, negative 
regulation of transcription from RNA polymerase II promoter 
Up in LM 1.51 
42.  P33316 Deoxyuridine 5-triphosphate 
nucleotidohydrolase, 
mitochondrial 
DNA replication, dUMP biosynthetic process, dUTP catabolic process and 
nucleobase-containing small molecule interconversion 
Up in LM 1.50 
43.  K7EIG1 Clustered mitochondria protein 
homolog (Fragment) 
Intracellular distribution of mitochondria Up in LM 1.50 
44.  Q7Z434 Mitochondrial antiviral-signalling 
protein 
Activation of innate immune response  to bacterium and virus, negative regulation 
of type I interferon production, positive regulation of chemokine (C-C motif) ligand 
5 production, positive regulation of I-kappaB kinase/NF-kappaB signalling, positive 
regulation of protein import into nucleus, translocation and positive regulation of 
tumour necrosis factor secretion 
Up in LM 1.50 
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5.3.3.4 Inter-group comparison of metformin-untreated mammary cancer cells 
Concerningly, the present study reveals low number of proteins, only 22, 
including proteins that involved in the regulation of cellular respiration, metabolic 
processes, mitochondrial respiratory chain assembly and cancer cell growth and 
proliferation (Listed in table 5.4) are differentially expressed between the most 
commonly used triple negative human breast cancer cell lines, MDA-MB-231 and its 
bone homed variant. No difference in protein expression was detected between the 
parental and lung-homing cell variants except some potential contaminants from the 
cell-culture media (identified within database searching as Bos-taurus proteins). This 
is in contrast to previous studies and suggests that there may be issues with the data 
set330. 
The list of differentially expressed proteins generated in the present study was 
used to provide useful information about whether the differential protein expression 
seen with metformin treatment is solely attributed to the drug action or it is simply 
due to the changes that cells acquired during their progression to more aggressive 
phenotype in the absence of metformin influence. This comparison was extremely 
important to avoid false positive results and the choice of poor-quality candidates for 
further validation.  
Table 5.5, lists some target proteins of potential interest in BC metastasis 
which have been identified within the metformin-treated cells, as well as the reasons 
why they have not been taken forward to be validated by Western blotting. The main 
reason is that some of these proteins stimulate cell proliferation, inhibit cell death and 
potentiate metastasis, therefore, if they were further up-regulated by metformin 
treatment, none of these proteins would satisfy the criteria to be chosen as potential 
targets for anti-metastasis therapy within BC.  
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Table 5.4: Proteins identified as significantly differentially expressed within the untreated bone and lung homing cells 
compared to the parental MDA-MB-231 cell-line.  
Proteins here are up-regulated and have at least a 1.5-fold increase between the untreated BM and LM cells when compared to the untreated 
PCC cells. Fold change (FC) was calculated by comparing mean normalized LFQ intensity-values between samples. Status indicates the 
direction of the differential expression and in which cell type: BM = bone homing BC cells and LM= lung homing BC cells. Entry refers to 
UniProt entry http://www.uniprot.org/.  
 Entry Protein names Biological Functions Status  FC 
1.  P08133 Annexin A6 Apoptotic signalling pathway, mitochondrial calcium ion homeostasis and ion 
transmembrane transport  
UP in BM 3.90 
2.  P17252 Protein kinase C alpha type Positive regulation of angiogenesis, apoptotic signalling pathway, positive 
regulation of cell migration and adhesion, ERBB2 signalling pathway, histone 
H3-T6 phosphorylation, intracellular signal transduction, positive regulation of 
lipopolysaccharide-mediated signalling pathway, positive regulation of mitotic 
cell cycle and regulation of insulin secretion  
UP in BM 2.68 
3.  B7Z574 Calpastatin Endogenous calpain (calcium-dependent cysteine protease) inhibitor; involved in 
the proteolysis of amyloid precursor protein 
UP in BM 2.52 
4.  P10515 Dihydrolipoyllysine-residue 
acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial 
Regulation of acetyl-CoA biosynthetic process from pyruvate, glucose metabolic 
process, pyruvate metabolic process, cellular nitrogen compound metabolic 
process and tricarboxylic acid cycle 
UP in BM 2.25 
5.  P02794 Ferritin heavy chain Cellular iron ion homeostasis, negative regulation of cell proliferation, iron ion 
transport and negative regulation of fibroblast proliferation  
UP in BM 2.21 
6.  B8ZZA8 Glutaminase kidney isoform, mitochondrial Glutamine metabolic process UP in BM 2.08 
7.  O14933 Ubiquitin/ISG15-conjugating enzyme E2 L6 Cellular protein metabolic process, ISG15-protein conjugation and modification-
dependent protein catabolic process  
UP in BM 2.06 
8.  B4DJ81 NADH-ubiquinone oxidoreductase 75 kDa          
subunit, mitochondrial 
ATP synthesis coupled electron transport 
 
UP in BM 2.04 
9.  Q2TAM5  RELA protein Positive regulation of NF-kappaB transcription factor activity UP in BM 2.02 
10.  Q9NQ50 39S ribosomal protein L40, mitochondrial Mitochondrial translational elongation and termination  UP in BM 1.92 
11.  Q9Y3B7 39S ribosomal protein L11, mitochondrial Mitochondrial translational elongation and termination  UP in BM 1.88 
12.  Q9P0J0 NADH dehydrogenase 1 alpha subcomplex 
subunit 13 
Negative regulation of cell growth, mitochondrial electron transport, 
mitochondrial respiratory chain complex I assembly, negative regulation of 
apoptotic signalling pathway, positive regulation of protein catabolic process.  
UP in BM 1.83 
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 Table 5.4: Continued (legend on previous page)   
13.  O43237 Cytoplasmic dynein 1 light intermediate 
chain 2 
ER to Golgi vesicle-mediated transport, microtubule cytoskeleton 
organization and sister chromatid cohesion 
UP in BM 1.80 
14.  P31040 Succinate dehydrogenase flavoprotein 
subunit, mitochondrial 
Anaerobic respiration, mitochondrial electron transport, respiratory electron 
transport chain, succinate metabolic process and tricarboxylic acid cycle 
UP in BM 1.70 
15.  Q8N183 Mimitin, mitochondrial Cellular respiration, mitochondrial respiratory chain complex I assembly, 
negative regulation of insulin secretion involved in cellular response to glucose 
stimulus and respiratory electron transport chain 
UP in BM 1.68 
16.  Q92522 Histone H1x Nucleosome assembly UP in BM 1.67 
17.  Q99798 Aconitate hydratase, mitochondrial Citrate metabolic process, generation of precursor metabolites and energy and 
tricarboxylic acid cycle  
UP in BM 1.63 
18.  P51970 NADH dehydrogenase 1 alpha subcomplex  
subunit 8 
Mitochondrial electron transport and mitochondrial respiratory chain complex I 
assembly 
UP in BM 1.63 
19.  Q6WCQ1 Myosin phosphatase Rho-interacting 
protein 
Actin binding  UP in BM 1.60 
20.  Q9H9H4 Vacuolar protein sorting-associated protein 
37B 
Macroautophagy and protein transport  UP in BM 1.60 
21.  P35221 Catenin alpha-1 Epithelial cell-cell adhesion, establishment or maintenance of cell polarity, gap 
junction assembly, negative regulation of cell motility, negative regulation of 
extrinsic apoptotic signalling pathway and response to oestrogen 
UP in BM 1.53 
22.  P49588 Alanine--tRNA ligase, cytoplasmic Alanyl-tRNA aminoacylation, tRNA aminoacylation for protein translation, tRNA 
processing and modification  
UP in BM 1.50 
23.  P13645 Keratin, type I cytoskeletal (Human) Contaminant, human skin  UP in LM 18 
24.  P12763 Alpha-2-HS-glycoprotein precursor                               
(Bos taurus) 
Contaminant, bovine serum UP in LM 4.09 
25.  Q3SZ57 Alpha-fetoprotein precursor (Bos taurus) Contaminant, bovine serum UP in LM 4.01 
26.  P02769 Bovine serum albumin precursor (Bos 
taurus) 
Contaminant, bovine serum UP in LM 3.90 
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Table 5.5: Proteins identified as potential targets and reasons why not further 
validated by Western blot  
Potential 
candidate 
Status Fold 
change 
Reasons why not taken for 
future validation  
Annexin A6  Up in BM+ 5 
mM metformin 
4.99 Up in BM without treatment by 
3.9-fold, it is a negative 
regulator of apoptotic process 
Ferritin heavy chain  Up in BM+5 
mM metformin 
4.13 Up in BM without treatment by 
2.21-fold, also it has a positive 
regulation of cell proliferation 
and was up-regulated by 
treatment 
Calpastatin Up in BM+5 
mM metformin 
2.64 Up-regulated by 2.5-fold in 
untreated BM cells and has zero 
LFQ-intensity in one of the 
triplicate samples 
Histon H1x Up in BM+5 
mM metformin 
2.27 Up-regulated by 1.6-fold in 
untreated BM cells and has zero 
LFQ-intensity in one of the 
triplicate samples 
Protein kinase C 
alpha type 
Up in BM+ 5 
mM metformin 
1.5 Has not passed the 1.5 cut-off 
point in one of the triplicate 
samples 
Catenin alpha-1 Up in BM+5 
mM metformin 
1.27 Has one zero LFQ-intensity and 
has not passed the 1.5 cut-off 
point in one of the triplicate 
samples 
Methionine 
aminopeptidase-2 
Up in LM+ 5 
mM metformin 
31.39 Involved in up-regulation of 
angiogenesis, and considered as 
a potential target for anti-
angiogenic drugs 
Protein S100-A2  Up in LM+ 5 
mM metformin 
16.58 Has zero LFQ-intensity in one 
of the triplicate samples 
Tubulin beta-4A 
chain 
Up in PCC+ 5 
mM metformin 
1.53 Has zero LFQ-intensity and has 
not passed the 1.5 cut-off point 
in one of the triplicate samples 
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5.3.3.5 Global pathway regulation in response to metformin treatment within the 
Spike-In SILAC (SIS) proteomics experiment 
Functional network-based analyses of the 44 proteins altered between 
metformin-treated (PCC, BM, LM cells) and the metformin-untreated control cells 
revealed marked activation of molecular processes involved in protein synthesis, 
cellular respiration, oxidative phosphorylation, ATP synthesis, cellular metabolism, 
and assembly of mitochondrial respiratory chain complex-1 (RCC-1), as well as 
signalling pathways associated with cell death and apoptosis and NF-kappa B 
signalling pathway (Figure 5.10). These altered pathways are all proposed among the 
direct mechanisms through which metformin can inhibit tumour development331.  
The Uniprot identifiers of the 44 proteins were then uploaded to the STITCH 
website where the output revealed a few interactions between the proteins that were in 
the majority mitochondrial dehydrogenases, as well as enzyme complexes located 
within the inner mitochondrial membrane, which are involved in the mitochondrial 
electron transport chain, oxidative phosphorylation and ATP synthesis (Figure 5.11).  
However, when the non-connected nodes were removed the interactions were neither 
significant nor interesting between the other proteins, with the exception of the 
mitochondrial dehydrogenases, with few unverified and predicted interactions, which 
indicate that these proteins are not functionally and/or biologically connected.  
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Figure 5.10: Key biological processes and pathways modified by metformin 
treatment in the parental, bone and lung metastatic breast cancer cells.  
Bar graph shows the biological (BP) and KEGG pathways significantly 
overrepresented in upregulated proteins (Benjamin Hochberg FDR<0.05) following 
exposure to 5 mM metformin in the MDA-MB-231(BM) and MAD-MB-231(LM) 
cells. In the x-axis, the false discovery rate (enrichment factor) of each category is 
plotted. TCA: Tricarboxylic acid cycle, Mitochondrial RCC1: Mitochondrial 
respiratory chain complex. 
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Figure 5.10: Networks identified by STITCH analysis showing the pattern of 
interactions between the proteins up-regulated by metformin treatment in the 
three cell lines, with non-connected nodes removed.  
Protein-protein interactions are displayed in confidence view. In the network image, 
the red circle represents the first shell of interaction; NDUFS7: NADH:ubiquinone 
oxidoreductase core subunit S7. The edges between the nodes that represent protein-
protein associations reflect the reliability and confidence of the interaction evidence; 
thicker lines represent stronger associations. Standard nomenclature gene name 
abbreviations were used to annotate individual proteins (This can be searched on 
www.Uniprot.org for more details).  
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5.3.3.6 Re-testing for candidate proteins identified in the pilot study 
In order to examine the reproducibility of our pilot study, the 5 candidate 
proteins identified in the pilot study were re-examined in the SILAC-based 
experiment. Generally, there are two forms of data analyses, the first form is based on 
the analysis of statistically significant differences in the mean intensities between the 
samples, which have we employed earlier in our LFQ and SILAC-based studies. The 
second form is based on the detection of unique peptides and statistical significance, 
which we employed to re-test the targets.  
We found that all of them were identified within the 2728 proteins obtained 
after the data filtration and removal of all proteins with < 1 unique + razor peptide 
across all samples. However, none of them survived the t-test suggesting that they 
were not significantly changed. However, these proteins can still be presented as 
differentially expressed based on the number of unique razor peptides across the three 
samples (At least 1 unique razor peptide) and importantly the direction of change 
(increase versus decrease of protein expression or fold-change) fits with the 
observations in the pilot study analysis, suggesting that these proteins may have 
relevance, albeit with the caveat that they did not reach the P<0.05 level or pass the 
cut-off point of 1.5-fold or more for up-regulation and <0.7-fold or less for down-
regulation (Table 5.6) in the SILAC -based experiment.  
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Table 5.6: Re-test of candidate proteins within the Spike-In SILAC (SIS)-analysis data identified as potential targets for metformin 
 
 
 
 
 
 
 
 
 
 
 
Target 
protein ID 
Wild-type cell+5 mM of metformin Bone-homing cell+ 5mM of metformin Lung-homing cell+ 5mM of metformin 
Number of 
unique razor 
peptides 
 
 
 
P-value 
 
 
 
Fold change 
Number of 
unique razor 
peptides 
 
 
 
P-value 
 
 
 
Fold change 
Number of 
unique razor 
peptides 
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Fold change 
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TNFAIP8 2 2 2 0.12 0.91 1 2 2 0.74 0.8 2 1 2 0.65 0.65 
GRB2 10 10 11 0.72 1.27 9 11 11 0.81 0.79 9 11 10 0.21 0.72 
STAT3 16 14 11 0.45 0.85 15 17 17 0.14 1.23 14 9 16 0.15 0.97 
Calmodulin 10 11 11 0.20 1.24 10 11 10 0.22 1.28 11 8 9 0.25 1.32 
TSPO 3 2 2 0.65 1.34 2 3 3 0.45 0.87 4 3 2 0.52 0.91 
Blue numbers; represent up-regulation, Red numbers; represent down-regulation. 
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5.4 Discussion 
Understanding the molecular mechanisms associated with the anti-
proliferative effects of metformin on triple negative metastatic breast cancer cells, and 
whether they are direct or indirect, primary or secondary (compensatory) effects, or 
ubiquitous or cell-type specific phenomenon, is fundamental to assess whether 
metformin can prevent, treat or ameliorate complications caused by cancer metastasis. 
In an effort to further characterize the complex molecular mechanisms/pathways of 
metformin action, our proteomic study of breast cancer cell lines, which have the 
propensity to undergo bone and lung metastasis, revealed several target proteins for 
metformin action, having functions in, for example, cellular metabolism, cell 
growth/proliferation, necrotic cell death and apoptosis, cell adhesion/motility 
/metastasis, signal transduction and transport. Mass spectrometry-based proteomics 
methods have been very useful in the analysis of complex biological samples across a 
great many disease types. These studies can both identify and quantify individual 
protein levels in a global and unbiased manner, and therefore can further improve our 
understanding of the molecular biology of cancer cells and highlight the cellular 
processes that are altered within such systems.  
5.4.1 Quantitative proteomic analysis of metformin-action within breast cancer: 
current knowledge and literature gaps 
To date, very few proteomic studies have attempted to determine the distinct 
features of invasive and metastatic breast cancer cell lines in response to metformin332, 
333. Only one previous in vitro proteomic study has been carried out which compared 
the effect of metformin on triple negative human breast cancer cell lines in which the 
investigators have attempted to examine the effects of metformin and phenformin in 
the context of breast cancer lung metastasis but, so far, no study has looked at BC 
bone metastasis333.  The study demonstrated that metformin was able to inhibit local 
BC growth in immune-deficient mice injected with MDA-MB-436 breast cancer cells 
and reduced the number of metastatic lesions in the lungs. Metformin has also been 
shown to target the endothelial compartment in the blood vessels within the tumour 
resulting in a significant reduction of the endothelial cell component and the 
generation of dysplastic blood vessels. In the same study, a proteomic assay 
demonstrated that 5 mM metformin decreased the concentration of several crucial 
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angiogenesis-related proteins in a co-culture of triple negative BC cells and white 
adipose tissue  (WAT) progenitor cells (targeting both neoplastic and 
microenvironment cells). However, lower doses of phenformin; a potent biguanide 
drug, were significantly more efficacious than metformin both in vitro and in vivo333.  
Another study using both proteomic and phosphoproteomic label-free 
quantification methods reported that treating MCF7 cells with 10 mM metformin 
makes them less sensitive to the pro-growth stimuli and more sensitive to the 
apoptotic stimuli332. Additionally, another study was conducted where the researchers 
attempted to identify whether metformin treatment would affect breast cancer lung 
metastasis, and reported that the administration of 825 mg/kg/day of metformin over 
27 days, to female balb/c mice injected with 66cl4 cells, had a little or no effect on the 
number or size of metastatic lung lesions334. However, it was also noted that the 
metastatic lung lesions displayed increased signals for phosphorylated AMPK, when 
compared to surrounding normal lung tissue, suggesting that metformin treatment 
exerted an effect on the metastatic lung lesion. Moreover, a small epidemiological 
study involving 1,448 diabetic women with TNBC, reported that women who were 
taking metformin had a lower risk of distant metastases compared to those not taking 
metformin335.  
Overall, there seems to be enough evidence to indicate a potential anti-
metastasis role for metformin within breast cancer. Here, we present a large-scale 
quantitative global proteomic approach aimed at identifying metformin-induced 
changes at the proteome level. Observations from this study would provide an 
integrated picture of the complex alterations within metformin-regulated pathways in 
metastatic BC cell lines and highlight the modulation of expression of key signalling 
proteins. 
5.4.2 Comparison of cell lines by global proteomics 
We examined the similarity and differences of protein expression between the 
cell lines using two different proteomic techniques. 
Initially label-free quantification was used, in a small-scale pilot experiment, 
to quantify and compare the levels of proteins between the wild-type MDA-MB-231 
(PCC) cell-line and its bone-homed (BM) variant. For this study, the analysis was 
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performed where the MS signal intensities of the same peptides identified within both 
cell lines are quantified relative to each other without the use of an isotopic standard 
peptide. This is a frequently used method for determining the abundance of 
proteins within a proteome.   
Next, the spike-In-SILAC labelling system was used which allowed reliable 
comparisons of proteomic differences between the two heavy and light-labelled 
samples within a single gel for each replicate, thus avoiding the difficulties associated 
with gel-to-gel variation and technical variation introduced when samples are 
prepared separately336. Furthermore, the labelling within the SILAC-based approach 
occurs at the protein level allowing samples to be mixed directly (in a 1:1 ratio) after 
cell lysis thus avoiding the variability associated with sample preparation. Next, the 
quantitative differences in protein abundance between the samples can be determined 
by analysing the MS signals of the labelled and unlabelled peptides in the spectrum. 
As a consequence, one potential limitation is the requirement for matching peptide 
pairs to be present in both samples; this can lead to a fraction of peptides that cannot 
be quantified (due to absence of a peptide in one isotopic channel) and consequently a 
failure to analyse proteins which are significantly expressed in one sample only. Other 
limitations include the requirements for a high signal-to-noise ratio and high mass 
accuracy within mass-spectrometry.   
In our study, the depth of both proteomic analyses was limited to about 4070 
proteins; this limitation might be partially attributed to the high degree of similarity of 
the three cell lines being compared at the protein level, as well as the limited front-end 
fractionation (with the use of only 5 SDS-PAGE gel bands). Indeed, more 
comprehensive mass spectrometric analysis of different BC cell lines can be 
performed to address this issue in order to further examine the generality of the 
enormous overlap of proteomes within an increasing number of molecular subtypes. 
Both the label-free and SILAC-based quantifications showed an overlap in 
output data that was much higher than that frequently reported in any other 
metformin-based proteomics studies. However, in the previous studies332, 333, the 
proteome was not sampled with the same degree of rigour as there was a selection of 
specific pathway-related peptides used for sequencing which can subsequently lead to 
substantial differences in the identified proteins. Additionally, this overlap is also 
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potentially expected as we have looked at changes in global protein expression and 
not the phosphoproteomics which is expected to change a lot more. This illustrates the 
importance of comprehensive proteomic coverage for accurate comparison between 
cell lines.  
The data in this chapter demonstrated that treatment with the potential tissue 
accumulated doses of metformin results in a significant change in a number of 
proteomic markers in the non-metastatic TN breast cancer cell line (PCC) as well as 
the metastatic bone- and lung-derived cells. Of the 4070 proteins identified by label-
free quantification, 33 proteins were significantly differentially expressed when 
compared to untreated cells, after adjusting for multiple comparisons. These proteins 
reflect a wide range of cellular activities that can be related to cancer, including 
PI3K/AKT signalling, proliferation, invasion/motility, apoptosis/cell cycle regulation 
and metastasis. 
We observed an increase in the level of GRB2, and TSPO proteins and 
reduction in the expression of STAT3 and TNFAIP8, by both mass spectrometry and 
Western blotting after metformin treatment in the primary TN cell line (PCC). These 
associations have not been previously reported. However, most of the molecular, 
cellular, KEGG and signalling pathways reported in our mass spectrometry study are 
consistent with prior pre-clinical observations reported by another study, which was 
performed primarily in the MCF7 cells exposed to 10 mM of metformin332. Therefore, 
metformin treatment at a dose as low as 0.3 mM can alter these identified pathways. 
This is a novel and promising finding for the role of therapeutically relevant 
concentrations of metformin within BC prevention and treatment in the clinical 
setting.   
Interestingly, most, but not all, candidate proteins that were identified as 
changed by mass spectrometry analysis were consistently altered following metformin 
treatment in all three triple negative BC cancer cell lines, when assessed by Western 
blot, calmodulin is a good example of this, and this appears to be the case with other 
proteins detected in this study.  
Inconsistent with the list of molecular and signalling pathways identified in 
the pilot study, most of the pathways identified to be up-regulated in the large-scale 
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Spike-In-SILAC experiment, were apparently related to molecular mitochondrial 
processes. In some ways this is not surprising as in diabetes, metformin has been 
reported to be a weak mitochondrial poison, working as a respiratory chain inhibitor 
and thereby reducing mitochondrial activity. This shifts cellular respiration toward 
aerobic glycolysis, a process called the conventional “Warburg effect”. In cancer, 
metformin is thought to prevent malignant cells from using their mitochondria for 
energy production. However, it has been suggested by several studies that aggressive 
cancer cells have functional mitochondria that can rescue the aerobic glycolysis 
process337-339. Additionally, a proteomic analysis of breast cancer cells with a tendency 
for brain homing has directly demonstrated up-regulation of mitochondrial enzymes 
involved in the tricarboxylic acid cycle (TCA) and oxidative phosphorylation340.  
In our study, the current analysis (Figure 5.10) also supports an association 
between the up-regulation of mitochondrial oxidative phosphorylation and the TCA 
cycle in the three untreated cancer cells as well as an association with the tendency for 
BC metastasis, due to these proteins being up-regulated more in the BM and LM cells 
compared to PCC. However, we could not draw a firm conclusion as to whether the 
up-regulation of mitochondrial enzymes seen after metformin exposure was as a result 
of the direct effects of the drug or as a result of the aggressive phenotype of the cells 
used, as there is always one zero LFQ-value in each of the treatment groups. That 
said, mostly the same enzymes were also identified to be up-regulated by roughly a 
similar magnitude of fold changes in the untreated cells (1.5-2 fold), and these folds 
were not significantly higher after metformin treatment suggesting that it is not a 
metformin effect.  
Our results are also consistent with the notion that mitochondrial toxins should 
be used for cancer chemoprevention as well as chemotherapy and provide further 
circumstantial evidence that at relatively high concentrations (5 mM), metformin 
targets the mitochondria. Although metformin is considered to be a weak 
mitochondrial toxin, this could be one of the mechanisms through which metformin 
can prevent cancer development.  
It is important to note that it was beyond the framework of this project to 
identify global changes in the proteome of the untreated cells, except as controls for 
the purpose of comparison with treated cells. However, our findings were inconsistent 
 193 
with previous work by Westbrook and colleagues who identified at least 75 proteins 
with statistically significant fold changes between BM and PCC cells330. In fact, they 
identified 8 proteins that were up-regulated in BM cells only and none of these 8 
proteins appeared on our list.   However, unlike our global proteomic approach, they 
used the 2D-DIGE gel-based method for proteomic analysis and not the Spike-in 
SILAC method which may account for some of the differences seen. Issues with the 
proteomic studies may also have accounted for these differences as discussed 
previously and below.  
5.4.3 Issues in performing proteomics studies using cell lines  
5.4.3.1 Candidate selection 
Interesting candidate proteins were drawn from the pilot study (TNFAIP8, 
GRB2, STAT3, TSPO and calmodulin), but not from the large-scale Spike-In SILAC 
experiment (reasons are explained in section 5.3.3.3 and table 5.4). None of these 
proteins have been previously identified as potential targets for metformin treatment 
within breast cancer metastasis. However, it should be noted that the fold differences 
were not profound (1.5-1.7-fold), albeit not atypical for proteomic studies, and only 
borderline in most cases, and there was no strong on and off effect in the mass 
spectrometry results (although this was not the case in Western blot analysis where 
clear differences were seen).   
The fold difference in these proteins within the three cell lines tested and 
within the treated and untreated groups is strongly influenced by the mean LFQ 
intensity, which is itself skewed if there is a zero value in one of the biological 
replicates (or even by a higher value in one sample). Although biological replicates 
are preferable to technical replicates for improving the efficiency of statistical testing, 
typically the biological variability is substantially greater than the technical 
variability. Therefore, our use of three biologically distinct repeats per cell line tested 
may account for the variability in mass spectrometry results within each triplicates of 
a biological population.  
When candidates from the pilot study were re-tested in the main experiment 
the results imply that they could still be potential candidates (based on the presence of 
at least 1 unique peptide), or excluded as candidates (based on a lack of statistical 
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significance, potentially for over-interpretation of a zero value in one sample and 
failure to meet the cut-off point overall). This demonstrates both the value and the 
limitations of mass spectrometry analyses where different approaches could be used 
to analyse the data. Another possible limitation is the use of STITCH pathway 
analysis as an important criterion for candidate selection, as this can be limited by the 
fact that some of the relationships between the identified target proteins might be 
based on low quality publications and/or indirectly inferred interactions.  
5.4.3.2 Technical issues and methodological constraints  
 
Generally, the accuracy of proteomics analysis relies on the methodological 
approach being used. In this study, we performed proteomic profiling of three 
biological replicates per cell line by 1D gel electrophoresis with consecutive mass 
spectrometric protein analysis and then confirmed the validity of protein expression 
data by Western blotting using specific antibodies.  
Major limitations of 1D gel electrophoresis include limiting the analysis to 
more abundant proteomic alterations because of the difficulties in detecting 
differentially expressed proteins of low abundance following peptide-extraction from 
the gel-slices, as well as the necessity for high-purity reagents to reduce interference 
by contaminants during heavy and light isotopic labelling. Therefore, in order to 
increase the sensitivity of the overall workflow and to overcome these limitations, 
several strategies can be employed such as optimization of the protein extraction 
protocol and downstream protein fractionation procedures.  
Moreover, discordance between the candidate proteins observed within small-
scale versus large-scale studies has been encountered in this work, which could be 
affected by both the biological system studied, variation between technical repeats 
and in addition the half-life and stability of the proteins being studied. These variables 
are critical to consider when interpreting proteomic findings based on pilot studies 
and show that interpretation of those results should be done with caution.  
However, despite these limitations, our study has some strengths including the 
fact that we performed a thorough exploration of the metformin treatment altered 
proteomic markers identified in the pilot study using the same whole cell lysates from 
the three biological replicates used for the large-scale experiment; as validated by 
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Western blot analysis of the five selected candidate proteins. In addition, we had a 
sufficient number of treated samples to compare to a control/untreated group. Even 
though the majority of our candidates have not survived the statistical significance test 
in the large-scale SILAC experiment, they have passed the number of unique peptides 
test (Table 5.6).  
Weaknesses of the SIS-analysis include a relatively small number of proteins 
identified as being differentially expressed. In addition, the cell lines used were 
primarily hormone receptor negative invasive and metastatic breast cancers, and it is 
unclear whether these results can be generalized to other BC subtypes. Ideally, we 
would have compared between the hormone receptor negative, hormone receptor 
positive (MCF7 or T47D) and early non-invasive (DCIS or ADH) cells to create a 
heterogeneous population of assessed tumour cell lines.  
The five candidate proteins identified (TNFAIP8, GRB2, STAT3, TSPO and 
calmodulin) are now discussed in more detail. 
5.4.4 Candidate proteins   
5.4.4.1 Tumour necrosis factor alpha-induced protein 8 (TNFAIP8, 21kDa) 
Tumour necrosis factor-α-induced protein 8 (TNFAIP8), an oncogenic anti-
apoptotic factor and NF-kappa-B-inducible protein, is the first discovered member of 
the conserved TIPE family (tumour necrosis factor-α-induced protein 8-like) of 
proteins. TIPE members are newly described regulators of cell proliferation, 
oncogenesis, tumour progression and inflammation341. However, the mechanisms 
behind these actions are as yet unknown.  
Overexpression of TNFAIP8 frequently occurs in several types of cancer 
including breast and is associated with poor prognosis342. Exogenous expression of 
TNFAIP8 in human breast cancer cells resulted in enhanced cell proliferation, 
migration and invasion 343. At the same time, knocking down TNFAIP8 expression in 
breast tumour cells reduced their tumorigenicity343. In a recent study by Zhang and 
colleagues344, down-regulation of TNFAIP8 expression in human prostate cancer cells 
reduced pulmonary colonization of malignant cells and improved sensitivity of the 
tumour xenograft to radiation and docetaxel. Moreover, TNFAIP8 knockdown in 
prostate and breast cancer cells was found to be associated with decreased expression 
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levels of several oncogenes including S100P, MALAT1, MET, KRAS and FOXA1 as 
well as increased expression of several apoptotic and anti-proliferative genes such as 
FAT3 and IL-24. Similarly, TNFAIP8 knockdown cells also manifested reduced 
expression of several oncoproteins such as EGFR, SRC, ABL1, IL5 and GAP43345. 
Additionally, TNFAIP8 has been also found to be predominately involved in the 
hypoxia-inducible factor-1α (HIF-1α) signalling pathway and cancer development 
signalling networks345. Collectively, these studies outline a critical role for TNFAIP8 
in the regulation of cancer cell survival and tumour progression in a multifaceted 
manner.  
Here we have investigated, for the first time, the effects of metformin on the 
protein expression profile of TNFAIP8 in breast cancer cells that have the ability to 
metastasize to bone and lung. Our results indicate a unique cell-type based response to 
metformin treatment, while all cells significantly respond to the 5 mM dose; the 
metastatic lung cells were particularly sensitive to the clinically relevant dose of 0.3 
mM. In conclusion, the present data demonstrated that metformin can significantly 
down-regulate the expression level of oncogenic TNFAIP8, and therefore may abolish 
its role in tumour progression. Moreover, in the era of targeted therapy, metformin 
may have the potential as an anti-metastatic agent to treat the lung spread of breast 
cancer.     
5.4.4.2 Growth factor receptor-bound protein 2 (25 kDa) 
The growth factor receptor-bound protein 2 (GRB2) has long been known as a 
key downstream protein in signal transduction initiated by various receptor tyrosine 
kinases (RTKs). Evidence suggests that GRB2 is used by RTKs to activate the 
mitogenic and transforming Ras/Raf/Mek/MAP kinase pathway346. Therefore, GRB2 
inhibition will lead to MAPK inactivation. GRB2 was also found to be critical for the 
proliferation of BC cells that express EGFR or ErbB2 tyrosine kinases347.  In a study 
that set out to determine the effect of disrupting the downstream tyrosine kinase 
signalling of EGFR in breast cancer cells that express high levels of ErbB2, down-
regulation of GRB2 resulted in selective growth inhibition in breast cancer cells347. 
Other studies showed that following EGFR activation, increased association with 
GRB2 occurs, which intensifies EGFR oncogenic signalling and promotes cell 
growth346. Conversely, when GRB2 protein was down-regulated, EGFR signalling 
was disrupted and growth suppression occured348 (Figure 5.12). 
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Furthermore, almost every paper that has been written on metformin in 
oncology proposes the impact of metformin on the role of insulin as a mechanism 
through which metformin might prevent cancer development. In this context, GRB2 
has been found to mediate cross talk (and to propagate the signals) between the 
insulin receptor and the Ras/Raf/ERK pathway, a known driver of cell growth and 
proliferation. Insulin/IGF-1 is involved in carcinogenesis through up-regulation of the 
insulin/IGF receptor signalling pathway (see introduction chapter) whereby IGF-1 
produced by the liver and binds to the IGF-1 and insulin receptors and transmits the 
signals to phosphoinositide 3-kinases (PI3K) and the Akt/protein kinase through 
insulin receptor substrate (IRS) proteins, and thus indirectly activating mTORC1 
(Figure 5.12). The findings that GRB2 plays a critical role in breast carcinogenesis 
and therefore may have strong implications for novel molecular targeting strategies, 
has provide a rational for us to choose this protein as a candidate to explore the impact 
of metformin treatment on our aggressive metastatic BC cell lines. To our knowledge 
this is the first study exploring the inhibition of this protein in response to metformin 
treatment in breast cancer.  
Consistent with the observations from our pilot study, Western blot validation 
analysis also demonstrated a significant up-regulation of GRB2 protein in the parental 
triple negative breast cancer cells and down-regulation in the fully bone-homed and 
lung homed cells. The most surprising aspect of the data is the strong on and off effect 
that metformin has on this protein in the parental and lung-homed cells respectively. 
The profound down-regulation of GRB2 in some cells may partially explain why it 
was undetectable in metformin-treated bone- and lung-homed cells in the large-scale 
experiment. However, the GRB2 was profoundly up-regulated following exposure to 
5 mM of metformin in the parental MDA-MB-231 cell line, which may therefore, 
suggest that metformin might have a harmful effect in the early metastatic stage of 
triple negative BC. However, it is important to note, that this is only a single protein 
in a very complex set of pathways and its effects may be counteracted by the effects 
of metformin on another protein.    
 
 198 
 
Figure 5.12: GRB2 mediates signalling between various receptor tyrosine kinases 
(RTKs) and the Raf/MEK/AMPK and PI3K/ERK pathways.  
Upon ligand binding, activation of IGFR, EGFR or VEGFR occurs, which leads to 
increased receptor association with GRB2, followed by phosphorylation of SOS and 
subsequent activation of Ras. Ras, in turn, fosters several oncogenic signalling 
pathways, thereby increasing cell survival and proliferation through Raf/MEK/AMPK 
and PI3K/Akt/mTOR pathways. Conversely, when phosphorylation of GRB2 is 
inhibited or down-regulated, EGFR/IGFR/VEGFR signalling is disrupted and growth 
inhibition occurs (some elements of this figure were produced using Servier Medical 
Art: http://www.servier.com/Powerpoint‐image‐bank).  
 
Together these findings provide an important insight into another 
unrecognized molecular action through which metformin may curtail the growth of 
TN metastatic breast cancer cells. Nonetheless, it remains to be elucidated if this 
action was exerted through the EGFR or the RAS/RAF/MAPK pathways via MAPK-
dependent and/or independent mechanisms. 
5.4.4.3 Signal transducer and activator of transcription-3 (85 kDa) 
Signal transducer and activator of transcription-3 (STAT3), belongs to a 
family of transcription factors, which transcriptionally regulate a divergent array of 
cellular processes via integrating cytokine and growth factor signalling349. STAT3 is 
aberrantly constitutively activated in numerous epithelial and haematological 
malignancies, including more than 40% of breast cancer subtypes. Indeed, in breast 
cancer it is most frequently associated with triple-negative tumours and is thought to 
play a critical role in the pathogenesis of this highly aggressive cancer subtype349. In 
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contrast to tight regulation of STAT3 as a latent transcription factor in normal breast 
cells, its signalling in breast carcinogenesis is multifaceted. In various breast cancer 
types, STAT3 activation can be induced both directly or indirectly by receptors with 
intrinsic kinase activity such as epidermal growth factor receptors (EGFR) and 
vascular endothelial growth factor receptors (VEGFR). Furthermore, abnormal 
STAT3 signalling enhances BC progression through dysregulation of expression of 
the downstream target genes which regulate cell proliferation (e.g Bcl-2, and cyclin 
D), angiogenesis (e.g VEGF and Hif1α) and epithelial to mesenchymal transition (e.g 
MMP-7, MMP-9 and Vimentin) (Figure 5.13).  
Indeed, several studies have provided compelling evidence for the critical role 
of aberrant STAT3 activity in controlling a large number of phenotypic responses 
such as cell proliferation, survival, anti-apoptosis, angiogenesis, epithelial to 
mesenchymal transition, invasion and metastasis, therefore validating STAT3 as a 
promising therapeutic target for breast cancer337, 350 (reviewed in detail in references349, 
351, 352). These multiple modes of interactions make STAT3 a master linking point for a 
great number of signalling processes. However, this highly interconnected nature 
might render it difficult to target STAT3 signalling pathway as a treatment strategy 
due to lack of selectivity and risk of possible side effects. 
Previous research has indicated that STAT3 is a critical regulator of 
metformin action in a panel of triple negative breast cancer cells (MDA-MB-231, 
MDA-MB-468, BT20, HCC70, HCC1806 and HCC1937) using a dose range of 10-
20 mM.  While ectopic expression of STAT3 partially attenuated the effect of 
metformin on these cells, STAT3 knockdown enhanced metformin-dependent growth 
inhibition and induced apoptosis353. In the same vein, metformin has been shown to 
act synergistically with a selective STAT3 inhibitor to inhibit cell growth and induce 
apoptosis in TNBC353. Additionally, recent studies suggest that metformin treatment 
reduces the expression of several key drivers of the epithelial-mesenchymal transition 
machinery in several types of cancer224, 354-356. However, the potential activity of 
clinically relevant doses of metformin against STAT3 in the aggressive metastatic 
bone and lung homed cells has not been previously tested.    
Due to its critical role in human oncogenesis, STAT3 activation may be 
paramount in the BC metastasis to bone and lung. Given the aforementioned 
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associations between activation of the STAT3 pathway in TNBC cells and stem cell 
maintenance, as well as the unique biological effect that metformin has exerted on 
both cells, the effect of the clinical and potential tissue accumulated doses of 
metformin on STAT3 levels in the three metastatic cell lines was investigated.  
 In our proteomic pilot study, we found that metformin significantly down-
regulated STAT3 protein levels in both the parental and bone metastatic cell lines. We 
also performed Western blot analysis and demonstrated for the first time that the total 
STAT3 expression was significantly down-regulated in the three metastatic cell lines 
at both tested concentrations including a dose as low as 0.3 mM, with the lung-homed 
cells being the most responsive. However, the molecular mechanism by which 
metformin suppresses STAT3 in these cells remains unclear. Most noteworthy, 
however, STAT3 was not highly expressed by the three control cells when untreated, 
as demonstrated by their weak signal strength in Western blot. 
 
 
Figure 5.13: Activation and regulation of the STAT3 signalling pathway.  
The recruitment and phosphorylation of the STAT3 pathway is triggered by activation 
of cell surface receptors (G-protein coupled receptor, growth factor Tall-like receptor 
4, IL-6 or cytokine receptors) leading to activation of the JAK-family of proteins.  
Phosphorylation of STAT3 results in translocation of activated STAT3 dimers to the 
nucleus. In the nucleus, STAT3 binds to the promoters of genes and activates a 
sequence of downstream cellular processes that are required for cancer progression. 
STAT3, signal transducers and activators of transcription 3; JAK, Janus kinase; 
GPCR: G-protein coupled receptor, TLR-4: Tall-like receptor 4 and IL-6: interleukin-
6 (some elements of this figure were produced using Servier Medical Art: 
http://www.servier.com/Powerpoint‐image‐bank). 
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5.4.4.4 Translocator protein (TSPO, 18kDa) 
The translocator protein (TSPO), previously known as the peripheral 
benzodiazepine receptor (PBR), is an 18kDa outer mitochondrial membrane protein. 
TSPO is expressed in almost all tissues, although its expression is particularly high in 
organs involved in steroidogenesis, the process by which cholesterol is converted to 
active steroid hormones, such as adrenal glands, testes, prostate and ovaries, owing to 
the major role TSPO plays in steroid biosynthesis357. A large body of literature 
supports the notion that TSPO is excessively over-expressed in highly aggressive 
tumour phenotypes, including those of the breast, and this expression is strongly 
involved in mammary gland morphogenesis and advancing BC stage358, 359.  When 
compared with oestrogen receptor positive breast tumours, TSPO levels are found to 
be higher in ER-negative breast tumours. Furthermore, stable overexpression of TSPO 
in the non-transformed MCF10A cell line, in a 3D matrigel culture system, drives 
acinar cell proliferation and contributes to resistance to luminal apoptosis; changes 
that resemble phenotypes found in early stages of BC such as ADH and DCIS360. On 
the other hand, TSPO overexpression promotes the proliferation of MCF7 cells 
(luminal ER+), whereas silencing this protein diminishes the proliferation of MDA-
MB- 231 cells (ER-, claudin-low)361. Moreover, treating multiple cancer cells with 
synthetic TSPO ligands resulted in increased apoptosis and reduced the viability of 
both ER-positive and ER-negative cells362. Taken together, these data suggest that 
targeting TSPO may prove useful for the treatment of receptor-negative BC subtypes, 
particularly in combination with other mitochondria-targeting agents providing a 
rational for testing the effect of metformin on TSPO protein expression at the most 
advance stages of breast cancer progression, namely bone and lung metastasis.  
Consistent with our proteomic analysis data, this study reports for the first 
time that TSPO was up-regulated in the parental MDA-MB-231 cells treated with 5 
mM of metformin and significantly down-regulated at both testing doses in both 
bone- and lung-homed cells, although it did not pass the statistical significance test in 
the large scale-experiment.  These findings suggest that metformin could be effective 
against TSPO expression in the most aggressive phenotypes of BC that will home to 
the lung or the bone. 
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5.4.4.5 Calmodulin (17 kDa) 
It has been recently demonstrated that the ubiquitous calcium-receptor protein, 
calmodulin, mediated EGF-initiated activation of the oncogenic Akt pathway in the 
majority of BC cell lines363. This effect was particularly evident in the ER-negative 
but not ER-positive phenotypes364. Calmodulin antagonists were shown to abolish the 
Akt pathway activation in mouse mammary epithelial cells and human ER-negative 
BC cells, thereby inactivating a number of apoptosis related proteins and interfering 
with programmed cell death, therefore, confirming the involvement of Akt signalling 
transduction pathways365.  
Based on the broad spectrum functions of calmodulin; which are required by 
the malignant cells to achieve certain physiological processes such as growth, 
angiogenesis, metastasis and tumour stemness363, one can conclude that targeting of 
calmodulin-dependent signalling processes might offer great potential for the 
treatment of breast cancer.  
Although calmodulin was reported to be significantly down-regulated by both 
drug doses in our pilot study, contrary to expectations, our Western blot study did not 
find a significant difference in calmodulin expression between metformin-treated and 
untreated parental and bone metastatic breast cancer cells and furthermore it did not 
pass the statistical significance test in the large-scale experiment. Surprisingly, the 
metastatic lung-homed cell line showed a unique response to both clinical and tissue 
accumulation doses of metformin demonstrating a clear reduction in calmodulin 
expression. The findings from our proteomics study and Western blot analysis in the 
presence of metformin treatment in the context of breast cancer represents a novel 
area that has not been tested before and the data suggest that although the action of 
metformin might not be calmodulin-dependent and not significantly important for 
bone metastasis, this pathway is potentially important for BC cells metastasizing to 
the lung.  
In summary, to our knowledge this is the first study that evaluates the effect of 
the clinical relevant dose of 0.3 mM of metformin in the three metastatic breast cancer 
cell lines using global proteomics. In this chapter we have demonstrated that clinical- 
and potential tissue-relevant doses of metformin are associated with a number of 
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significant proteomic changes, including previously unreported changes in TNFAIP8, 
GRB2, STAT3, TSPO and calmodulin proteins in TNBC cells as well as their 
aggressive lung and bone homing metastatic variants, observed under our in vitro 
conditions. Our observation of these interactions suggest that treatment with 
metformin may provide significant benefits to triple negative cancer patients and 
combination targeting may have the potential for enhancing metformin’s efficacy in 
the clinical setting. We have yet to determine if the GRB2, STAT3, TNFAIP8 and 
TSPO proteins are critical for metformin action in other molecular subtypes of breast 
cancer.  
Although the label-free quantification pilot study used earlier in this project 
was promising, it was hampered with its limited capacity to achieve great depth and 
unfortunately most of the identified markers have not been further validated due to the 
time constraint. The complexity and overlap of the cellular proteome and the lack of 
reproducibility of some samples also hampered the in-depth quantitative proteomic 
profiling using Spike-in SILAC. This leads to a limitation in the interpretation of the 
data as only two of each triplicate clustered together as duplicates rendering it 
difficult to detect a statistical significant difference within small sample sizes; any test 
used will be much less powerful.  
Another caveat is that, we have expected to see the same candidates identified 
in the pilot study with the same magnitude of significance in the large-scale 
experiment but we have not and we still do not know why. Ideally, the SILAC-based 
experiment could have been repeated but time and cost prevented that. Therefore, 
further work is needed to confirm these findings and to establish whether these are the 
only mechanisms by which metformin is working.   
Furthermore, it would be interesting to compare the proteomic profiles of the 
metastatic cell lines with the pre-invasive models of disease in a  future experiment.  
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6. Chapter 6: General discussion 
The chemopreventive and chemotherapeutic effects of metformin are currently 
being evaluated for the treatment of different types of malignancies including breast 
cancer. Although its mechanism of action remains only partially understood, 
metformin is thought to curtail cell proliferation via activation of the AMPK 
signalling pathway, thus directly inhibiting the main anabolic processes that sustain 
cancer cell growth and proliferation. Although these mechanistic facts have long been 
appreciated, only recently significant uncertainties with respect to the right drug 
dosage to be used in the preclinical research have become a major concern.   For 
example, a frequently cited criticism of almost all preclinical studies involving 
metformin is the use of in vitro concentrations that are considered to be 10-100 times 
higher than the maximally achievable therapeutic serum concentrations found in 
diabetic patients366. In contrast to the therapeutic serum concentrations of metformin 
in diabetic patients that is achieved in the micromolar range (approximately 
20µmol/ml, in patients treated with 500-2000 mg/day orally), metformin toxicity 
across various breast cancer cell lines was achieved in the millimolar range (1-10 
mM)367.  
Although this appears to be quite a difference, there may be a few possible 
explanations. To begin with, the media used in tissue culture often contains 
supraphysiologic glucose concentrations (17 mM which is typically incompatible with 
human life) that may limit the response to metformin. Furthermore, it has been shown 
that metformin accumulates in the tissues of diabetic mice250 and humans368 at 
concentrations significantly higher than those in blood, which potentially justifies the 
use of the 1 mM and 5 mM concentrations applied in this study, to be considered 
potential tissue accumulation doses. Using a formula for dose translation from human 
to the in vitro setting based on the molecular weight of metformin and human plasma 
equivalency dosing range of 4 mg/l to 40 mg/l244, 245, 248, 249, it is considered that a 
range of 0.03 mM to 0.3 mM would be similar, and certainly not higher, to that 
expected in human plasma. It should be taken into consideration that there is huge 
variation in the therapeutic concentrations reported to date due to inter-individual 
variations in the plasma concentration of metformin.  Another critical issue is data on 
metformin concentrations in the major deep compartments and tumour tissues are 
evidently not available in clinical practice, therefore, the plasma values obtained 
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should be interpreted with caution as they are less informative and do not necessarily 
reflect metformin tissue concentrations. Indeed, this thesis set out to evaluate the in 
vitro effects of the clinically relevant doses of metformin, as well as the potential 
tissue accumulated doses on breast cancer growth and proliferation.  
A growing body of evidence suggests that the anti-neoplastic activity of 
metformin in breast cancer tissues requires the expression of the right cell surface 
transport molecules as well as adequate tissue concentrations of the drug. 
Consequently, tumour cells that do not express the required transporters are immune 
to the direct effects of metformin as it is unlikely that metformin would accumulate to 
a concentration that would allow for direct action following conventional doses used 
in diabetic patients.   
As a result, this thesis first aimed to investigate the expression of metformin 
transporters and their potential contribution to the antiproliferative effects of 
metformin more fully. The work performed in this thesis demonstrated that normal, 
pre-malignant, pre-invasive and invasive human breast cell lines and tissues as well as 
the metastatic bone-homed cell line express sufficient amount of metformin uptake 
(OCT1-2, PMAT) and efflux (MATE1) transporters to facilitate metformin 
disposition into various breast cells, which suggests that metformin has the potential 
to be efficacious in these cell lines.  
To our knowledge this is the first time a comprehensive investigation of 
metformin uptake and efflux transporters in cultured cell lines/tissues representing the 
entire spectrum of breast disease progression has been demonstrated, although OCTs 
and MATEs expression has been previously reported in some of the invasive breast 
cancer cells279. Data from the in vitro cell-based assays, RT-qPCR and Western blot, 
suggest that gene and protein expression of metformin transporters differ at various 
stages of breast cancer development and probably reflect the role of these proteins in 
the delivery of essential nutrients and drugs into normal as well as cancer cells. 
Furthermore, data also suggest that multiple transporters are likely to be involved in 
metformin transport in breast cell lines and tissues and there might be an overlap 
between them. Both MCF7, T47D and MDA-MB-231(BM) cells expressed high level 
of OCT2, PMAT and MATE1 proteins and low level of OCT1 protein while the 
MDA-MB-231 cells expressed high level of OCT2, OCT3, PMAT and MATE1 
proteins and low level of OCT1. Expression data demonstrate that unlike liver tissue 
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in which OCT1 has been demonstrated to be essential for metformin entry into the 
hepatocytes, OCT2-3 and PMAT may play a major role in metformin intracellular 
uptake in breast cancer cells.  
In order to assess whether metformin activity requires expression of specific 
transporters, assessment of the relative contribution of each individual transporter to 
metformin uptake and excretion is required as future work. This can be achieved by 
using a combination of transporter-specific inhibitors and a cocktail of inhibitors to 
estimate their contribution to metformin transport.  Alternatively, both transporter-
competent, transporter-deficient and transporter-overexpressing cell lines can be used 
to confirm the involvement of a specific transporter in metformin uptake. 
Additionally, stable transporter-knockdown clones can be generated to elucidate the 
contributions of several transporters in metformin transport across biologic barriers. 
These models can be applied in future studies to explore intracellular accumulation 
and optimal dosing of metformin. However, the only caveat would be the presence of 
unidentified transporters that might also contribute to metformin uptake and 
excretion.  
Data in this thesis also suggest that metformin might be actively transported 
across the mammary epithelium and accumulate in breast cancer cells due to 
inefficient egress as a result of lack of MATE2 efflux transporter but the relevance of 
this observation remains unclear until further uptake studies are performed. Uptake 
studies such as flow cytometry with fluorescently labelled metformin would enable 
the measurement of intracellular metformin concentrations and consequently 
determine the optimal dosing required for promotion of the anti-cancer activity. This 
emphasizes the need to screen cancer cell lines for transporter expression prior to 
selecting relevant cell lines for investigating the anticancer effects of metformin and 
also suggest the use of MATE2 as a potential clinical biomarker of metformin 
resistance. However, cellular uptake and excretion are not the only limiting factors for 
the anti-neoplastic activity of metformin as the presence of competent signalling 
pathways is also of prime importance. 
In parallel with the cell-based assays results, an ex vivo experiment in the form 
of immunohistochemical staining of human surgical specimens also suggests that 
metformin might be of clinical significance in patients with pre-invasive disease as 
well as early stages of invasive breast cancer (stage I-II). However, it is quite 
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interesting to look at the hormonal receptor status in relation to transporter expression 
in breast tissues in future experiments. 
 Our in vitro and ex vivo data demonstrating variability in the influx 
transporter expression profiles in human breast cell lines and tissues, thus reflect the 
degree of variability among cells comprising human breast tumours, and hence 
suggest that the outcomes to metformin therapy in breast cancer could be highly 
variable. Hence it is vitally important that the relationship between transporter 
expression and metformin response in patient tumours should also be established in 
future studies.  
It is also worth considering, the finding that invasive BC cell lines express low 
levels of some cationic transporters, compared to the normal, pre-malignant and pre-
invasive cells, may justify the use of supra-pharmacological drug concentrations to 
target these immortalised cells in vitro. Interestingly, previous literature demonstrated 
that the uptake of metformin into BC cell lines could be greatly enhanced by ectopic 
expression of organic cation transporters such as OCT3279. This therefore, underscores 
the importance of the balance between the dosage and time of exposure as a key 
determinant for metformin’s action to overcome the low abundance of tissue/cell-
specific organic transporters.  
While most of the previous investigators examined the effects of supra-
pharmacological doses of metformin in breast cancer cell lines, in this study the anti-
proliferative activity of the clinically relevant doses has been profiled across a panel 
of increasingly transformed human breast cell lines using 3 different cell proliferation 
assays (Chapter 4). In the cell counting and BrdU assays, metformin was found to 
inhibit the proliferation in a dose dependent manner in most cell lines. Data 
demonstrated that the clinical and potential tissue accumulation doses of metformin 
are potent inhibitors of the highly aggressive triple negative breast cancer cell line and 
its metastatic bone-homed variant compared to invasive breast cancer cells with 
positive oestrogen receptor status, although the pre-invasive cells were the most 
sensitive. Indeed, the ability of metformin to inhibit the proliferation of the pre-
malignant cells might underlie the epidemiological observation that diabetics treated 
with metformin have a lower incidence of breast cancer. However, there is a caveat to 
the data as these pre-malignant cells have been transformed to grow in culture and 
have a much higher proliferation rate than the invasive cells, and than they would in 
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situ, so the results may simply relate to proliferation rate and not to their pre-
invasive/pre-malignant nature.  
Interestingly, there was a more uniform response to the anti-proliferative 
effect of the lowest clinical relevant dose of metformin (0.03 mM) in the colony 
survival assays across all the tested pre-invasive, invasive and metastatic bone-homed 
cell lines. Similarly, the clinically relevant doses have been also shown to arrest cell 
cycle progression in all breast cells regardless of their stage and hormonal receptor 
status. Additionally, these doses were effective in suppressing the migration ability of 
the three invasive cancer cells investigated. 
Therefore, the data in this thesis demonstrate that clinical doses of metformin 
can produce anti-proliferative, anti-invasive and anti-metastatic effects in vitro 
indicating that metformin can act directly on target cells and is not solely reliant on 
reducing serum insulin levels. This does not minimize the proposed indirect, insulin-
dependent, mechanism of action of metformin, but, rather, indicates that the anti-
neoplastic effects of metformin on breast cancer likely represent a combination of 
both direct and indirect effects.  
Importantly, in this thesis the cytotoxic effect of clinical doses of metformin 
has been assessed in assay media containing supraphysiological but sub-lethal glucose 
concentrations, namely 15.4 mmol/l (compared to 17 mmol/L in most of the previous 
studies). However, this dose is still 3 times higher than the mean fasting blood glucose 
values of healthy individuals (usually maintained between 4-6 mM)251, 369.  Although, 
high glucose concentrations have been reported to reduce metformin efficacy and 
promote the growth, motility, aggression and clonogenicity of breast cancer cells, in 
vitro251, 369, 370, in this thesis, when the assay time was prolonged (72 hours) and the 
media were not renewed throughout the assay time, metformin was effective against 
all the cell lines.   
Recently, there has been a rapid expansion in the number of in vitro studies 
evaluating the anti-tumour effects of metformin in both normal- and low-
concentration glucose culture conditions. The results of these studies are promising 
and suggest that low glucose concentrations can enhance the cytotoxicity of 
metformin to cancer cells both in vitro and in vivo184, 356, 369-373, particularly those 
with impaired glucose utilization136. Interestingly, metformin sensitivity of some 
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breast cancer cells, such as T47D, has been shown to be independent of glucose 
concentrations371. Moreover, it should be noted that culturing the cells in low glucose 
medium could potentially cause a genetic drift effect that would alter the results 
obtained as the cells become adjusted to the low glucose environment. Although it 
was not the primary focus of this study to use different glucose concentrations media 
to test the efficacy of metformin dosage, this would be an interesting future 
experiment.  
Furthermore, the presence of high glutamine concentration in the culture 
medium is known to be protective toward electron transport chain dysfunction and 
might interfere with cellular response to metformin136, however, to eliminate the 
variability in celluar response similar concentrations of glutamine were used to grow 
the pre-invasive and invasive cell lines in this project. 
Furthermore, while our data provided some insight to the direct antineoplastic 
effects of metformin in the cultured cell model of breast cancer disease progression, 
however, due to the time constraint it was not possible to further examine the 
mechanisms that make some cells more sensitive to the clinical doses of metformin 
than others. In this context, previous studies suggesting that the LKB1-AMPK 
pathway activation within breast cancer cells is involved in the direct inhibitory effect 
of metformin are documented in vitro and indeed in vivo176, 177, 296, 374, 375. It is now 
well established that the pre-neoplastic breast cells have functional LKB1/AMPK 
pathway, suggesting therefore, that metformin can restrain their growth and delay the 
onset of tumorigenesis, with its ability to induce a cytostatic effect376 (schematically 
represented in Figure 6.1). Similarly, MCF7 and T47D cells have been shown to have 
a competent LKB1/AMPK pathway while MDA-MB-231 has been demonstrated to 
be LKB1 deficient279, 376. LKB1 is an upstream regulator that is required for the 
phosphorylation and activation of AMPK.   
Our results demonstrating that clinical doses of metformin appeared to have an 
inhibitory effect against both the pre-neoplastic and neoplastic cells; regardless of 
their LKB1 status, with the greatest inhibitory effect seen in the breast cancer cell line 
lacking or having a dysfunctional liver kinase B1 compared to their cancer cells 
counterparts with competent LKB1/AMPK intracellular cascade. 
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 Recently, the dependence of the antineoplastic activity of metformin on 
AMPK activation was confirmed by a study showing that metformin does not exert 
anti-proliferative effects in a cell line that expresses metformin transporters but lacks 
LKB1, namely MDA-MB-231 cells, despite achieving high intracellular 
concentrations, while low transporter expression cell line with a functional LKB1; 
such as MCF-7 and BT-20 cells, were more responsive279. This contradicts our 
finding that the MDA-MB-231 cells are more responsive to the cytostatic effect of 
metformin despite the lack of LKB1. A possible explanation for these contradictory 
findings is recent data that suggests that metformin can inhibit the growth of LKB1-
deficient tumours by a separate mechanism involving induction of cellular-energy 
deficiency, by decreasing the mitochondrial ATP production and therefore failure to 
trigger a fully compensatory decrease in energy expenditure, leading to energy crisis 
causing cell death and necrosis, an observation that has been seen both in vitro and in 
vivo377, 378. 
By the same token, it should be noted that ascribing the antitumor properties 
of metformin to AMPK activation has been criticized both in vitro and in vivo as 
several other AMPK-independent mechanisms have been described in different 
cancer types including breast cancer124, 179, 209, 217, 376, 379-384. Moreover, in light of the 
recent discovery of the so-called “biguanide paradox”, which suggests that 
metformin-mediated suppression of cancer growth does not depend on AMPK 
activation but rather, on its downregulation, in specific contexts, it has been suggested 
that biguanides may be more effective in combination with AMPK inhibitors, rather 
than AMPK activators385. Thus metformin dependence on AMPK activation remains 
a controversial issue.  
As a result, it would be very interesting to thoroughly examine whether 
AMPK activation is required in both tumour and non-tumour breast cell lines to elicit 
the anti-proliferative effect of metformin. In this context AMPK-activators and 
AMPK-inhibitors compounds, such as AICAR and compound C respectively, could 
be employed in a series of experiments to assess whether they would abrogate or 
potentiate the effects of metformin. Indeed, it remains to be elucidated if screening the 
patients for genetic variability of the cation-selective transporters (OCT1-3 and 
PMAT) and LKB1 in neoplastic tissues may be necessary to establish their potential 
responsiveness to metformin treatment. 
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Figure 6.1: Mechanisms by which metformin is therapeutically beneficial in 
LKB1-positive and LKB1-negative cancer cells.   
Metformin may act directly on target cells, provided that the cellular pharmacokinetic 
conditions are satisfied. (A) Metformin activates AMPK in normal cells, as well as 
some transformed cells where the LKB1-AMPK pathway is intact. In this case cells 
are able to cope with a modest degree of metformin-induced energy stress, in part by 
reducing the AMPK-dependent energy-consuming processes such as protein and lipid 
synthesis, thereby forcing the cell to adopt to the restrictions of a “low-energy” 
lifestyle to relieve the energetic stress, which ultimately leads to a cytostatic effect. 
(B) Metformin inhibits mitochondrial ATP synthesis and promotes cell death in 
LKB1-AMPK deficient neoplastic cells, as these cells are incapable of compensating 
for metformin-induced energy stress that renders them more sensitive, leading to a 
cytotoxic effect on the tumour cells. (Some elements of this figure were produced 
using Servier Medical Art: http://www.servier.com/Powerpoint‐image‐bank). 
 
Moreover, based on the fact that cells growing in three-dimensional (3D) 
environments (e.g spheroids) express a number of physiological characteristics that 
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are more representative to the native tissue from which they originate than the same 
cells grown in classical two-dimensional (2D) culture flasks. Therefore, growing the 
breast cells in spheroids and treat them with the clinical and potential tissue 
accumulation doses of metformin will provide an in vitro model that sufficiently 
mimic in vivo condition, this is to evaluate if higher doses of metformin are required 
to target the tumour cells and this would be an interesting future experiment. 
 
 In light of the promising results from the proliferation studies, in chapter five 
the effects of metformin on the global proteomics in the highly aggressive triple 
negative cell (MDA-MB-231) and its bone- and lung-homed variants were 
investigated. Unfortunately, the Spike-In SILAC proteomics experiment, despite 
numerous repeats and protocol amendments, was not perfected due to several issues 
that were encountered during the processing of samples. The main issue was the 
difficulty in the reproducibility and the clustering of the three biological samples (all 
other limitations are previously discussed in section 5.4.3). This meant that important 
differences between the three metastatic subtypes might have been masked. Due to 
this, there is therefore no corroborative finding to compare the proteomic pilot study 
to, which was one of the aims of the SILAC study. Further work would therefore be to 
repeat the SILAC-based proteomics experiment (time and money constraints 
prevented this). As the majority of metformin effects are likely to be due to changes in 
phosphorylation rather than in the global proteome, further more informative 
phosphoproteomic studies using the same cell lines is also warranted 
However, the preliminary findings of the proteomic pilot study of this thesis 
contribute new insights into the role of metformin in metastatic breast cancer. 
Additionally, the investigation into the importance of the identified candidate 
proteins; using Western blotting, validates and strengthens current data and 
demonstrates that metformin might work as a novel inhibitor for some attractive 
therapeutic target such as TNFAIP8 and STAT3; but the mechanisms mediating this 
inhibitory effect remain to be fully identified. Nevertheless, it is an important and 
interesting finding suggesting that metformin can hit important cellular targets and 
therefore may lead to new anti-cancer treatment strategies. Although this is a 
promising result, the proteomic analysis should be cautiously interpreted due to the 
issues encountered during the process, with the consideration of further assessment by 
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other protein expression methods, such as immunohistochemistry using tissue sections 
of patients treated with metformin before surgery. Ideally the results of this study 
would be further validated both in vivo and in a prospective clinical trial. If 
confirmed, the associations between these changes and the impact of metformin on 
breast cancer outcome should be evaluated.  
6.1 General limitations of this thesis 
This thesis, generally attempted to build a breast cancer disease case model 
that could test the effects of metformin in relevant cell lines such as MCF10AT, DCIS 
cell type, MCF7, T47D, MDA-MB-231 and one of the end-stage bone-homed breast 
cancer cells.  However, with the benefit of hindsight there are several areas of this 
thesis that could be improved. Generally, there are obvious disadvantages when 
conducting work with cultured cell lines as previously noted386. Cell lines are prone to 
genotypic and phenotypic changes during their continual culture, resulting in 
variations in their growth rate, changes in hormone receptor content and 
clonogenicity292, in order to attempt to control for this, low passage numbers have 
been consistently used throughout this thesis work292, 386. Moreover, it is imperative to 
identify and characterize the cell lines to avoid the use of a false or contaminated cell 
line. As the cells were bought fresh from the ATCC at the beginning of the project we 
are confident that these are not contaminated or false, but if time and money 
permitting we could have double checked at the end of the thesis using HLA typing, 
karyotyping or DNA fingerprinting, or short tandem repeat (STR) profiling387. This 
was not done due to money constraints. 
The other issue with most of these long established breast cancer cell lines is 
that they are derived from distant metastatic sites, especially aspirates or pleural 
effusions and not derived from primary breast tumours. This implies that most of 
these cell lines are derived from more aggressive and often metastatic tumours, which 
may therefore not reflect the specific types, grades or stages observed in primary 
breast cancer. Consequently, studies that rely on these lines will be biased toward 
more rapidly progressive and late-stage disease types of breast carcinoma, rather than 
earlier stages of breast cancer. Therefore, it would be of more clinical relevance to use 
cells that are derived directly from a primary tumour, as most drug therapies are 
directed against these. Furthermore, ex vivo models such as human tissue specimens 
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used in this study can maintain the architecture of the tissues closer to the in 
vivo setting, overtaking some of the limitations of the in vitro studies. However, using 
fixed tissue does not allow assessment of metformin activity and this would require 
ethics to collect fresh human samples, which are difficult to maintain in culture.  
Further work encompassing a variety of breast cancer cell lines with different 
receptor status (ER, PR and HER2) would be beneficial to investigate the anti-
neoplastic effect of metformin and explore the expression profile of metformin 
transporters, to resemble the variety of breast tumours with differing patterns of 
hormone receptor expression encountered in the clinical settings.  
In the in vitro cell-based work, only one experimental technique was used to 
quantify the expression of metformin transporter proteins, namely Western blotting. 
Alternative techniques, such as immunocytochemistry and fluorescent cell surface 
protein expression using flow cytometry (FACS) could have been used to further 
corroborate and compliment the results obtained by Western blotting. Additionally, 
after confirmation of the transporter proteins expression, few other techniques can be 
used to block the expression/accumulation of the transporter proteins, leading to a 
decrease in their levels and eventual knockdown/silencing such as small interfering 
RNAs (siRNAs) or short hairpin RNAs (shRNAs), or the suppression of translation of 
specific mRNAs, as induced by microRNA (miRNA) to evaluate the contribution of 
each individual transporter in metformin response. The use of siRNAs and shRNAs 
techniques are future experiments that should be considered to take the results of this 
thesis forward and allow a detailed comparison of the transporter protein involvement 
in metformin response across all cell lines. 
Furthermore, with regard to the ex vivo study, although the total sample size of 
133 breast tissue specimens represents an adequate number and to date there is no 
equivalent published study to compare this number with, a larger number of tissue 
samples would have increased the statistical power of the study enabled improved 
conclusions to be drawn. Moreover, although the overall sample size was large, the 
number of specimens in each group was relatively small and this is a limitation of this 
study. Plausibly a total of 40 specimens per breast tissue subtype would provide an 
enhanced design to the body of the work performed. Particularly, the number of grade 
three specimens stained was 4, which is low when compared to other tissue subtypes. 
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However, time and resources prevented increasing the sample sizes in each group.  
Further work could potentially include investigating the expression of these 
transporters in full tissue sections rather than microarrays and increasing the sample 
sizes.  
One of the general limitations of the in vitro cell based assays is that they are 
not 100% predictive. Therefore, inhibition of one step in the metastatic cascade by 
metformin treatment, such as migration, or inhibition of metastatic cell proliferation 
does not necessarily translate to complete inhibition of metastasis in vivo.  
Although this thesis has demonstrated the expression of the transporters and 
an effect of metformin on breast epithelial cells, it is not known whether metformin 
treatment will inhibit the development of breast cancer prior to diagnosis. The 
promising results with metformin treatment in the pre-neoplastic and pre-invasive 
cells raise the questions of whether metformin alone can prevent the development of 
hyperplasia or revert early stages of breast cancer to normal breast epithelium. Thus 
future in vivo work using an animal model of spontaneous mammary tumour growth 
such as the PYMT model is warranted to establish whether metformin would have a 
preventative effect against breast cancer development.  
Finally, it must be stressed that as metformin can accumulate in tissues over 
time and the cancer cells could be more sensitive in their tumour microenvironment, 
where they are deprived of the nutrients and growth factors found in culture 
conditions, in vivo studies are also warranted as future work to test the effect of the 
clinically relevant doses on tumour growth. Removal of the tissue after treatment will 
enable effects on the tumour microenvironment, such as angiogenesis, to also be 
assessed.  
6.2 Final conclusion 
In conclusion, the data in this thesis have shown that metformin transporters 
are present on breast epithelial cells, pre-neoplastic, pre-invasive and invasive breast 
cancer cells and that metformin has a cytostatic effect on the proliferation of these 
cells, causing cell cycle arrest, but not apoptosis at clinically relevant doses. The 
proteomic data suggest that metformin inhibits the expression of proteins within key 
cellular pathways in both triple negative breast cancer and the bone- and lung-homed 
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variants, with the lung-homed cells showing a greater response to metformin 
treatment.  Taken together these data suggest that metformin has the potential to be a 
useful treatment for breast cancer, but further research is certainly required to identify 
biomarkers of response and mechanisms of action in breast cancer before metformin 
can be recommended in clinical practice.  
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